US20090131905A1 - Microneedle devices and methods of manufacture and use thereof - Google Patents

Microneedle devices and methods of manufacture and use thereof Download PDF

Info

Publication number
US20090131905A1
US20090131905A1 US12/150,945 US15094508A US2009131905A1 US 20090131905 A1 US20090131905 A1 US 20090131905A1 US 15094508 A US15094508 A US 15094508A US 2009131905 A1 US2009131905 A1 US 2009131905A1
Authority
US
United States
Prior art keywords
microneedles
microneedle
micromold
hollow
mold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/150,945
Inventor
Mark G. Allen
Mark R. Prausnitz
Devin V. McAllister
Florent Paul Marcel Cros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgia Tech Research Corp
Original Assignee
Georgia Tech Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/010,723 external-priority patent/US20020138049A1/en
Application filed by Georgia Tech Research Corp filed Critical Georgia Tech Research Corp
Priority to US12/150,945 priority Critical patent/US20090131905A1/en
Assigned to GEORGIA TECH RESEARCH CORPORATION reassignment GEORGIA TECH RESEARCH CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PRAUSNITZ, MARK R., ALLEN, MARK G., CROS, FLORENT, MCALLISTER, DEVIN V.
Publication of US20090131905A1 publication Critical patent/US20090131905A1/en
Priority to US12/853,082 priority patent/US8708966B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B81MICROSTRUCTURAL TECHNOLOGY
    • B81CPROCESSES OR APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OR TREATMENT OF MICROSTRUCTURAL DEVICES OR SYSTEMS
    • B81C1/00Manufacture or treatment of devices or systems in or on a substrate
    • B81C1/00015Manufacture or treatment of devices or systems in or on a substrate for manufacturing microsystems
    • B81C1/00023Manufacture or treatment of devices or systems in or on a substrate for manufacturing microsystems without movable or flexible elements
    • B81C1/00111Tips, pillars, i.e. raised structures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/1451Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
    • A61B5/14514Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150015Source of blood
    • A61B5/150022Source of blood for capillary blood or interstitial fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150007Details
    • A61B5/150206Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
    • A61B5/150274Manufacture or production processes or steps for blood sampling devices
    • A61B5/150282Manufacture or production processes or steps for blood sampling devices for piercing elements, e.g. blade, lancet, canula, needle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/15Devices for taking samples of blood
    • A61B5/150977Arrays of piercing elements for simultaneous piercing
    • A61B5/150984Microneedles or microblades
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/20Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303Constructional details
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A61B17/205Vaccinating by means of needles or other puncturing devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • A61B10/0045Devices for taking samples of body liquids
    • A61B2010/008Interstitial fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/003Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a lumen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0053Methods for producing microneedles
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B33ADDITIVE MANUFACTURING TECHNOLOGY
    • B33YADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00Products made by additive manufacturing
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B81MICROSTRUCTURAL TECHNOLOGY
    • B81BMICROSTRUCTURAL DEVICES OR SYSTEMS, e.g. MICROMECHANICAL DEVICES
    • B81B2201/00Specific applications of microelectromechanical systems
    • B81B2201/05Microfluidics
    • B81B2201/055Microneedles

Definitions

  • This invention is generally in the field of devices for the transport of therapeutic or biological molecules across tissue barriers, such as for drug delivery.
  • Drugs are commonly administered orally as pills or capsules. However, many drugs cannot be effectively delivered in this manner, due to degradation in the gastrointestinal tract and/or elimination by the liver. Moreover, some drugs cannot effectively diffuse across the intestinal mucosa. Patient compliance may also be a problem, for example, in therapies requiring that pills be taken at particular intervals over a prolonged time.
  • Needle techniques also generally require administration by one trained in its use. The needle technique also is undesirable for long term, controlled continuous drug delivery.
  • An alternative delivery technique is the transdermal patch, which usually relies on diffusion of the drug across the skin.
  • this method is not useful for many drugs, due to the poor permeability (i.e. effective barrier properties) of the skin.
  • the rate of diffusion depends in part on the size and hydrophilicity of the drug molecules and the concentration gradient across the stratum corneum.
  • Few drugs have the necessary physiochemical properties to be effectively delivered through the skin by passive diffusion.
  • Iontophoresis, electroporation, ultrasound, and heat have been used in an attempt to improve the rate of delivery. While providing varying degrees of enhancement, these techniques are not suitable for all types of drugs, failing to provide the desired level of delivery. In some cases, they are also painful and inconvenient or impractical for continuous controlled drug delivery over a period of hours or days. Attempts have been made to design alternative devices for active transfer of drugs, or analyte to be measured, through the skin.
  • U.S. Pat. No. 5,879,326 to Godshall et al. and PCT WO 96/37256 by Silicon Microdevices, Inc. disclose a transdermal drug delivery apparatus that includes a cutter portion having a plurality of microprotrusions, which have straight sidewalls, extending from a substrate that is in communication with a drug reservoir.
  • the microprotrusions penetrate the skin until limited by a stop region of the substrate and then are moved parallel to the skin to create incisions. Because the microprotrusions are dragged across the skin, the device creates a wound sufficiently large to be a site of infection.
  • Channels in the substrate adjacent to the microprotrusions allow drug from the reservoir to flow to the skin near the area disrupted by the microprotrusions.
  • U.S. Pat. No. 5,250,023 to Lee et al. discloses a transdermal drug delivery device, which includes a plurality of skin needles having a diameter in the range of 50 to 400 ⁇ m.
  • the skin needles are supported in a water-swellable polymer substrate through which a drug solution permeates to contact the surface of the skin.
  • An electric current is applied to the device to open the pathways created by the skin needles, following their withdrawal from the skin upon swelling of the polymer substrate.
  • PCT WO 93/17754 by Gross et al. discloses another transdermal drug delivery device that includes a housing having a liquid drug reservoir and a plurality of tubular elements for transporting liquid drug into the skin.
  • the tubular elements may be in the form of hollow needles having inner diameters of less than 1 mm and an outer diameter of 1.0 mm.
  • Microneedle devices for transport of molecules, including drugs and biological molecules, across tissue, and methods for manufacturing the devices are provided.
  • the microneedle devices permit drug delivery or removal of body fluids at clinically relevant rates across skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue.
  • Microneedles can be formed of biodegradable or non-biodegradable polymeric materials or metals.
  • the microneedles are formed of a biodegradable polymer.
  • the device includes a means for temporarily securing the microneedle device to the biological barrier to facilitate transport.
  • a preferred method for making a microneedle includes forming a micromold having sidewalls which define the outer surface of the microneedle.
  • the micromold can be formed, for example, by photolithographically defining one or more holes in a substrate, or by laser based cutting (either serially or by using lithographic projection), or by using a mold-insert.
  • the method includes electroplating the sidewalls to form the hollow microneedle, and then removing the micromold from the microneedle.
  • the microneedle device is useful for delivery of fluid material into or across a biological barrier wherein the fluid material is delivered from one or more chambers in fluid connection with at least one of the microneedles.
  • the device preferably further includes a means for controlling the flow of material through the microneedles. Representative examples of these means include the use of permeable membranes, fracturable impermeable membranes, valves, and pumps, and electrical means.
  • FIG. 1 a is a side elevational view of a preferred embodiment of the microneedle device inserted into human skin.
  • FIG. 1 b is a diagram of one embodiment of microneedles.
  • FIGS. 2 a - e are side cross-sectional views of a method for making microneedles.
  • FIGS. 3 a - g are side cross-sectional views of a method for making a hollow microneedle.
  • FIGS. 4 a through 4 d are side cross-sectional views illustrating a preferred method for making hollow microneedles.
  • FIGS. 5 a through 5 d are side cross-sectional views illustrating a preferred method for making hollow silicon microtubes.
  • FIGS. 6 a through 6 e are side cross-sectional views illustrating a preferred method for making hollow metal microtubes.
  • FIGS. 7 a through 7 d are side cross-sectional views illustrating a preferred method for making tapered metal microneedles.
  • FIGS. 8 a through 8 d are side cross-sectional views illustrating a method for making tapered microneedles using laser-formed molds.
  • FIGS. 9 a through 9 f are side cross-sectional views illustrating a second method for making tapered microneedles using laser-formed molds.
  • the devices disclosed herein are useful in transport of material into or across biological barriers including the skin (or parts thereof); the blood-brain barrier; mucosal tissue (e.g., oral, nasal, ocular, vaginal, urethral, gastrointestinal, respiratory); blood vessels; lymphatic vessels; or cell membranes (e.g., for the introduction of material into the interior of a cell or cells).
  • the biological barriers can be in humans or other types of animals, as well as in plants, insects, or other organisms, including bacteria, yeast, fungi, and embryos.
  • microneedle devices can be applied to tissue internally with the aid of a catheter or laparoscope.
  • the devices can be surgically implanted.
  • the microneedle device disclosed herein is typically applied to skin.
  • the stratum corneum is the outer layer, generally between 10 and 50 cells, or between 10 and 20 ⁇ m thick. Unlike other tissue in the body, the stratum corneum contains “cells” (called keratinocytes) filled with bundles of cross-linked keratin and keratohyalin surrounded by an extracellular matrix of lipids. It is this structure that is believed to give skin its barrier properties, which prevents therapeutic transdermal administration of many drugs.
  • Below the stratum corneum is the viable epidermis, which is between 50 and 100 ⁇ m thick. The viable epidermis contains no blood vessels, and it exchanges metabolites by diffusion to and from the dermis. Beneath the viable epidermis is the dermis, which is between 1 and 3 mm thick and contains blood vessels, lymphatics, and nerves.
  • microneedle devices disclosed herein include a substrate; one or more microneedles; and, optionally, a reservoir for delivery of drugs or collection of analyte, as well as pump(s), sensor(s), and/or microprocessor(s) to control the interaction of the foregoing.
  • the substrate of the device can be constructed from a variety of materials, including metals, ceramics, semiconductors, organics, polymers, and composites.
  • the substrate includes the base to which the microneedles are attached or integrally formed.
  • a reservoir may also be attached to the substrate.
  • the microneedles of the device can be constructed from a variety of materials, including metals, ceramics, semiconductors, organics, polymers, and composites.
  • Preferred materials of construction include pharmaceutical grade stainless steel, gold, titanium, nickel, iron, gold, tin, chromium, copper, alloys of these or other metals, silicon, silicon dioxide, and polymers.
  • Representative biodegradable polymers include polymers of hydroxy acids such as lactic acid and glycolic acid polylactide, polyglycolide, polylactide-co-glycolide, and copolymers with PEG, polyanhydrides, poly(ortho)esters, polyurethanes, poly(butyric acid), poly(valeric acid), and poly(lactide-co-caprolactone).
  • Representative non-biodegradable polymers include polycarbonate, polymethacrylic acid, ethylenevinyl acetate, polytetrafluoroacetate (TEFLONTM), and polyesters.
  • the microneedles should have the mechanical strength to remain intact for delivery of drugs, or serve as a conduit for the collection of biological fluid, while being inserted into the skin, while remaining in place for up to a number of days, and while being removed.
  • this mechanical requirement is less stringent, since the microneedles or tips thereof can break off, for example in the skin, and will biodegrade. Nonetheless, even a biodegradable microneedle still needs to remain intact at least long enough for the microneedle to serve its intended purpose (e.g, its conduit function). Therefore, biodegradable microneedles can provide an increased level of safety, as compared to nonbiodegradable ones.
  • the microneedles should be sterilizable using standard methods.
  • the microneedles can be formed of a porous solid, with or without a sealed coating or exterior portion, or hollow.
  • porous means having pores or voids throughout at least a portion of the microneedle structure, sufficiently large and sufficiently interconnected to permit passage of fluid and/or solid materials through the microneedle.
  • the term “hollow” means having one or more substantially annular bores or channels through the interior of the microneedle structure, having a diameter sufficiently large to permit passage of fluid and/or solid materials through the microneedle.
  • the annular bores may extend throughout all or a portion of the needle in the direction of the tip to the base, extending parallel to the direction of the needle or branching or exiting at a side of the needle, as appropriate.
  • a solid or porous microneedle can be hollow.
  • One of skill in the art can select the appropriate porosity and/or bore features required for specific applications. For example, one can adjust the pore size or bore diameter to permit passage of the particular material to be transported through the microneedle device.
  • the microneedles can have straight or tapered shafts.
  • the term “microneedle” includes both microtubes and tapered needles unless otherwise indicated.
  • the diameter of the microneedle is greatest at the base end of the microneedle and tapers to a point at the end distal the base.
  • the microneedle can also be fabricated to have a shaft that includes both a straight (untapered) portion and a tapered portion.
  • the microneedles can be formed with shafts that have a circular cross-section in the perpendicular, or the cross-section can be non-circular.
  • the cross-section of the microneedle can be polygonal (e.g. star-shaped, square, triangular), oblong, or another shape.
  • the shaft can have one or more bores.
  • the cross-sectional dimensions typically are between about 10 nm and 1 mm, preferably between 1 micron and 200 microns, and more preferably between 10 and 100 ⁇ m.
  • the outer diameter is typically between about 10 ⁇ m and about 100 ⁇ m
  • the inner diameter is typically between about 3 ⁇ m and about 80 ⁇ m.
  • the length of the microneedles typically is between about 1 ⁇ m and 1 mm, preferably between 10 microns and 500 microns, and more preferably between 30 and 200 ⁇ m. The length is selected for the particular application, accounting for both an inserted and uninserted portion.
  • An array of microneedles can include a mixture of microneedles having, for example, various lengths, outer diameters, inner diameters, cross-sectional shapes, and spacings between the microneedles.
  • the microneedles can be oriented perpendicular or at an angle to the substrate.
  • the microneedles are oriented perpendicular to the substrate so that a larger density of microneedles per unit area of substrate can be provided.
  • An array of microneedles can include a mixture of microneedle orientations, heights, or other parameters.
  • the substrate and/or microneedles, as well as other components are formed from flexible materials to allow the device to fit the contours of the biological barrier, such as the skin, vessel walls, or the eye, to which the device is applied.
  • a flexible device will facilitate more consistent penetration during use, since penetration can be limited by deviations in the attachment surface. For example, the surface of human skin is not flat due to dermatoglyphics (i.e. tiny wrinkles) and hair.
  • the microneedle device may include a reservoir in communication with the microneedles.
  • the reservoir can be attached to the substrate by any suitable means.
  • the reservoir is attached to the back of the substrate (opposite the microneedles) around the periphery, using an adhesive agent (e.g., glue).
  • a gasket may also be used to facilitate formation of a fluid-tight seal.
  • the reservoir contains drug, for delivery through the microneedles.
  • the reservoir may be a hollow vessel, a porous matrix, or a solid form including drug which is transported therefrom.
  • the reservoir can be formed from a variety of materials that are compatible with the drug or biological fluid contained therein. Preferred materials include natural and synthetic polymers, metals, ceramics, semiconductors, organics, and composites.
  • the microneedle device can include one or a plurality of chambers for storing materials to be delivered. In the embodiment having multiple chambers, each can be in fluid connection with all or a portion of the microneedles of the device array. In one embodiment, at least two chambers are used to separately contain drug (e.g., a lyophilized drug, such as a vaccine) and an administration vehicle (e.g., saline) in order to prevent or minimize degradation during storage. Immediately before use, the contents of the chambers are mixed. Mixing can be triggered by any means, including, for example, mechanical disruption (i.e. puncturing or breaking), changing the porosity, or electrochemical degradation of the walls or membranes separating the chambers. In another embodiment, a single device is used to deliver different drugs, which are stored separately in different chambers. In this embodiment, the rate of delivery of each drug can be independently controlled.
  • drug e.g., a lyophilized drug, such as a vaccine
  • an administration vehicle e.g., s
  • the reservoir should be in direct contact with the microneedles and have holes through which drug could exit the reservoir and flow into the interior of hollow or porous microneedles.
  • the reservoir has holes which permit the drug to transport out of the reservoir and onto the skin surface. From there, drug is transported into the skin, either through hollow or porous microneedles, along the sides of solid microneedles, or through pathways created by microneedles in the skin.
  • the microneedle device also must be capable of transporting material across the barrier at a useful rate.
  • the microneedle device must be capable of delivering drug across the skin at a rate sufficient to be therapeutically useful.
  • the device may include a housing with microelectronics and other micromachined structures to control the rate of delivery either according to a preprogrammed schedule or through active interface with the patient, a healthcare professional, or a biosensor.
  • the rate can be controlled by manipulating a variety of factors, including the characteristics of the drug formulation to be delivered (e.g., its viscosity, electric charge, and chemical composition); the dimensions of each microneedle (e.g., its outer diameter and the area of porous or hollow openings); the number of microneedles in the device; the application of a driving force (e.g., a concentration gradient, a voltage gradient, a pressure gradient); and the use of a valve.
  • a driving force e.g., a concentration gradient, a voltage gradient, a pressure gradient
  • the rate also can be controlled by interposing between the drug in the reservoir and the opening(s) at the base end of the microneedle polymeric or other materials selected for their diffusion characteristics.
  • the material composition and layer thickness can be manipulated using methods known in the art to vary the rate of diffusion of the drug of interest through the material, thereby controlling the rate at which the drug flows from the reservoir through the microneedle and into the tissue.
  • microneedles Transportation of molecules through the microneedles can be controlled or monitored using, for example, various combinations of valves, pumps, sensors, actuators, and microprocessors. These components can be produced using standard manufacturing or microfabrication techniques. Actuators that may be useful with the microneedle devices disclosed herein include micropumps, microvalves, and positioners. In a preferred embodiment, a microprocessor is programmed to control a pump or valve, thereby controlling the rate of delivery.
  • Flow of molecules through the microneedles can occur based on diffusion, capillary action, or can be induced using conventional mechanical pumps or nonmechanical driving forces, such as electroosmosis or electrophoresis, or convection.
  • electroosmosis electrodes are positioned on the biological barrier surface, one or more microneedles, and/or the substrate adjacent the needles, to create a convective flow which carries oppositely charged ionic species and/or neutral molecules toward or into the biological barrier.
  • the microneedle device is used in combination with another mechanism that enhances the permeability of the biological barrier, for example by increasing cell uptake or membrane disruption, using electric fields, ultrasound, chemical enhancers, viruses, pH, heat and/or light.
  • Passage of the microneedles, or drug to be transported via the microneedles can be manipulated by shaping the microneedle surface, or by selection of the material forming the microneedle surface (which could be a coating rather than the microneedle per se).
  • one or more grooves on the outside surface of the microneedles can be used to direct the passage of drug, particularly in a liquid state.
  • the physical surface properties of the microneedle could be manipulated to either promote or inhibit transport of material along the microneedle surface, such as by controlling hydrophilicity or hydrophobicity.
  • valves or gates can be the type that are selectively and repeatedly opened and closed, or they can be single-use types.
  • a fracturable barrier or one-way gate may be installed in the device between the reservoir and the opening of the microneedles. When ready to use, the barrier can be broken or gate opened to permit flow through the microneedles.
  • Other valves or gates used in the microneedle devices can be activated thermally, electrochemically, mechanically, or magnetically to selectively initiate, modulate, or stop the flow of molecules through the needles. In a preferred embodiment, flow is controlled by using a rate-limiting membrane as a “valve.”
  • the microneedle devices can further include a flowmeter or other means to monitor flow through the microneedles and to coordinate use of the pumps and valves.
  • Useful sensors may include sensors of pressure, temperature, chemicals, and/or electro-magnetic fields.
  • Biosensors can be located on the microneedle surface, inside a hollow or porous microneedle, or inside a device in communication with the body tissue via the microneedle (solid, hollow, or porous).
  • These microneedle biosensors can include four classes of principal transducers: potentiometric, amperometric, optical, and physiochemical.
  • An amperometric sensor monitors currents generated when electrons are exchanged between a biological system and an electrode. Blood glucose sensors frequently are of this type.
  • the microneedle may function as a conduit for fluids, solutes, electric charge, light, or other materials.
  • hollow microneedles can be filled with a substance, such as a gel, that has a sensing functionality associated with it.
  • the substrate or enzyme can be immobilized in the needle interior, which would be especially useful in a porous needle to create an integral needle/sensor.
  • Wave guides can be incorporated into the microneedle device to direct light to a specific location, or for dection, for example, using means such as a pH dye for color evaluation.
  • heat, electricity, light or other energy forms may be precisely transmitted to directly stimulate, damage, or heal a specific tissue or intermediary (e.g., tattoo remove for dark skinned persons), or diagnostic purposes, such as measurement of blood glucose based on IR spectra or by chromatographic means, measuring a color change in the presence of immobilized glucose oxidase in combination with an appropriate substrate.
  • a collar or flange also can be provided with the device, for example, around the periphery of the substrate or the base. It preferably is attached to the device, but alternatively can be formed as integral part of the substrate, for example by forming microneedles only near the center of an “oversized” substrate.
  • the collar can also emanate from other parts of the device. The collar can provide an interface to attach the microneedle array to the rest of the device, and can facilitate handling of the smaller devices.
  • the microneedle device includes an adhesive to temporarily secure the device to the surface of the biological barrier.
  • the adhesive can be essentially anywhere on the device to facilitate contact with the biological barrier.
  • the adhesive can be on the surface of the collar (same side as microneedles), on the surface of the substrate between the microneedles (near the base of the microneedles), or a combination thereof.
  • FIG. 1 a is a side elevational view of a schematic of a preferred embodiment of the microneedle device inserted into skin.
  • the device 10 includes an upper portion or substrate 11 from which a plurality of microneedles 12 protrude.
  • the height of the upper portion 11 is between about 1 ⁇ m and 1 cm, and the width of the upper portion is between about 1 mm and 10 cm.
  • the upper portion 11 of the device can be solid or hollow, and may include multiple compartments.
  • the upper portion 11 contains one or more drugs to be delivered.
  • the upper portion include one or more sensors and/or an apparatus (e.g., pump or electrode) to drive (provide/direct the force) transport of the drug or other molecules.
  • an apparatus e.g., pump or electrode
  • the height (or length) of the microneedles 12 generally is between about 1 ⁇ m and 1 mm.
  • the diameter and length both affect pain as well as functional properties of the needles.
  • the “insertion depth” of the microneedles 12 is preferably less than about 100 ⁇ m, more preferably about 30 ⁇ m, so that insertion of the microneedles 12 into the skin through the stratum corneum 14 does not penetrate past the epidermis 16 into the dermis 18 (as described below), thereby avoiding contacting nerves and reducing the potential for causing pain.
  • the actual length of the microneedles may be longer, since the portion of the microneedles distal the tip may not be inserted into the skin; the uninserted length depends on the particular device design and configuration.
  • the actual (overall) height or length of microneedles 12 should be equal to the insertion depth plus the uninserted length.
  • each microneedle 12 generally is between about 10 nm and 1 mm, and preferably leaves a residual hole (following microneedle insertion and withdrawal) of less than about 1 ⁇ m, to avoid making a hole which would allow bacteria to enter the penetration wound.
  • the actual microneedle diameter should be larger than 1 ⁇ m, since the hole likely will contract following withdrawal of the microneedle.
  • the diameter of microneedle 12 more preferably is between about 1 ⁇ m and 100 ⁇ m. Larger diameter and longer microneedles are acceptable, so long as the microneedle can penetrate the biological barrier to the desired depth and the hole remaining in the skin or other tissue following withdrawal of the microneedle is sufficiently small, preferably small enough to exclude bacterial entry.
  • the microneedles 12 can be solid or porous, and can include one or more bores connected to upper portion 11 .
  • microneedle devices are made by microfabrication processes, by creating small mechanical structures in silicon, metal, polymer, and other materials. These microfabrication processes are based on well-established methods used to make integrated circuits, electronic packages and other microelectronic devices, augmented by additional methods used in the field of micromachining.
  • the microneedle devices can have dimensions as small as a few nanometers and can be mass-produced at low per-unit costs.
  • Microfabrication processes that may be used in making the microneedles disclosed herein include lithography; etching techniques, such as wet chemical, dry, and photoresist removal; thermal oxidation of silicon; electroplating and electroless plating; diffusion processes, such as boron, phosphorus, arsenic, and antimony diffusion; ion implantation; film deposition, such as evaporation (filament, electron beam, flash, and shadowing and step coverage), sputtering, chemical vapor deposition (CVD), epitaxy (vapor phase, liquid phase, and molecular beam), electroplating, screen printing, lamination, stereolithography, laser machining, and laser ablation (including projection ablation).
  • lithography etching techniques, such as wet chemical, dry, and photoresist removal
  • thermal oxidation of silicon such as boron, phosphorus, arsenic, and antimony diffusion
  • ion implantation film deposition, such as evaporation (filament, electron beam, flash, and
  • microneedles The following methods are preferred for making microneedles.
  • electrochemical etching of solid silicon to porous silicon is used to create extremely fine (on the order of 0.01 ⁇ m) silicon networks which can be used as piercing structures.
  • This method uses electrolytic anodization of silicon in aqueous hydrofluoric acid, potentially in combination with light, to etch channels into the silicon. By varying the doping concentration of the silicon wafer to be etched, the electrolytic potential during etching, the incident light intensity, and the electrolyte concentration, control over the ultimate pore structure can be achieved. The material not etched (i.e. the silicon remaining) forms the microneedles. This method has been used to produce irregular needle-type structures measuring tens of nanometers in width.
  • This process uses deep plasma etching of silicon to create microneedles with diameters on the order of 0.1 ⁇ m or larger. Needles are patterned directly using photolithography, rather than indirectly by controlling the voltage (as in electrochemical etching), thus providing greater control over the final microneedle geometry.
  • an appropriate masking material e.g., metal
  • a silicon wafer substrate is then subjected to a carefully controlled plasma based on fluorine/oxygen chemistries to etch very deep, high aspect ratio trenches into the silicon. See, e.g., Jansen, et al., “The Black Silicon Method IV: The Fabrication of Three-Dimensional Structures in Silicon with High Aspect Ratios for Scanning Probe Microscopy and Other Applications,” IEEE Proceedings of Micro Electro Mechanical Systems Conference , pp. 88-93 (1995). Those regions protected by the metal mask remain and form the needles. This method is further described in Example 1 below.
  • FIG. 1 b provides a diagram of microneedles fabricated by this method.
  • a metal layer is first evaporated onto a planar substrate.
  • a layer of photoresist is then deposited onto the metal to form a patterned mold which leaves an exposed-metal region in the shape of needles.
  • the mold bounded by photoresist can be filled with electroplated material.
  • the substrate and photoresist mold are removed, leaving the finished microneedle array.
  • the microneedles produced by this process generally have diameters on the order of 1 ⁇ m or larger. See, e.g., Frazier, et al., “Two dimensional metallic microelectrode arrays for extracellular stimulation and recording of neurons”, IEEE Proceedings of the Micro Electro Mechanical Systems Conference , pp. 195-200 (1993).
  • microneedles made of silicon or other materials Another method for forming microneedles made of silicon or other materials is to use microfabrication techniques such as photolithography, plasma etching, or laser ablation to make a mold form (A), transferring that mold form to other materials using standard mold transfer techniques, such as embossing or injection molding (B), and reproducing the shape of the original mold form (A) using the newly-created mold (B) to yield the final microneedles (C).
  • the creation of the mold form (A) could be skipped and the mold (B) could be microfabricated directly, which could then be used to create the final microneedles (C).
  • Another method of forming solid silicon microneedles is by using epitaxial growth on silicon substrates, as is utilized by Containerless Research, Inc. (Evanston, Ill., USA) for its products.
  • microneedles are made with pores or other pathways through which material may be transported.
  • the following descriptions outline representative methods for fabricating either porous or hollow microneedles.
  • porous needles are filled with a network of channels or pores which allow conduction of fluid or energy through the needle shaft. It has been shown that by appropriate electrochemical oxidation of silicon, pore arrays with high aspect ratios and a range of different pore size regimes can be formed; these pore regimes are defined as (1) microporous regime with average pore dimensions less than 2 nm, (2) mesoporous regime with average pore sizes of between 2 nm and 50 nm, and (3) macroporous regime with pores greater than 50 nm. The mesoporous and macroporous regimes are expected to be most useful for drug delivery.
  • porous needles Two approaches to porous needles are generally available, either (a) the silicon wafer is first made porous and then etched as described above to form needles or (b) solid microneedles are etched and then rendered porous, for example, by means of electrochemical oxidation, such as by anodization of a silicon substrate in a hydrofluoric acid electrolyte.
  • electrochemical oxidation such as by anodization of a silicon substrate in a hydrofluoric acid electrolyte.
  • the size distribution of the etched porous structure is highly dependent on several variables, including doping kind and illumination conditions, as detailed in Lehmann, “Porous Silicon—A New Material for MEMS”, IEEE Proceedings of the Micro Electro Mechanical Systems Conference , pp. 1-6 (1996).
  • Porous polymer or metallic microneedles can be formed, for example, by micromolding a polymer containing a volatilizable or leachable material, such as a volatile salt, dispersed in the polymer or metal, and then volatilizing or leaching the dispersed material, leaving a porous polymer matrix in the shape of the microneedle.
  • a volatilizable or leachable material such as a volatile salt
  • Three-dimensional arrays of hollow microneedles can be fabricated, for example, using combinations of dry etching processes (Laermer, et al., “Bosch Deep Silicon Etching: Improving Uniformity and Etch Rate for Advanced MEMS Applications,” Micro Electro Mechanical Systems , Orlando, Fla., USA, (Jan. 17-21, 1999); Despont et al., “High-Aspect-Ratio, Ultrathick, Negative-Tone Near-UV Photoresist for MEMS”, Proc. of IEEE 10 th Annual International Workshop on MEMS, Nagoya, Japan, pp. 518-522 (Jan. 26-30, 1997)); micromold creation in lithographically-defined and/or laser ablated polymers and selective sidewall electroplating; or direct micromolding techniques using epoxy mold transfers.
  • dry etching processes Laermer, et al., “Bosch Deep Silicon Etching: Improving Uniformity and Etch Rate for Advanced MEMS Applications,” Micro Electro Mechanical Systems , Orlando, Fla.
  • the microneedle has a single annular pathway along the center axis of the microneedle. This pathway can be achieved by initially chemically or physically etching the holes in the material and then etching away microneedles around the hole. Alternatively, the microneedles and their holes can be made simultaneously or holes can be etched into existing microneedles. As another option, a microneedle form or mold can be made, then coated, and then etched away, leaving only the outer coating to form a hollow microneedle. Coatings can be formed either by deposition of a film or by oxidation of the silicon microneedles to a specific thickness, followed by removal of the interior silicon. Also, holes from the backside of the wafer to the underside of the hollow needles can be created using a front-to-backside infrared alignment followed by etching from the backside of the wafer.
  • One method for hollow needle fabrication is to replace the solid mask used in the formation of solid needles by a mask that includes a solid shape with one or more interior regions of the solid shape removed.
  • a mask that includes a solid shape with one or more interior regions of the solid shape removed.
  • One example is a “donut-shaped” mask.
  • interior regions of the needle are etched simultaneously with their side walls. Due to lateral etching of the inner side walls of the needle, this may not produce sufficiently sharp walls.
  • two plasma etches must be used, one to form the outer walls of the microneedle (i.e., the ‘standard’ etch), and one to form the inner hollow core (which is an extremely anisotropic etch, such as in inductively-coupled-plasma “ICP” etch).
  • the ICP etch can be used to form the interior region of the needle followed by a second photolithography step and a standard etch to form the outer walls of the microneedle.
  • FIG. 2 a represents a silicon wafer 82 with a patterned photoresist layer 84 on top of the wafer 82 .
  • the wafer 82 is anisotrophically etched ( FIG. 2 b ) to form a cavity 86 through its entire thickness ( FIG. 2 c ).
  • the wafer 82 is then coated with a chromium layer 88 followed by a second photoresist layer 90 patterned so as to cover the cavity 86 and form a circular mask for subsequent etching ( FIG. 2 d ).
  • the wafer 82 is then etched by a standard etch to form the outer tapered walls 92 of the microneedle ( FIG. 2 e ).
  • this structure can be achieved by substituting the chromium mask used for the solid microneedles described in Example 1 by a silicon nitride layer 94 on the silicon substrate 95 covered with chromium 96 , deposited as shown in FIG. 3 a and patterned as shown in FIG. 3 b .
  • Solid microneedles are then etched as described in Example 1 as shown FIG. 3 c , the chromium 88 is stripped ( FIG. 3 d ), and the silicon 95 is oxidized to form a thin layer of silicon dioxide 97 on all exposed silicon surfaces ( FIG. 3 e ).
  • the silicon nitride layer 94 prevents oxidation at the needle tip.
  • the silicon nitride 94 is then stripped ( FIG.
  • Silica needles or metal needles can be formed using different methods. Silica needles can be formed by creating needle structures similar to the ICP needles described above prior to the oxidation described above. The wafers are then oxidized to a controlled thickness, forming a layer on the shaft of the needle form which will eventually become the hollow microneedle. The silicon nitride is then stripped and the silicon core selectively etched away (e.g., in a wet alkaline solution) to form a hollow silica microneedle.
  • an array of hollow silicon microtubes is made using deep reactive ion etching combined with a modified black silicon process in a conventional reactive ion etcher, as described in Example 3 below.
  • arrays of circular holes are patterned through photoresist into SiO 2 , such as on a silicon wafer.
  • the silicon can be etched using deep reactive ion etching (DRIE) in an inductively coupled plasma (ICP) reactor to etch deep vertical holes.
  • DRIE deep reactive ion etching
  • ICP inductively coupled plasma
  • a second photolithography step patterns the remaining SiO 2 layer into circles concentric to the holes, leaving ring shaped oxide masks surrounding the holes.
  • the photoresist is then removed and the silicon wafer again deep silicon etched, such that the holes are etched completely through the wafer (inside the SiO 2 ring) and simultaneously the silicon is etched around the SiO 2 ring leaving a cylinder.
  • This latter process can be varied to produce hollow, tapered microneedles.
  • the photoresist and SiO 2 layers are replaced with conformal DC sputtered chromium rings.
  • the second ICP etch is replaced with a SF 6 /O 2 plasma etch in a reactive ion etcher (RIE), which results in positively sloping outer sidewalls.
  • RIE reactive ion etcher
  • Metal needles can be formed by physical vapor deposition of appropriate metal layers on solid needle forms, which can be made of silicon using the techniques described above, or which can be formed using other standard mold techniques such as embossing or injection molding.
  • the metals are selectively removed from the tips of the needles using electropolishing techniques, in which an applied anodic potential in an electrolytic solution will cause dissolution of metals more rapidly at sharp points, due to concentration of electric field lines at the sharp points.
  • electropolishing techniques in which an applied anodic potential in an electrolytic solution will cause dissolution of metals more rapidly at sharp points, due to concentration of electric field lines at the sharp points.
  • the silicon needle forms Once the underlying silicon needle forms have been exposed at the tips, the silicon is selectively etched away to form hollow metallic needle structures. This process could also be used to make hollow needles made from other materials by depositing a material other than metal on the needle forms and following the procedure described above.
  • a preferred method of fabricating hollow metal microneedles utilizes micromold plating techniques, for example which are described as follows and in Examples 4 and 5.
  • a photo-defined mold first is first produced, for example, by spin casting a thick layer, typically 150 ⁇ m, of an epoxy (e.g., SU-8) onto a substrate that has been coated with a thin sacrificial layer, typically about 10 to 50 nm.
  • Arrays of cylindrical holes are then photolithographically defined through the epoxy layer, which typically is about 150 ⁇ m thick.
  • the copper laminate is selectively removed using wet etching.
  • a seed layer such as Ti/Cu/Ti (e.g., 30 nm/200 nm/30 nm)
  • Ti/Cu/Ti conformally DC sputter-deposited onto the upper surface of the epoxy mold and onto the sidewalks of the cylindrical holes.
  • the seed layer should be electrically isolated from the substrate.
  • one or more electroplatable metals or alloys such as Ni, NiFe, Au, Cu, or Ti are electroplated onto the seed layer.
  • the surrounding epoxy is then removed, leaving microtubes which each have an interior annular hole that extends through the base metal supporting the tubes. The rate and duration of electroplating is controlled in order to define the wall thickness and inner diameter of the microtubes.
  • this method was used to produce microtubes having a height of between about 150 and 250 ⁇ m, an outer diameter of between about 40 and 120 ⁇ m, and an inner diameter of between about 30 and 110 ⁇ m (i.e., having a wall thickness of 10 ⁇ m).
  • the microtubes have a tube center-to-center spacing of about 150 ⁇ m, but can vary depending on the desired needle density.
  • a variation of this method is preferred for forming tapered microneedles.
  • photolithography yields holes in the epoxy which have vertical sidewalls, such that the resulting shafts of the microneedles are straight, not tapered.
  • This vertical sidewall limitation can be overcome by molding a preexisting 3D structure, i.e., a mold-insert. The subsequent removal of the mold-insert leaves a mold which can be surface plated similarly to the holes produced by photolithography described above.
  • non-vertical sidewalls can be produced directly in the polymeric mold into which electroplating will take place.
  • conventional photoresists known in the art can be exposed and developed in such as way as to have the surface immediately adjacent to the mask be wider than the other surface.
  • Specialized greyscale photoresists in combination with greyscale masks can accomplish the same effect.
  • Laser-ablated molds can also be made with tapered sidewalls, e.g., by optical adjustment of the beam (in the case of serial hole fabrication) or of the reticle or mold during ablation (in the case of projection ablation).
  • non-vertical sidewalls can be produced directly in the polymeric mold into which electroplating will take place.
  • laser-ablated molds can also be made with tapered sidewalls, e.g., by optical adjustment of the beam (in the case of serial hole fabrication) or of the reticle or mold during ablation (in the case of projection ablation).
  • the mold-insert is an array of solid silicon microneedles, formed as described in Henry, et al., “Micromachined Needles for the Transdermal Delivery of Drugs,” Micro Electro Mechanical Systems , Heidelberg, Germany, Jan. 26-29, pp. 494-498-(1998).
  • a layer of a material such as an epoxy (e.g., SU-8) is spin cast onto the array of silicon microneedles to completely blanket the entire array.
  • the epoxy settles during pre-bake to create a planar surface above the silicon needle tips; the material is then fully pre-baked, photolithographically cross-linked, and post-baked.
  • the upper surface of the epoxy is then etched away, for example with an O 2 /CHF 3 plasma, until the needle tips are exposed, preferably leaving between about 1 and 5 ⁇ m of tip protruding from the epoxy.
  • the silicon is then selectively removed, for example by using a SF 6 plasma or a HNO 3 /H solution.
  • the remaining epoxy micromold is the negative of the microneedles and has a small diameter hole where the tip of the microneedle formerly protruded.
  • a seed layer such as Ti—Cu—Ti is conformally sputter-deposited onto the epoxy micromold.
  • one or more electroplatable metals or alloys such as Ni, NiFe, Au, or Cu, are electroplated onto the seed layer.
  • the epoxy is removed, for example by using an O 2 /CHF 3 plasma, leaving an array of hollow metal microneedles.
  • this method is used to produce microneedles having a height of between about 150 and 250 ⁇ m, an outer diameter of between about 40 and 120 ⁇ m, and an inner diameter of between about 50 and 100 ⁇ m.
  • the microtubes In a typical array, the microtubes have a tube center-to-center spacing of about 150 ⁇ m, but can vary depending on the desired needle density.
  • the microneedles are 150 ⁇ m in height with a base diameter of 80 ⁇ m, a tip diameter of 10 ⁇ m, and a needle to needle spacing of 150 ⁇ m.
  • Hollow microneedles formed of silicon dioxide can be made by oxidizing the surface of the silicon microneedle forms (as described above), rather than depositing a metal and then etching away the solid needle forms to leave the hollow silicon dioxide structures. This method is illustrated in FIGS. 4 a - 4 d .
  • FIG. 4 a shows an array 24 of needle forms 26 with masks 28 on their tips.
  • the needle forms 26 have been coated with a layer 30 of metal, silicon dioxide or other material.
  • FIG. 4 c shows the coated needle forms 26 with the masks 28 removed.
  • the needle forms 26 have been etched away, leaving hollow needles 30 made of metal, silicon dioxide, or other materials.
  • hollow, porous, or solid microneedles are provided with longitudinal grooves or other modifications to the exterior surface of the microneedles. Grooves, for example, should be useful in directing the flow of molecules along the outside of microneedles.
  • polymeric microneedles are made using microfabricated molds.
  • the epoxy molds can be made as described above and injection molding techniques can be applied to form the microneedles in the molds (Weber, et al., “Micromolding—a powerful tool for the large scale production of precise microstructures”, Proc. SPIE—International Soc. Optical Engineer. 2879, 156-167 (1996); Schift, et al., “Fabrication of replicated high precision insert elements for micro-optical bench arrangements” Proc. SPIE-International Soc. Optical Engineer. 3513, 122-134 (1998).
  • These micromolding techniques are preferred over other techniques described herein, since they can provide relatively less expensive replication, i.e. lower cost of mass production.
  • the polymer is biodegradable.
  • the device may be used for single or multiple uses for rapid transport across a biological barrier or may be left in place for longer times (e.g., hours or days) for long-term transport of molecules.
  • the device may be used to introduce or remove molecules at specific locations.
  • FIG. 1 shows a side elevational view of a schematic of a preferred embodiment of the microneedle device 10 in a transdermal application.
  • the device 10 is applied to the skin such that the microneedles 12 penetrate through the stratum corneum and enter the viable epidermis so that the tip of the microneedle at least penetrates into the viable epidermis.
  • drug molecules in a reservoir within the upper portion 11 flow through or around the microneedles and into the viable epidermis, where the drug molecules then diffuse into the dermis for local treatment or for transport through the body.
  • a variety of forces or mechanisms can be employed. These include pressure gradients, concentration gradients, electricity, ultrasound, receptor binding, heat, chemicals, and chemical reactions. Mechanical or other gates in conjunction with the forces and mechanisms described above can be used to selectively control transport of the material.
  • the device should be “user-friendly.” For example, in some transdermal applications, affixing the device to the skin should be relatively simple, and not require special skills.
  • This embodiment of a microneedle may include an array of microneedles attached to a housing containing drug in an internal reservoir, wherein the housing has a bioadhesive coating around the microneedles. The patient can remove a peel-away backing to expose an adhesive coating, and then press the device onto a clean part of the skin, leaving it to administer drug over the course of, for example, several days.
  • Drugs can be proteins, enzymes, polysaccharides, polynucleotide molecules, and synthetic organic and inorganic compounds.
  • a preferred drug is insulin.
  • Representative agents include anti-infectives, hormones, growth regulators, drugs regulating cardiac action or blood flow, and drugs for pain control.
  • the drug can be for local treatment or for regional or systemic therapy. The following are representative examples, and disorders they are used to treat:
  • the rate can be controlled by varying a number of design factors, including the outer diameter of the microneedle, the number and size of pores or channels in each microneedle, the number of microneedles in an array, the magnitude and frequency of application of the force driving the drug through the microneedle and/or the holes created by the microneedles.
  • design factors including the outer diameter of the microneedle, the number and size of pores or channels in each microneedle, the number of microneedles in an array, the magnitude and frequency of application of the force driving the drug through the microneedle and/or the holes created by the microneedles.
  • devices designed to deliver drug at different rates might have more microneedles for more rapid delivery and fewer microneedles for less rapid delivery.
  • a device designed to deliver drug at a variable rate could vary the driving force (e.g., pressure gradient controlled by a pump) for transport according to a schedule which was pre-programmed or controlled by, for example, the user or his doctor.
  • the devices can be affixed to the skin or other tissue to deliver drugs continuously or intermittently, for durations ranging from a few seconds to several hours or days.
  • One of skill in the art can measure the rate of drug delivery for particular microneedle devices using in vitro and in vivo methods known in the art.
  • human cadaver skin mounted on standard diffusion chambers can be used to predict actual rates. See Hadgraft & Guy, eds., Transdermal Drug Delivery: Developmental Issues and Research Initiatives (Marcel Dekker, New York 1989); Bronaugh & Maibach, Percutaneous Absorption, Mechanisms—Methodology—Drug Delivery (Marcel Dekker, New York 1989).
  • a microneedle array is inserted into the stratum corneum; a drug solution is placed in the reservoir of the microneedle device; and samples of the saline solution are taken over time and assayed to determine the rates of drug transport.
  • biodegradable or non-biodegradable microneedles can be used as the entire drug delivery device, where biodegradable microneedles are a preferred embodiment.
  • the microneedles may be formed of a biodegradable polymer containing a dispersion of an active agent for local or systemic delivery. The agent could be released over time, according to a profile determined by the composition and geometry of the microneedles, the concentration of the drug and other factors. In this way, the drug reservoir is within the matrix of one or more of the microneedles.
  • these microneedles may be purposefully sheared off from the substrate after penetrating the biological barrier. In this way, a portion of the microneedles would remain within or on the other side of the biological barrier and a portion of the microneedles and their substrate would be removed from the biological barrier. In the case of skin, this could involve inserting an array into the skin, manually or otherwise breaking off the microneedles tips and then remove the base of the microneedles. The portion of the microneedles which remains in the skin or in or across another biological barrier could then release drug over time according to a profile determined by the composition and geometry of the microneedles, the concentration of the drug and other factors:
  • the microneedles are made of a biodegradable polymer. The release of drug from the biodegradable microneedle tips could be controlled by the rate of polymer degradation. Microneedle tips could release drugs for local or systemic effect, but could also release other agents, such as perfume, insect repellent and sun block.
  • Microneedle shape and content could be designed to control the breakage of microneedles.
  • a notch could be introduced into microneedles either at the time of fabrication or as a subsequent step. In this way, microneedles would preferentially break at the site of the notch.
  • the size and shape of the portion of microneedles which break off could be controlled not only for specific drug release patterns, but also for specific interactions with cells in the body. For example, objects of a few microns in size are known to be taken up by macrophages. The portions of microneedles that break off could be controlled to be bigger or smaller than that to prevent uptake by macrophages or could be that size to promote uptake by macrophages, which could be desirable for delivery of vaccines.
  • One embodiment of the devices described herein may be used to remove material from the body across a biological barrier, i.e. for minimally invasive diagnostic sensing.
  • fluids can be transported from interstitial fluid in a tissue into a reservoir in the upper portion of the device. The fluid can then be assayed while in the reservoir or the fluid can be removed from the reservoir to be assayed, for diagnostic or other purposes.
  • interstitial fluids can be removed from the epidermis across the stratum corneum to assay for glucose concentration, which should be useful in aiding diabetics in determining their required insulin dose.
  • Other substances or properties that would be desirable to detect include lactate (important for athletes), oxygen, pH, alcohol, tobacco metabolites, and illegal drugs (important for both medical diagnosis and law enforcement).
  • the sensing device can be in or attached to one or more microneedles, or in a housing adapted to the substrate.
  • Sensing information or signals can be transferred optically (e.g., refractive index) or electrically (e.g., measuring changes in electrical impedance, resistance, current, voltage, or combination thereof).
  • optically e.g., refractive index
  • electrically e.g., measuring changes in electrical impedance, resistance, current, voltage, or combination thereof.
  • one or more microneedle devices can be used for (1) withdrawal of interstitial fluid, (2) assay of the fluid, and/or (3) delivery of the appropriate amount of a therapeutic agent based on the results of the assay, either automatically or with human intervention.
  • a sensor delivery system may be combined to form, for example, a system which withdraws bodily fluid, measures its glucose content, and delivers an appropriate amount of insulin.
  • the sensing or delivery step also can be performed using conventional techniques, which would be integrated into use of the microneedle device.
  • the microneedle device could be used to withdraw and assay glucose, and a conventional syringe and needle used to administer the insulin, or vice versa.
  • microneedles may be purposefully sheared off from the substrate after penetrating the biological barrier, as described above.
  • the portion of the microneedles which remain within or on the other side of the biological barrier could contain one or more biosensors.
  • the sensor could change color as its output. For microneedles sheared off in the skin, this color change could be observed through the skin by visual inspection or with the aid of an optical apparatus.
  • the microneedles may be used to transmit or transfer other materials and energy forms, such as light, electricity, heat, or pressure.
  • the microneedles could be used to direct light to specific locations within the body, in order that the light can directly act on a tissue or on an intermediary, such as light-sensitive molecules in photodynamic therapy.
  • the microneedles can also be used for aerosolization or delivery for example directly to a mucosal surface in the nasal or buccal regions or to the pulmonary system.
  • microneedle devices disclosed herein also should be useful for controlling transport across tissues other than skin.
  • microneedles could be inserted into the eye across, for example, conjunctiva, sclera, and/or cornea, to facilitate delivery of drugs into the eye.
  • microneedles inserted into the eye could facilitate transport of fluid out of the eye, which may be of benefit for treatment of glaucoma.
  • Microneedles may also be inserted into the buccal (oral), nasal, vaginal, or other accessible mucosa to facilitate transport into, out of, or across those tissues.
  • a drug may be delivered across the buccal mucosa for local treatment in the mouth or for systemic uptake and delivery.
  • microneedle devices may be used internally within the body on, for example, the lining of the gastrointestinal tract to facilitate uptake of orally-ingested drugs or the lining of blood vessels to facilitate penetration of drugs into the vessel wall.
  • cardiovascular applications include using microneedle devices to facilitate vessel distension or immobilization, similarly to a stent, wherein the microneedles/substrate can function as a “staple-like” device to penetrate into different tissue segments and hold their relative positions for a period of time to permit tissue regeneration. This application would be particularly useful with biodegradable devices. These uses may involve invasive procedures to introduce the microneedle devices into the body or could involve swallowing, inhaling, injecting or otherwise introducing the devices in a non-invasive or minimally-invasive manner.
  • a chromium masking material was deposited onto silicon wafers and patterned into dots having a diameter approximately equal to the base of the desired microneedles.
  • the wafers were then loaded into a reactive ion etcher and subjected to a carefully controlled plasma based on fluorine/oxygen chemistries to etch very deep, high aspect ratio valleys into the silicon. Those regions protected by the metal mask remain and form the microneedles.
  • ⁇ 100>-oriented, prime grade, 450-550 ⁇ m thick, 10-15 ⁇ -cm silicon wafers (Nova Electronic Materials Inc., Richardson, Tex.) were used as the starting material.
  • the wafers were cleaned in a solution of 5 parts by volume deionized water, 1 part 30% hydrogen peroxide, and 1 part 30% ammonium hydroxide (J. T. Baker, Phillipsburg, N.J.) at approximately 80° C. for 15 minutes, and then dried in an oven (Blue M Electric, Watertown, Wis.) at 150° C. for 10 minutes.
  • chromium (Mat-Vac Technology, Flagler Beach, Fla.) was deposited onto the wafers using a DC-sputterer (601 Sputtering System, CVC Products, Rochester, N.Y.). The chromium layer was patterned into 20 by 20 arrays of 80 ⁇ m diameter dots with 150 ⁇ m center-to-center spacing using the lithographic process described below.
  • a layer of photosensitive material (1827 photoresist, Shipley, Marlborough, Mass.) was deposited onto the chromium layer covering the silicon wafers.
  • a standard lithographic mask (Telic, Santa Monica, Calif.) bearing the appropriate dot array pattern was positioned on top of the photoresist layer.
  • the wafer and photoreist were then exposed to ultraviolet (UV) Light through the mask by means of an optical mask aligner (Hybralign Series 500, Optical Associates, Inc., Milpitas, Calif.).
  • the exposed photoresist was removed by soaking the wafers in a liquid developer (354 developer, Shipley, Marlborough, Mass.) leaving the desired dot array of photoresist on the chromium layer.
  • the wafers were dipped into a chromium etchant (CR-75; Cyanteck Fremont, Calif.), which etched the chromium that had been exposed during the photolithography step, leaving dot arrays of chromium (covered with photoresist) on the surface of the silicon wafer.
  • a chromium etchant CR-75; Cyanteck Fremont, Calif.
  • the photoresist still present on the chromium dots formed the masks needed for fabrication of the microneedles, described below.
  • the microneedles were fabricated using a reactive ion etching techniques based on the Black Silicon Method developed at the University of Twente.
  • the patterned wafers were etched in a reactive ion etcher (700 series wafer/batch Plasma Processing System, Plasma Therm, St. Russia, Fla.) with means for ensuring good thermal contact between the wafers and the underlying platen (Apiezon N, K. J. Lesker, Clairton, Pa.).
  • the wafers were etched using the following gases and conditions: SF 6 (20 standard cubic centimeters per minute) and O 2 (15 standard cubic centimeters per minute) at a pressure of 150 mTorr and a power of 150 W for a run time of approximately 250 minutes.
  • microfabricated microneedles were made using a deep plasma etching technique. Their ability to penetrate human skin without breaking was tested and the resulting changes in transdermal transport were measured.
  • Arrays of microneedles were fabricated having extremely sharp tips (radius of curvature less than 1 ⁇ m) which facilitate easy piercing into the skin, and are approximately 150 ⁇ m long. Because the skin surface is not flat due to dermatoglyphics and hair, the full length of these microneedles will not penetrate the skin. All experiments were performed at room temperature (23 ⁇ 2° C.).
  • microneedles to pierce skin without breaking was then tested. Insertion of the arrays into skin required only gentle pushing. Inspection by light and electron microscopy showed that more than 95% of microneedles within an array pierced across the stratum corneum of the epidermis samples. Moreover, essentially all of the microneedles that penetrated the epidermis remained intact. On those very few which broke, only the top 5-10 ⁇ m was damaged. Microneedle arrays could also be removed without difficulty or additional damage, as well as re-inserted into skin multiple times.
  • calcein permeability of human epidermis with and without inserted microneedle arrays was measured. Calcein crosses skin very poorly under normal circumstances and therefore represents an especially difficult compound to deliver. As expected, passive permeability of calcein across unaltered skin was very low, indicating that the epidermis samples were intact.
  • Insertion of microneedles into skin was capable of dramatically increasing permeability to calcein.
  • calcein permeability was increased by more than 1000-fold.
  • insertion of a microneedle array for 1 h, followed by its removal increased skin permeability by about 25,000-fold.
  • Permeabilities for skin with microneedles inserted and then removed are higher than for skin with microneedles remaining embedded probably because the microneedles themselves or the silicon plate supporting the array may block access to the microscopic holes created in the skin. Light microscopy showed that the holes which remained in the skin after microneedles were removed were approximately 1 ⁇ m in size.
  • microneedles were easily inserted into the skin of the forearm or hand. Moreover, insertion of microneedle arrays was never reported to be painful, but sometimes elicited a mild “wearing” sensation described as a weak pressure or the feeling of a piece of tape affixed to the skin. Although transport experiments were not performed in vivo, skin electrical resistance was measured before and after microneedle insertion.
  • Microneedles caused a 50-fold drop in skin resistance, a drop similar to that caused by the insertion of a 30-gauge “macroneedle.” Inspection of the site immediately after microneedle insertion showed no holes visible by light microscopy. No erythema, edema or other reaction to microneedles was observed over the hours and days which followed. This indicates that microneedle arrays can permeabilize skin in human subjects in a non-painful and safe manner.
  • FIGS. 5 a - d Three-dimensional arrays of microtubes were fabricated from silicon, using deep reactive ion etching combined with a modified black silicon process in a conventional reactive ion etcher.
  • the fabrication process is illustrated in FIGS. 5 a - d .
  • arrays of 40 ⁇ m diameter circular holes 32 were patterned through photoresist 34 into a 1 ⁇ m thick SiO 2 layer 36 on a two inch silicon wafer 38 ( FIG. 5 a ).
  • the wafer 38 was then etched using deep reactive ion etching (DRIE) (Laermer, et al., “Bosch Deep Silicon Etching: Improving Uniformity and Etch Rate for Advanced MEMS Applications,” Micro Electro Mechanical Systems , Orlando, Fla., USA (Jan.
  • DRIE deep reactive ion etching
  • ICP inductively coupled plasma
  • the deep silicon etch was stopped after the holes 40 are approximately 200 ⁇ m deep into the silicon substrate 38 ( FIG. 5 b ) and the photoresist 34 was removed.
  • a second photolithography step patterned the remaining SiO 2 layer 36 into circles concentric to the holes, thus leaving ring shaped oxide masks 34 surrounding the holes ( FIG. 5 c ).
  • the photoresist 34 was then removed and the wafer 38 was again deep silicon etched, while simultaneously the holes 40 were etched completely through the wafer 38 (inside the SiO 2 ring) and the silicon was etched around the SiO 2 ring 38 leaving a cylinder 42 ( FIG. 5 d ).
  • the resulting tubes were 150 ⁇ m in height, with an outer diameter of 80 ⁇ m, an inner diameter of 40 ⁇ m, and a tube center-to-center spacing of 300 ⁇ m.
  • Hollow metal microtubes were prepared without dry silicon etching, using a thick, photo-defined mold of epoxy. The sequences are illustrated in FIGS. 6 a - e .
  • a thick layer of SU-8 epoxy 44 was spin cast onto a silicon or glass substrate 46 that had been coated with 30 nm of titanium 48 , the sacrificial layer.
  • Arrays of cylindrical holes 49 were then photolithographically defined through an epoxy layer 44 , typically 150 ⁇ m thick ( FIG. 6 a ).
  • the sacrificial layer then was partially removed using a wet etching solution containing hydrofluoric acid and water at the bottom of the cylindrical holes in the SU-8 photoresist 46 ( FIG. 6 b ).
  • a seed layer of Ti/Cu/Ti (30 nm/200 nm/30 nm) 48 was then conformally DC sputter-deposited onto the upper surface of the epoxy mold and onto the sidewalls of the cylindrical holes 49 ( FIG. 6 c ). As shown in FIG. 6 c , the seed layer 48 was electrically isolated from the substrate. Subsequently, NiFe was electroplated onto the seed layer 48 ( FIG. 6 d ), the epoxy 44 was removed from the substrate, and the surrounding epoxy 44 was removed ( FIG. 6 e ). The resulting microtubes are 200 ⁇ m in height with an outer diameter of 80 ⁇ m, an inner diameter of 60 ⁇ m, and a tube center-to-center spacing of 150 ⁇ m. The holes in the interior of the microtubes protrude through the base metal supporting the tubes.
  • a micromold having tapered walls was fabricated by molding a preexisting 3-D array of microneedles, i.e. the mold-insert, and subsequently removing the mold insert.
  • the micromold was then surface plated in a manner similar to that for the microtubes described in Example 4. The fabrication sequence is illustrated in FIGS. 7 a - 7 d.
  • an array of solid silicon microneedles 50 were prepared as described in Henry, et al., “Micromachined Needles for the Transdermal Delivery of Drugs,” Micro Electro Mechanical Systems , Heidelberg, Germany, Jan. 26-29, pp. 494-498 (1998).
  • a layer of epoxy 52 (SU-8) was spin cast onto the microneedle array to completely blanket the array ( FIG. 7 a ).
  • the epoxy 52 settled during pre-bake to create a planar surface above the tips of the microneedles 50 .
  • the epoxy 52 was then fully pre-baked, photolithographically cross-linked, and post-baked.
  • the upper surface of the epoxy 52 was etched away using an O 2 /CHF 3 plasma until approximately 1 to 2 ⁇ m of the needle tips 54 were exposed, protruding from the epoxy 52 ( FIG. 7 b ).
  • the silicon was then selectively removed by using a SF 6 plasma ( FIG. 7 c ).
  • the remaining epoxy mold 52 provided a negative of the microneedles with a small diameter hole where the tip of the silicon needle protruded.
  • a seed layer of Ti—Cu—Ti 54 was conformally sputter-deposited onto the top and sidewalls of the epoxy micromold 52 .
  • NiFe was then electroplated onto the seed layer 54 ( FIG. 7 c ).
  • the epoxy was removed using an O 2 /CHF 3 plasma, leaving a 20 ⁇ 20 array of NiFe hollow metal microneedles 54 ( FIG. 7 d ).
  • the microneedles 54 were 150 ⁇ m in height with a base diameter of 80 ⁇ m, a tip diameter of 10 ⁇ m, and a needle to needle spacing of 150 ⁇ m.
  • a micromold having tapered walls was fabricated by use of laser ablation techniques, as shown in FIGS. 8 a - d .
  • a laser-ablatable polymer sheet 60 such as KAPTONTM polymide approximately 150 microns in thickness was optionally laminated to a thin (10-30 micron) metal sheet 62 such as titanium ( FIG. 8 a ).
  • a tapered hole 64 was formed in the metal/polymer laminate 60 / 62 using a laser technique such as excimer laser ablation ( FIG. 8 b ). The entry hole of the laser spot was on the metal side 62 , and a through hole was made through both the metal sheet and the polymer film.
  • the through hole 64 was tapered in combination with either defocusing or appropriate substrate motion to create a taper such that the wide end of the hole 64 (typically 40-50 microns) was on the metal side 62 and the narrow end of the hole 64 (typically 10-20 microns) was on the polymer 60 side.
  • a thin layer of metal 66 e.g. titanium, of thickness 0.1 micron was then deposited, e.g., using a sputter-deposition technique, in such a way that the metal 66 deposited on the metal film side and coated the polymer sidewalls, but did not coat the polymer 60 side of the laminate ( FIG. 8 c ).
  • Electrodeposition of metal 68 e.g., gold, to a thickness of 1-5 microns was then performed on the titanium-coated metal surface 66 , and polymer sidewalls curved section of 60 next to 64 . Finally, the polymer 60 was removed, using e.g. an oxygen plasma, to form the completed microneedles ( FIG. 8 d ).
  • polymer removal methods such as thermal, solvent, aqueous, or phodegradation followed by solvent or aqueous removal, are also possible if the polymer material is chosen appropriately (e.g., a photoresist resin).
  • FIGS. 9 a - 9 f Formation of a microneedle by embossing is shown in FIGS. 9 a - 9 f .
  • a polymeric layer 70 ( FIG. 9 a ) is embossed by a solid microneedle or microneedle array 72 ( FIG. 9 b ).
  • the array 72 is removed ( FIG. 9 c ), and the layer 70 is etched from the non-embossed side 74 until the embossed cavity 76 is exposed ( FIG. 9 d ).
  • a metallic layer 78 is then deposited on the embossed side and the sidewalls, but not on the non-embossed side 74 ( FIG. 9 e ).
  • This layer 78 is optionally thickened by electrodeposition of an additional metal layer 80 on top of it ( FIG. 9 e ).
  • the polymer layer 70 is then removed to form the microneedles 78 / 80 ( FIG. 9 f ).
  • microneedles and microtubes were evaluated to determine their suitability for these functions.
  • Hollow metal and silicon microneedles produced as described in Examples 3-5, were inserted through human skin epidermis with no apparent clogging of the needle bores. Scanning electron microscopy of a hollow metal (NiFe) microneedle penetrating up through the underside of human epidermis showed the microneedle remains intact, with the tip free of debris. Similarly, silicon microneedles, metal microneedles, and metal microtubes were successfully inserted through human skin. Also, the hollow microneedles were shown to permit the flow of water through their bores.
  • the transdermal delivery of calcein, insulin, bovine serum albumin and nanoparticles was measured. Delivery refers to the ability to transport these compounds from the stratum corneum side of the epidermis to the viable epidermis side. This is the direction of transport associated with delivering drugs into the body. Removal of calcein was also measured. Removal refers to the ability to transport calcein from the viable epidermis side of the epidermis to the stratum corneum side. This is the direction of transport associated with removing from the body compounds found in the body, such as glucose.

Abstract

Microneedle devices are provided for transport of therapeutic and biological molecules across tissue barriers and for use as microflameholders. In a preferred embodiment for transport across tissue, the microneedles are formed of a biodegradable polymer. Methods of making these devices, which can include hollow and/or porous microneedles, are also provided. A preferred method for making a microneedle includes forming a micromold having sidewalls which define the outer surface of the microneedle, electroplating the sidewalls to form the hollow microneedle, and then removing the micromold from the microneedle. In a preferred method of use, the microneedle device is used to deliver fluid material into or across a biological barrier from one or more chambers in fluid connection with at least one of the microneedles. The device preferably further includes a means for controlling the flow of material through the microneedles. Representative examples of these means include the use of permeable membranes, fracturable impermeable membranes, valves, and pumps.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This is a continuation-in-part of U.S. Ser. No. 09/095,221, filed Jun. 10, 1998.
  • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
  • The government has certain rights in this invention by virtue of Grant Number BES-9813321 awarded by the U.S. National Science Foundation to Mark R. Prausnitz, and support from the Defense Advanced Research Projects Agency (DARPA) to Mark G. Allen.
  • BACKGROUND OF THE INVENTION
  • This invention is generally in the field of devices for the transport of therapeutic or biological molecules across tissue barriers, such as for drug delivery.
  • Numerous drugs and therapeutic agents have been developed in the battle against disease and illness. However, a frequent limitation of these drugs is their delivery: how to transport drugs across biological barriers in the body (e.g., the skin, the oral mucosa, the blood-brain barrier), which normally do not transport drugs at rates that are therapeutically useful or optimal.
  • Drugs are commonly administered orally as pills or capsules. However, many drugs cannot be effectively delivered in this manner, due to degradation in the gastrointestinal tract and/or elimination by the liver. Moreover, some drugs cannot effectively diffuse across the intestinal mucosa. Patient compliance may also be a problem, for example, in therapies requiring that pills be taken at particular intervals over a prolonged time.
  • Another common technique for delivering drugs across a biological barrier is the use of a needle, such as those used with standard syringes or catheters, to transport drugs across (through) the skin. While effective for this purpose, needles generally cause pain; local damage to the skin at the site of insertion; bleeding, which increases the risk of disease transmission; and a wound sufficiently large to be a site of infection. The withdrawal of bodily fluids, such as for diagnostic purposes, using a conventional needle has these same disadvantages. Needle techniques also generally require administration by one trained in its use. The needle technique also is undesirable for long term, controlled continuous drug delivery.
  • Similarly, current methods of sampling biological fluids are invasive and suffer from the same disadvantages. For example, needles are not preferred for frequent routine use, such as sampling of a diabetic's blood glucose or delivery of insulin, due to the vascular damage caused by repeated punctures. No alternative methodologies are currently in use. Proposed alternatives to the needle require the use of lasers or heat to create a hole in the skin, which is inconvenient, expensive, or undesirable for repeated use.
  • An alternative delivery technique is the transdermal patch, which usually relies on diffusion of the drug across the skin. However, this method is not useful for many drugs, due to the poor permeability (i.e. effective barrier properties) of the skin. The rate of diffusion depends in part on the size and hydrophilicity of the drug molecules and the concentration gradient across the stratum corneum. Few drugs have the necessary physiochemical properties to be effectively delivered through the skin by passive diffusion. Iontophoresis, electroporation, ultrasound, and heat (so-called active systems) have been used in an attempt to improve the rate of delivery. While providing varying degrees of enhancement, these techniques are not suitable for all types of drugs, failing to provide the desired level of delivery. In some cases, they are also painful and inconvenient or impractical for continuous controlled drug delivery over a period of hours or days. Attempts have been made to design alternative devices for active transfer of drugs, or analyte to be measured, through the skin.
  • For example, U.S. Pat. No. 5,879,326 to Godshall et al. and PCT WO 96/37256 by Silicon Microdevices, Inc. disclose a transdermal drug delivery apparatus that includes a cutter portion having a plurality of microprotrusions, which have straight sidewalls, extending from a substrate that is in communication with a drug reservoir. In operation, the microprotrusions penetrate the skin until limited by a stop region of the substrate and then are moved parallel to the skin to create incisions. Because the microprotrusions are dragged across the skin, the device creates a wound sufficiently large to be a site of infection. Channels in the substrate adjacent to the microprotrusions allow drug from the reservoir to flow to the skin near the area disrupted by the microprotrusions. Merely creating a wound, rather than using a needle which conveys drug through an enclosed channel into the site of administration, also creates more variability in dosage.
  • U.S. Pat. No. 5,250,023 to Lee et al. discloses a transdermal drug delivery device, which includes a plurality of skin needles having a diameter in the range of 50 to 400 μm. The skin needles are supported in a water-swellable polymer substrate through which a drug solution permeates to contact the surface of the skin. An electric current is applied to the device to open the pathways created by the skin needles, following their withdrawal from the skin upon swelling of the polymer substrate.
  • PCT WO 93/17754 by Gross et al. discloses another transdermal drug delivery device that includes a housing having a liquid drug reservoir and a plurality of tubular elements for transporting liquid drug into the skin. The tubular elements may be in the form of hollow needles having inner diameters of less than 1 mm and an outer diameter of 1.0 mm.
  • While each of these devices has potential use, there remains a need for better drug delivery devices, which make smaller incisions, deliver drug with greater efficiency (greater drug delivery per quantity applied) and less variability of drug administration, and/or are easier to use.
  • It is therefore an object of the present invention to provide a microneedle device for relatively painless, controlled, safe, convenient transdermal delivery of a variety of drugs.
  • It is another object of the present invention to provide a microneedle device for controlled sampling of biological fluids in a minimally-invasive, painless, and convenient manner.
  • It is still another object of the present invention to provide a hollow microneedle array for use in delivery or sensing of drugs or biological fluids or molecules.
  • SUMMARY OF THE INVENTION
  • Microneedle devices for transport of molecules, including drugs and biological molecules, across tissue, and methods for manufacturing the devices, are provided. The microneedle devices permit drug delivery or removal of body fluids at clinically relevant rates across skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue. Microneedles can be formed of biodegradable or non-biodegradable polymeric materials or metals. In a preferred embodiment, the microneedles are formed of a biodegradable polymer. In another preferred embodiment, the device includes a means for temporarily securing the microneedle device to the biological barrier to facilitate transport.
  • Methods are provided for making porous or hollow microneedles. A preferred method for making a microneedle includes forming a micromold having sidewalls which define the outer surface of the microneedle. The micromold can be formed, for example, by photolithographically defining one or more holes in a substrate, or by laser based cutting (either serially or by using lithographic projection), or by using a mold-insert. In a preferred embodiment, the method includes electroplating the sidewalls to form the hollow microneedle, and then removing the micromold from the microneedle.
  • The microneedle device is useful for delivery of fluid material into or across a biological barrier wherein the fluid material is delivered from one or more chambers in fluid connection with at least one of the microneedles. The device preferably further includes a means for controlling the flow of material through the microneedles. Representative examples of these means include the use of permeable membranes, fracturable impermeable membranes, valves, and pumps, and electrical means.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 a is a side elevational view of a preferred embodiment of the microneedle device inserted into human skin. FIG. 1 b is a diagram of one embodiment of microneedles.
  • FIGS. 2 a-e are side cross-sectional views of a method for making microneedles.
  • FIGS. 3 a-g are side cross-sectional views of a method for making a hollow microneedle.
  • FIGS. 4 a through 4 d are side cross-sectional views illustrating a preferred method for making hollow microneedles.
  • FIGS. 5 a through 5 d are side cross-sectional views illustrating a preferred method for making hollow silicon microtubes.
  • FIGS. 6 a through 6 e are side cross-sectional views illustrating a preferred method for making hollow metal microtubes.
  • FIGS. 7 a through 7 d are side cross-sectional views illustrating a preferred method for making tapered metal microneedles.
  • FIGS. 8 a through 8 d are side cross-sectional views illustrating a method for making tapered microneedles using laser-formed molds.
  • FIGS. 9 a through 9 f are side cross-sectional views illustrating a second method for making tapered microneedles using laser-formed molds.
  • DETAILED DESCRIPTION OF THE INVENTION 1. Biological Barriers
  • The devices disclosed herein are useful in transport of material into or across biological barriers including the skin (or parts thereof); the blood-brain barrier; mucosal tissue (e.g., oral, nasal, ocular, vaginal, urethral, gastrointestinal, respiratory); blood vessels; lymphatic vessels; or cell membranes (e.g., for the introduction of material into the interior of a cell or cells). The biological barriers can be in humans or other types of animals, as well as in plants, insects, or other organisms, including bacteria, yeast, fungi, and embryos.
  • The microneedle devices can be applied to tissue internally with the aid of a catheter or laparoscope. For certain applications, such as for drug delivery to an internal tissue, the devices can be surgically implanted.
  • The microneedle device disclosed herein is typically applied to skin. The stratum corneum is the outer layer, generally between 10 and 50 cells, or between 10 and 20 μm thick. Unlike other tissue in the body, the stratum corneum contains “cells” (called keratinocytes) filled with bundles of cross-linked keratin and keratohyalin surrounded by an extracellular matrix of lipids. It is this structure that is believed to give skin its barrier properties, which prevents therapeutic transdermal administration of many drugs. Below the stratum corneum is the viable epidermis, which is between 50 and 100 μm thick. The viable epidermis contains no blood vessels, and it exchanges metabolites by diffusion to and from the dermis. Beneath the viable epidermis is the dermis, which is between 1 and 3 mm thick and contains blood vessels, lymphatics, and nerves.
  • 2. The Microneedle Device
  • The microneedle devices disclosed herein include a substrate; one or more microneedles; and, optionally, a reservoir for delivery of drugs or collection of analyte, as well as pump(s), sensor(s), and/or microprocessor(s) to control the interaction of the foregoing.
  • a. Substrate
  • The substrate of the device can be constructed from a variety of materials, including metals, ceramics, semiconductors, organics, polymers, and composites. The substrate includes the base to which the microneedles are attached or integrally formed. A reservoir may also be attached to the substrate.
  • b. Microneedle
  • The microneedles of the device can be constructed from a variety of materials, including metals, ceramics, semiconductors, organics, polymers, and composites. Preferred materials of construction include pharmaceutical grade stainless steel, gold, titanium, nickel, iron, gold, tin, chromium, copper, alloys of these or other metals, silicon, silicon dioxide, and polymers. Representative biodegradable polymers include polymers of hydroxy acids such as lactic acid and glycolic acid polylactide, polyglycolide, polylactide-co-glycolide, and copolymers with PEG, polyanhydrides, poly(ortho)esters, polyurethanes, poly(butyric acid), poly(valeric acid), and poly(lactide-co-caprolactone). Representative non-biodegradable polymers include polycarbonate, polymethacrylic acid, ethylenevinyl acetate, polytetrafluoroacetate (TEFLON™), and polyesters.
  • Generally, the microneedles should have the mechanical strength to remain intact for delivery of drugs, or serve as a conduit for the collection of biological fluid, while being inserted into the skin, while remaining in place for up to a number of days, and while being removed. In embodiments where the microneedles are formed of biodegradable polymers, however, this mechanical requirement is less stringent, since the microneedles or tips thereof can break off, for example in the skin, and will biodegrade. Nonetheless, even a biodegradable microneedle still needs to remain intact at least long enough for the microneedle to serve its intended purpose (e.g, its conduit function). Therefore, biodegradable microneedles can provide an increased level of safety, as compared to nonbiodegradable ones. The microneedles should be sterilizable using standard methods.
  • The microneedles can be formed of a porous solid, with or without a sealed coating or exterior portion, or hollow. As used herein, the term “porous” means having pores or voids throughout at least a portion of the microneedle structure, sufficiently large and sufficiently interconnected to permit passage of fluid and/or solid materials through the microneedle. As used herein, the term “hollow” means having one or more substantially annular bores or channels through the interior of the microneedle structure, having a diameter sufficiently large to permit passage of fluid and/or solid materials through the microneedle. The annular bores may extend throughout all or a portion of the needle in the direction of the tip to the base, extending parallel to the direction of the needle or branching or exiting at a side of the needle, as appropriate. A solid or porous microneedle can be hollow. One of skill in the art can select the appropriate porosity and/or bore features required for specific applications. For example, one can adjust the pore size or bore diameter to permit passage of the particular material to be transported through the microneedle device.
  • The microneedles can have straight or tapered shafts. A hollow microneedle that has a substantially uniform diameter, which needle does not taper to a point, is referred to herein as a “microtube.” As used herein, the term “microneedle” includes both microtubes and tapered needles unless otherwise indicated. In a preferred embodiment, the diameter of the microneedle is greatest at the base end of the microneedle and tapers to a point at the end distal the base. The microneedle can also be fabricated to have a shaft that includes both a straight (untapered) portion and a tapered portion.
  • The microneedles can be formed with shafts that have a circular cross-section in the perpendicular, or the cross-section can be non-circular. For example, the cross-section of the microneedle can be polygonal (e.g. star-shaped, square, triangular), oblong, or another shape. The shaft can have one or more bores. The cross-sectional dimensions typically are between about 10 nm and 1 mm, preferably between 1 micron and 200 microns, and more preferably between 10 and 100 μm. The outer diameter is typically between about 10 μm and about 100 μm, and the inner diameter is typically between about 3 μm and about 80 μm.
  • The length of the microneedles typically is between about 1 μm and 1 mm, preferably between 10 microns and 500 microns, and more preferably between 30 and 200 μm. The length is selected for the particular application, accounting for both an inserted and uninserted portion. An array of microneedles can include a mixture of microneedles having, for example, various lengths, outer diameters, inner diameters, cross-sectional shapes, and spacings between the microneedles.
  • The microneedles can be oriented perpendicular or at an angle to the substrate. Preferably, the microneedles are oriented perpendicular to the substrate so that a larger density of microneedles per unit area of substrate can be provided. An array of microneedles can include a mixture of microneedle orientations, heights, or other parameters.
  • In a preferred embodiment of the device, the substrate and/or microneedles, as well as other components, are formed from flexible materials to allow the device to fit the contours of the biological barrier, such as the skin, vessel walls, or the eye, to which the device is applied. A flexible device will facilitate more consistent penetration during use, since penetration can be limited by deviations in the attachment surface. For example, the surface of human skin is not flat due to dermatoglyphics (i.e. tiny wrinkles) and hair.
  • c. Reservoir
  • The microneedle device may include a reservoir in communication with the microneedles. The reservoir can be attached to the substrate by any suitable means. In a preferred embodiment, the reservoir is attached to the back of the substrate (opposite the microneedles) around the periphery, using an adhesive agent (e.g., glue). A gasket may also be used to facilitate formation of a fluid-tight seal.
  • In a preferred embodiment, the reservoir contains drug, for delivery through the microneedles. The reservoir may be a hollow vessel, a porous matrix, or a solid form including drug which is transported therefrom. The reservoir can be formed from a variety of materials that are compatible with the drug or biological fluid contained therein. Preferred materials include natural and synthetic polymers, metals, ceramics, semiconductors, organics, and composites.
  • The microneedle device can include one or a plurality of chambers for storing materials to be delivered. In the embodiment having multiple chambers, each can be in fluid connection with all or a portion of the microneedles of the device array. In one embodiment, at least two chambers are used to separately contain drug (e.g., a lyophilized drug, such as a vaccine) and an administration vehicle (e.g., saline) in order to prevent or minimize degradation during storage. Immediately before use, the contents of the chambers are mixed. Mixing can be triggered by any means, including, for example, mechanical disruption (i.e. puncturing or breaking), changing the porosity, or electrochemical degradation of the walls or membranes separating the chambers. In another embodiment, a single device is used to deliver different drugs, which are stored separately in different chambers. In this embodiment, the rate of delivery of each drug can be independently controlled.
  • In a preferred embodiment, the reservoir should be in direct contact with the microneedles and have holes through which drug could exit the reservoir and flow into the interior of hollow or porous microneedles. In another preferred embodiment, the reservoir has holes which permit the drug to transport out of the reservoir and onto the skin surface. From there, drug is transported into the skin, either through hollow or porous microneedles, along the sides of solid microneedles, or through pathways created by microneedles in the skin.
  • d. Transport Control Components
  • The microneedle device also must be capable of transporting material across the barrier at a useful rate. For example, the microneedle device must be capable of delivering drug across the skin at a rate sufficient to be therapeutically useful. The device may include a housing with microelectronics and other micromachined structures to control the rate of delivery either according to a preprogrammed schedule or through active interface with the patient, a healthcare professional, or a biosensor. The rate can be controlled by manipulating a variety of factors, including the characteristics of the drug formulation to be delivered (e.g., its viscosity, electric charge, and chemical composition); the dimensions of each microneedle (e.g., its outer diameter and the area of porous or hollow openings); the number of microneedles in the device; the application of a driving force (e.g., a concentration gradient, a voltage gradient, a pressure gradient); and the use of a valve.
  • The rate also can be controlled by interposing between the drug in the reservoir and the opening(s) at the base end of the microneedle polymeric or other materials selected for their diffusion characteristics. For example, the material composition and layer thickness can be manipulated using methods known in the art to vary the rate of diffusion of the drug of interest through the material, thereby controlling the rate at which the drug flows from the reservoir through the microneedle and into the tissue.
  • Transportation of molecules through the microneedles can be controlled or monitored using, for example, various combinations of valves, pumps, sensors, actuators, and microprocessors. These components can be produced using standard manufacturing or microfabrication techniques. Actuators that may be useful with the microneedle devices disclosed herein include micropumps, microvalves, and positioners. In a preferred embodiment, a microprocessor is programmed to control a pump or valve, thereby controlling the rate of delivery.
  • Flow of molecules through the microneedles can occur based on diffusion, capillary action, or can be induced using conventional mechanical pumps or nonmechanical driving forces, such as electroosmosis or electrophoresis, or convection. For example, in electroosmosis, electrodes are positioned on the biological barrier surface, one or more microneedles, and/or the substrate adjacent the needles, to create a convective flow which carries oppositely charged ionic species and/or neutral molecules toward or into the biological barrier. In a preferred embodiment, the microneedle device is used in combination with another mechanism that enhances the permeability of the biological barrier, for example by increasing cell uptake or membrane disruption, using electric fields, ultrasound, chemical enhancers, viruses, pH, heat and/or light.
  • Passage of the microneedles, or drug to be transported via the microneedles, can be manipulated by shaping the microneedle surface, or by selection of the material forming the microneedle surface (which could be a coating rather than the microneedle per se). For example, one or more grooves on the outside surface of the microneedles can be used to direct the passage of drug, particularly in a liquid state. Alternatively, the physical surface properties of the microneedle could be manipulated to either promote or inhibit transport of material along the microneedle surface, such as by controlling hydrophilicity or hydrophobicity.
  • The flow of molecules can be regulated using a wide range of valves or gates. These valves can be the type that are selectively and repeatedly opened and closed, or they can be single-use types. For example, in a disposable, single-use drug delivery device, a fracturable barrier or one-way gate may be installed in the device between the reservoir and the opening of the microneedles. When ready to use, the barrier can be broken or gate opened to permit flow through the microneedles. Other valves or gates used in the microneedle devices can be activated thermally, electrochemically, mechanically, or magnetically to selectively initiate, modulate, or stop the flow of molecules through the needles. In a preferred embodiment, flow is controlled by using a rate-limiting membrane as a “valve.”
  • The microneedle devices can further include a flowmeter or other means to monitor flow through the microneedles and to coordinate use of the pumps and valves.
  • e. Sensors
  • Useful sensors may include sensors of pressure, temperature, chemicals, and/or electro-magnetic fields. Biosensors can be located on the microneedle surface, inside a hollow or porous microneedle, or inside a device in communication with the body tissue via the microneedle (solid, hollow, or porous). These microneedle biosensors can include four classes of principal transducers: potentiometric, amperometric, optical, and physiochemical. An amperometric sensor monitors currents generated when electrons are exchanged between a biological system and an electrode. Blood glucose sensors frequently are of this type.
  • The microneedle may function as a conduit for fluids, solutes, electric charge, light, or other materials. In one embodiment, hollow microneedles can be filled with a substance, such as a gel, that has a sensing functionality associated with it. In an application for sensing based on binding to a substrate or reaction mediated by an enzyme, the substrate or enzyme can be immobilized in the needle interior, which would be especially useful in a porous needle to create an integral needle/sensor.
  • Wave guides can be incorporated into the microneedle device to direct light to a specific location, or for dection, for example, using means such as a pH dye for color evaluation. Similarly, heat, electricity, light or other energy forms may be precisely transmitted to directly stimulate, damage, or heal a specific tissue or intermediary (e.g., tattoo remove for dark skinned persons), or diagnostic purposes, such as measurement of blood glucose based on IR spectra or by chromatographic means, measuring a color change in the presence of immobilized glucose oxidase in combination with an appropriate substrate.
  • f. Attachment Features
  • A collar or flange also can be provided with the device, for example, around the periphery of the substrate or the base. It preferably is attached to the device, but alternatively can be formed as integral part of the substrate, for example by forming microneedles only near the center of an “oversized” substrate. The collar can also emanate from other parts of the device. The collar can provide an interface to attach the microneedle array to the rest of the device, and can facilitate handling of the smaller devices.
  • In a preferred embodiment, the microneedle device includes an adhesive to temporarily secure the device to the surface of the biological barrier. The adhesive can be essentially anywhere on the device to facilitate contact with the biological barrier. For example, the adhesive can be on the surface of the collar (same side as microneedles), on the surface of the substrate between the microneedles (near the base of the microneedles), or a combination thereof.
  • g. Transdermal Microneedle Device
  • FIG. 1 a is a side elevational view of a schematic of a preferred embodiment of the microneedle device inserted into skin. The device 10 includes an upper portion or substrate 11 from which a plurality of microneedles 12 protrude. The height of the upper portion 11 is between about 1 μm and 1 cm, and the width of the upper portion is between about 1 mm and 10 cm. The upper portion 11 of the device can be solid or hollow, and may include multiple compartments. In a preferred embodiment for drug delivery, the upper portion 11 contains one or more drugs to be delivered. It is also preferred that the upper portion include one or more sensors and/or an apparatus (e.g., pump or electrode) to drive (provide/direct the force) transport of the drug or other molecules.
  • The height (or length) of the microneedles 12 generally is between about 1 μm and 1 mm. The diameter and length both affect pain as well as functional properties of the needles. In transdermal applications, the “insertion depth” of the microneedles 12 is preferably less than about 100 μm, more preferably about 30 μm, so that insertion of the microneedles 12 into the skin through the stratum corneum 14 does not penetrate past the epidermis 16 into the dermis 18 (as described below), thereby avoiding contacting nerves and reducing the potential for causing pain. In such applications, the actual length of the microneedles may be longer, since the portion of the microneedles distal the tip may not be inserted into the skin; the uninserted length depends on the particular device design and configuration. The actual (overall) height or length of microneedles 12 should be equal to the insertion depth plus the uninserted length.
  • The diameter of each microneedle 12 generally is between about 10 nm and 1 mm, and preferably leaves a residual hole (following microneedle insertion and withdrawal) of less than about 1 μm, to avoid making a hole which would allow bacteria to enter the penetration wound. The actual microneedle diameter should be larger than 1 μm, since the hole likely will contract following withdrawal of the microneedle. The diameter of microneedle 12 more preferably is between about 1 μm and 100 μm. Larger diameter and longer microneedles are acceptable, so long as the microneedle can penetrate the biological barrier to the desired depth and the hole remaining in the skin or other tissue following withdrawal of the microneedle is sufficiently small, preferably small enough to exclude bacterial entry. The microneedles 12 can be solid or porous, and can include one or more bores connected to upper portion 11.
  • 3. Methods of Making Microneedle Devices
  • The microneedle devices are made by microfabrication processes, by creating small mechanical structures in silicon, metal, polymer, and other materials. These microfabrication processes are based on well-established methods used to make integrated circuits, electronic packages and other microelectronic devices, augmented by additional methods used in the field of micromachining. The microneedle devices can have dimensions as small as a few nanometers and can be mass-produced at low per-unit costs.
  • a. Microfabrication Processes
  • Microfabrication processes that may be used in making the microneedles disclosed herein include lithography; etching techniques, such as wet chemical, dry, and photoresist removal; thermal oxidation of silicon; electroplating and electroless plating; diffusion processes, such as boron, phosphorus, arsenic, and antimony diffusion; ion implantation; film deposition, such as evaporation (filament, electron beam, flash, and shadowing and step coverage), sputtering, chemical vapor deposition (CVD), epitaxy (vapor phase, liquid phase, and molecular beam), electroplating, screen printing, lamination, stereolithography, laser machining, and laser ablation (including projection ablation). See generally Jaeger, Introduction to Microelectronic Fabrication (Addison-Wesley Publishing Co., Reading Mass. 1988); Runyan, et al. Semiconductor Integrated Circuit Processing Technology (Addison-Wesley Publishing Co., Reading Mass. 1990); Proceedings of the IEEE Micro Electro Mechanical Systems Conference 1987-1998; Rai-Choudhury, ed., Handbook of Microlithography, Micromachining & Microfabrication (SPIE Optical Engineering Press, Bellingham, Wash. 1997).
  • The following methods are preferred for making microneedles.
  • i. Electrochemical Etching of Silicon
  • In this method, electrochemical etching of solid silicon to porous silicon is used to create extremely fine (on the order of 0.01 μm) silicon networks which can be used as piercing structures. This method uses electrolytic anodization of silicon in aqueous hydrofluoric acid, potentially in combination with light, to etch channels into the silicon. By varying the doping concentration of the silicon wafer to be etched, the electrolytic potential during etching, the incident light intensity, and the electrolyte concentration, control over the ultimate pore structure can be achieved. The material not etched (i.e. the silicon remaining) forms the microneedles. This method has been used to produce irregular needle-type structures measuring tens of nanometers in width.
  • ii. Plasma Etching
  • This process uses deep plasma etching of silicon to create microneedles with diameters on the order of 0.1 μm or larger. Needles are patterned directly using photolithography, rather than indirectly by controlling the voltage (as in electrochemical etching), thus providing greater control over the final microneedle geometry.
  • In this process, an appropriate masking material (e.g., metal) is deposited onto a silicon wafer substrate and patterned into dots having the diameter of the desired microneedles. The wafer is then subjected to a carefully controlled plasma based on fluorine/oxygen chemistries to etch very deep, high aspect ratio trenches into the silicon. See, e.g., Jansen, et al., “The Black Silicon Method IV: The Fabrication of Three-Dimensional Structures in Silicon with High Aspect Ratios for Scanning Probe Microscopy and Other Applications,” IEEE Proceedings of Micro Electro Mechanical Systems Conference, pp. 88-93 (1995). Those regions protected by the metal mask remain and form the needles. This method is further described in Example 1 below. FIG. 1 b provides a diagram of microneedles fabricated by this method.
  • iii. Electroplating
  • In this process, a metal layer is first evaporated onto a planar substrate. A layer of photoresist is then deposited onto the metal to form a patterned mold which leaves an exposed-metal region in the shape of needles. By electroplating onto the exposed regions of the metal seed layer, the mold bounded by photoresist can be filled with electroplated material. Finally, the substrate and photoresist mold are removed, leaving the finished microneedle array. The microneedles produced by this process generally have diameters on the order of 1 μm or larger. See, e.g., Frazier, et al., “Two dimensional metallic microelectrode arrays for extracellular stimulation and recording of neurons”, IEEE Proceedings of the Micro Electro Mechanical Systems Conference, pp. 195-200 (1993).
  • iv. Other Processes
  • Another method for forming microneedles made of silicon or other materials is to use microfabrication techniques such as photolithography, plasma etching, or laser ablation to make a mold form (A), transferring that mold form to other materials using standard mold transfer techniques, such as embossing or injection molding (B), and reproducing the shape of the original mold form (A) using the newly-created mold (B) to yield the final microneedles (C). Alternatively, the creation of the mold form (A) could be skipped and the mold (B) could be microfabricated directly, which could then be used to create the final microneedles (C).
  • Another method of forming solid silicon microneedles is by using epitaxial growth on silicon substrates, as is utilized by Containerless Research, Inc. (Evanston, Ill., USA) for its products.
  • b. Hollow or Porous Microneedles
  • In a preferred embodiment, microneedles are made with pores or other pathways through which material may be transported. The following descriptions outline representative methods for fabricating either porous or hollow microneedles.
  • i. Porous Microneedles
  • Rather than having a single, well-defined hole down the length of the needle, porous needles are filled with a network of channels or pores which allow conduction of fluid or energy through the needle shaft. It has been shown that by appropriate electrochemical oxidation of silicon, pore arrays with high aspect ratios and a range of different pore size regimes can be formed; these pore regimes are defined as (1) microporous regime with average pore dimensions less than 2 nm, (2) mesoporous regime with average pore sizes of between 2 nm and 50 nm, and (3) macroporous regime with pores greater than 50 nm. The mesoporous and macroporous regimes are expected to be most useful for drug delivery. Two approaches to porous needles are generally available, either (a) the silicon wafer is first made porous and then etched as described above to form needles or (b) solid microneedles are etched and then rendered porous, for example, by means of electrochemical oxidation, such as by anodization of a silicon substrate in a hydrofluoric acid electrolyte. The size distribution of the etched porous structure is highly dependent on several variables, including doping kind and illumination conditions, as detailed in Lehmann, “Porous Silicon—A New Material for MEMS”, IEEE Proceedings of the Micro Electro Mechanical Systems Conference, pp. 1-6 (1996). Porous polymer or metallic microneedles can be formed, for example, by micromolding a polymer containing a volatilizable or leachable material, such as a volatile salt, dispersed in the polymer or metal, and then volatilizing or leaching the dispersed material, leaving a porous polymer matrix in the shape of the microneedle.
  • ii. Hollow Needles
  • Three-dimensional arrays of hollow microneedles can be fabricated, for example, using combinations of dry etching processes (Laermer, et al., “Bosch Deep Silicon Etching: Improving Uniformity and Etch Rate for Advanced MEMS Applications,” Micro Electro Mechanical Systems, Orlando, Fla., USA, (Jan. 17-21, 1999); Despont et al., “High-Aspect-Ratio, Ultrathick, Negative-Tone Near-UV Photoresist for MEMS”, Proc. of IEEE 10th Annual International Workshop on MEMS, Nagoya, Japan, pp. 518-522 (Jan. 26-30, 1997)); micromold creation in lithographically-defined and/or laser ablated polymers and selective sidewall electroplating; or direct micromolding techniques using epoxy mold transfers.
  • One or more distinct and continuous pathways are created through the interior of microneedles. In a preferred embodiment, the microneedle has a single annular pathway along the center axis of the microneedle. This pathway can be achieved by initially chemically or physically etching the holes in the material and then etching away microneedles around the hole. Alternatively, the microneedles and their holes can be made simultaneously or holes can be etched into existing microneedles. As another option, a microneedle form or mold can be made, then coated, and then etched away, leaving only the outer coating to form a hollow microneedle. Coatings can be formed either by deposition of a film or by oxidation of the silicon microneedles to a specific thickness, followed by removal of the interior silicon. Also, holes from the backside of the wafer to the underside of the hollow needles can be created using a front-to-backside infrared alignment followed by etching from the backside of the wafer.
  • a. Silicon Microneedles
  • One method for hollow needle fabrication is to replace the solid mask used in the formation of solid needles by a mask that includes a solid shape with one or more interior regions of the solid shape removed. One example is a “donut-shaped” mask. Using this type of mask, interior regions of the needle are etched simultaneously with their side walls. Due to lateral etching of the inner side walls of the needle, this may not produce sufficiently sharp walls. In that case, two plasma etches must be used, one to form the outer walls of the microneedle (i.e., the ‘standard’ etch), and one to form the inner hollow core (which is an extremely anisotropic etch, such as in inductively-coupled-plasma “ICP” etch). For example, the ICP etch can be used to form the interior region of the needle followed by a second photolithography step and a standard etch to form the outer walls of the microneedle. FIG. 2 a represents a silicon wafer 82 with a patterned photoresist layer 84 on top of the wafer 82. The wafer 82 is anisotrophically etched (FIG. 2 b) to form a cavity 86 through its entire thickness (FIG. 2 c). The wafer 82 is then coated with a chromium layer 88 followed by a second photoresist layer 90 patterned so as to cover the cavity 86 and form a circular mask for subsequent etching (FIG. 2 d). The wafer 82 is then etched by a standard etch to form the outer tapered walls 92 of the microneedle (FIG. 2 e).
  • Alternatively, this structure can be achieved by substituting the chromium mask used for the solid microneedles described in Example 1 by a silicon nitride layer 94 on the silicon substrate 95 covered with chromium 96, deposited as shown in FIG. 3 a and patterned as shown in FIG. 3 b. Solid microneedles are then etched as described in Example 1 as shown FIG. 3 c, the chromium 88 is stripped (FIG. 3 d), and the silicon 95 is oxidized to form a thin layer of silicon dioxide 97 on all exposed silicon surfaces (FIG. 3 e). The silicon nitride layer 94 prevents oxidation at the needle tip. The silicon nitride 94 is then stripped (FIG. 3 f), leaving exposed silicon at the tip of the needle and oxide-covered silicon 97 everywhere else. The needle is then exposed to an ICP plasma which selectively etches the inner sidewalls of the silicon 95 in a highly anisotropic manner to form the interior hole of the needle (FIG. 3 g).
  • Another method uses the solid silicon needles described previously as ‘forms’ around which the actual needle structures are deposited. After deposition, the forms are etched away, yielding the hollow structures. Silica needles or metal needles can be formed using different methods. Silica needles can be formed by creating needle structures similar to the ICP needles described above prior to the oxidation described above. The wafers are then oxidized to a controlled thickness, forming a layer on the shaft of the needle form which will eventually become the hollow microneedle. The silicon nitride is then stripped and the silicon core selectively etched away (e.g., in a wet alkaline solution) to form a hollow silica microneedle.
  • In a preferred embodiment, an array of hollow silicon microtubes is made using deep reactive ion etching combined with a modified black silicon process in a conventional reactive ion etcher, as described in Example 3 below. First, arrays of circular holes are patterned through photoresist into SiO2, such as on a silicon wafer. Then the silicon can be etched using deep reactive ion etching (DRIE) in an inductively coupled plasma (ICP) reactor to etch deep vertical holes. The photoresist was then removed. Next, a second photolithography step patterns the remaining SiO2 layer into circles concentric to the holes, leaving ring shaped oxide masks surrounding the holes. The photoresist is then removed and the silicon wafer again deep silicon etched, such that the holes are etched completely through the wafer (inside the SiO2 ring) and simultaneously the silicon is etched around the SiO2 ring leaving a cylinder.
  • This latter process can be varied to produce hollow, tapered microneedles. After an array of holes is fabricated as described above, the photoresist and SiO2 layers are replaced with conformal DC sputtered chromium rings. The second ICP etch is replaced with a SF6/O2 plasma etch in a reactive ion etcher (RIE), which results in positively sloping outer sidewalls. Henry, et al., “Micromachined Needles for the Transdermal Delivery of Drugs,” Micro Electro Mechanical Systems, Heidelberg, Germany, pp. 494-498 (Jan. 26-29, 1998).
  • b. Metal Microneedles
  • Metal needles can be formed by physical vapor deposition of appropriate metal layers on solid needle forms, which can be made of silicon using the techniques described above, or which can be formed using other standard mold techniques such as embossing or injection molding. The metals are selectively removed from the tips of the needles using electropolishing techniques, in which an applied anodic potential in an electrolytic solution will cause dissolution of metals more rapidly at sharp points, due to concentration of electric field lines at the sharp points. Once the underlying silicon needle forms have been exposed at the tips, the silicon is selectively etched away to form hollow metallic needle structures. This process could also be used to make hollow needles made from other materials by depositing a material other than metal on the needle forms and following the procedure described above.
  • A preferred method of fabricating hollow metal microneedles utilizes micromold plating techniques, for example which are described as follows and in Examples 4 and 5. In a method for making metal microtubes, which does not require dry silicon etching, a photo-defined mold first is first produced, for example, by spin casting a thick layer, typically 150 μm, of an epoxy (e.g., SU-8) onto a substrate that has been coated with a thin sacrificial layer, typically about 10 to 50 nm. Arrays of cylindrical holes are then photolithographically defined through the epoxy layer, which typically is about 150 μm thick. (Despont, et al., “High-Aspect-Ratio, Ultrathick, Negative-Tone Near-UV Photoresist for MEMS,” Proc. of IEEE 10th Annual International Workshop on MEMS, Nagoya, Japan, pp. 518-522 (Jan. 26-30, 1997)). The diameter of these cylindrical holes defines the outer diameter of the tubes. The upper surface of the substrate, the sacrificial layer, is then partially removed at the bottom of the cylindrical holes in the photoresist. The exact method chosen depends on the choice of substrate. For example, the process has been successfully performed on silicon and glass substrates (in which the upper surface is etched using isotropic wet or dry etching techniques) and copper-clad printed wiring board substrates. In the latter case, the copper laminate is selectively removed using wet etching. Then a seed layer, such as Ti/Cu/Ti (e.g., 30 nm/200 nm/30 nm), is conformally DC sputter-deposited onto the upper surface of the epoxy mold and onto the sidewalks of the cylindrical holes. The seed layer should be electrically isolated from the substrate. Subsequently, one or more electroplatable metals or alloys, such as Ni, NiFe, Au, Cu, or Ti are electroplated onto the seed layer. The surrounding epoxy is then removed, leaving microtubes which each have an interior annular hole that extends through the base metal supporting the tubes. The rate and duration of electroplating is controlled in order to define the wall thickness and inner diameter of the microtubes. In one embodiment, this method was used to produce microtubes having a height of between about 150 and 250 μm, an outer diameter of between about 40 and 120 μm, and an inner diameter of between about 30 and 110 μm (i.e., having a wall thickness of 10 μm). In a typical array, the microtubes have a tube center-to-center spacing of about 150 μm, but can vary depending on the desired needle density.
  • A variation of this method is preferred for forming tapered microneedles. As described above, photolithography yields holes in the epoxy which have vertical sidewalls, such that the resulting shafts of the microneedles are straight, not tapered. This vertical sidewall limitation can be overcome by molding a preexisting 3D structure, i.e., a mold-insert. The subsequent removal of the mold-insert leaves a mold which can be surface plated similarly to the holes produced by photolithography described above.
  • Alternatively, non-vertical sidewalls can be produced directly in the polymeric mold into which electroplating will take place. For example, conventional photoresists known in the art can be exposed and developed in such as way as to have the surface immediately adjacent to the mask be wider than the other surface. Specialized greyscale photoresists in combination with greyscale masks can accomplish the same effect. Laser-ablated molds can also be made with tapered sidewalls, e.g., by optical adjustment of the beam (in the case of serial hole fabrication) or of the reticle or mold during ablation (in the case of projection ablation). Alternatively, non-vertical sidewalls can be produced directly in the polymeric mold into which electroplating will take place. For example, conventional photoresists known in the art can be exposed and developed in such a way as to have surface immediately adjacent to the mask be wider than the other surface. Specialized greyscale photoresists in combination with greyscale masks can accomplish the same effect. Laser-ablated molds can also be made with tapered sidewalls, e.g., by optical adjustment of the beam (in the case of serial hole fabrication) or of the reticle or mold during ablation (in the case of projection ablation).
  • To form hollow tapered microneedles, the mold-insert is an array of solid silicon microneedles, formed as described in Henry, et al., “Micromachined Needles for the Transdermal Delivery of Drugs,” Micro Electro Mechanical Systems, Heidelberg, Germany, Jan. 26-29, pp. 494-498-(1998). First, a layer of a material, such as an epoxy (e.g., SU-8), is spin cast onto the array of silicon microneedles to completely blanket the entire array. The epoxy settles during pre-bake to create a planar surface above the silicon needle tips; the material is then fully pre-baked, photolithographically cross-linked, and post-baked.
  • The upper surface of the epoxy is then etched away, for example with an O2/CHF3 plasma, until the needle tips are exposed, preferably leaving between about 1 and 5 μm of tip protruding from the epoxy. The silicon is then selectively removed, for example by using a SF6 plasma or a HNO3/H solution. The remaining epoxy micromold is the negative of the microneedles and has a small diameter hole where the tip of the microneedle formerly protruded.
  • After the removal of the silicon, a seed layer, such as Ti—Cu—Ti is conformally sputter-deposited onto the epoxy micromold. Following the same process sequence described for hollow metal microtubes, one or more electroplatable metals or alloys, such as Ni, NiFe, Au, or Cu, are electroplated onto the seed layer. Finally, the epoxy is removed, for example by using an O2/CHF3 plasma, leaving an array of hollow metal microneedles. In a preferred embodiment, this method is used to produce microneedles having a height of between about 150 and 250 μm, an outer diameter of between about 40 and 120 μm, and an inner diameter of between about 50 and 100 μm. In a typical array, the microtubes have a tube center-to-center spacing of about 150 μm, but can vary depending on the desired needle density. The microneedles are 150 μm in height with a base diameter of 80 μm, a tip diameter of 10 μm, and a needle to needle spacing of 150 μm.
  • c. Silicon Dioxide Microneedles
  • Hollow microneedles formed of silicon dioxide can be made by oxidizing the surface of the silicon microneedle forms (as described above), rather than depositing a metal and then etching away the solid needle forms to leave the hollow silicon dioxide structures. This method is illustrated in FIGS. 4 a-4 d. FIG. 4 a shows an array 24 of needle forms 26 with masks 28 on their tips. In FIG. 4 b, the needle forms 26 have been coated with a layer 30 of metal, silicon dioxide or other material. FIG. 4 c shows the coated needle forms 26 with the masks 28 removed. Finally, in FIG. 4 d, the needle forms 26 have been etched away, leaving hollow needles 30 made of metal, silicon dioxide, or other materials.
  • In one embodiment, hollow, porous, or solid microneedles are provided with longitudinal grooves or other modifications to the exterior surface of the microneedles. Grooves, for example, should be useful in directing the flow of molecules along the outside of microneedles.
  • d. Polymer Microneedles
  • In a preferred method, polymeric microneedles are made using microfabricated molds. For example, the epoxy molds can be made as described above and injection molding techniques can be applied to form the microneedles in the molds (Weber, et al., “Micromolding—a powerful tool for the large scale production of precise microstructures”, Proc. SPIE—International Soc. Optical Engineer. 2879, 156-167 (1996); Schift, et al., “Fabrication of replicated high precision insert elements for micro-optical bench arrangements” Proc. SPIE-International Soc. Optical Engineer. 3513, 122-134 (1998). These micromolding techniques are preferred over other techniques described herein, since they can provide relatively less expensive replication, i.e. lower cost of mass production. In a preferred embodiment, the polymer is biodegradable.
  • 4. Microneedle Device Applications
  • The device may be used for single or multiple uses for rapid transport across a biological barrier or may be left in place for longer times (e.g., hours or days) for long-term transport of molecules. Depending on the dimensions of the device, the application site, and the route in which the device is introduced into (or onto) the biological barrier, the device may be used to introduce or remove molecules at specific locations.
  • As discussed above, FIG. 1 shows a side elevational view of a schematic of a preferred embodiment of the microneedle device 10 in a transdermal application. The device 10 is applied to the skin such that the microneedles 12 penetrate through the stratum corneum and enter the viable epidermis so that the tip of the microneedle at least penetrates into the viable epidermis. In a preferred embodiment, drug molecules in a reservoir within the upper portion 11 flow through or around the microneedles and into the viable epidermis, where the drug molecules then diffuse into the dermis for local treatment or for transport through the body.
  • To control the transport of material out of or into the device through the microneedles, a variety of forces or mechanisms can be employed. These include pressure gradients, concentration gradients, electricity, ultrasound, receptor binding, heat, chemicals, and chemical reactions. Mechanical or other gates in conjunction with the forces and mechanisms described above can be used to selectively control transport of the material.
  • In particular embodiments, the device should be “user-friendly.” For example, in some transdermal applications, affixing the device to the skin should be relatively simple, and not require special skills. This embodiment of a microneedle may include an array of microneedles attached to a housing containing drug in an internal reservoir, wherein the housing has a bioadhesive coating around the microneedles. The patient can remove a peel-away backing to expose an adhesive coating, and then press the device onto a clean part of the skin, leaving it to administer drug over the course of, for example, several days.
  • a. Drug Delivery
  • Essentially any drug or other bioactive agents can be delivered using these devices. Drugs can be proteins, enzymes, polysaccharides, polynucleotide molecules, and synthetic organic and inorganic compounds. A preferred drug is insulin. Representative agents include anti-infectives, hormones, growth regulators, drugs regulating cardiac action or blood flow, and drugs for pain control. The drug can be for local treatment or for regional or systemic therapy. The following are representative examples, and disorders they are used to treat:
  • Calcitonin, osteoporosis
  • Enoxaprin, anticoagulant
  • Etanercept, rheumatoid arthritis
  • Erythropoietin, anemia
  • Fentanyl, postoperative and chronic pain
  • Filgrastin, low white blood cells from chemotherapy
  • Heparin, anticoagulant
  • Insulin, human, diabetes
  • Interferon Beta 1a, multiple sclerosis
  • Lidocaine, local anesthesia
  • Somatropin, growth hormone
  • Sumatriptan, migraine headaches
  • In this way, many drugs can be delivered at a variety of therapeutic rates. The rate can be controlled by varying a number of design factors, including the outer diameter of the microneedle, the number and size of pores or channels in each microneedle, the number of microneedles in an array, the magnitude and frequency of application of the force driving the drug through the microneedle and/or the holes created by the microneedles. For example, devices designed to deliver drug at different rates might have more microneedles for more rapid delivery and fewer microneedles for less rapid delivery. As another example, a device designed to deliver drug at a variable rate could vary the driving force (e.g., pressure gradient controlled by a pump) for transport according to a schedule which was pre-programmed or controlled by, for example, the user or his doctor. The devices can be affixed to the skin or other tissue to deliver drugs continuously or intermittently, for durations ranging from a few seconds to several hours or days.
  • One of skill in the art can measure the rate of drug delivery for particular microneedle devices using in vitro and in vivo methods known in the art. For example, to measure the rate of transdermal drug delivery, human cadaver skin mounted on standard diffusion chambers can be used to predict actual rates. See Hadgraft & Guy, eds., Transdermal Drug Delivery: Developmental Issues and Research Initiatives (Marcel Dekker, New York 1989); Bronaugh & Maibach, Percutaneous Absorption, Mechanisms—Methodology—Drug Delivery (Marcel Dekker, New York 1989). After filling the compartment on the dermis side of the diffusion chamber with saline, a microneedle array is inserted into the stratum corneum; a drug solution is placed in the reservoir of the microneedle device; and samples of the saline solution are taken over time and assayed to determine the rates of drug transport.
  • In an alternate embodiment, biodegradable or non-biodegradable microneedles can be used as the entire drug delivery device, where biodegradable microneedles are a preferred embodiment. For example, the microneedles may be formed of a biodegradable polymer containing a dispersion of an active agent for local or systemic delivery. The agent could be released over time, according to a profile determined by the composition and geometry of the microneedles, the concentration of the drug and other factors. In this way, the drug reservoir is within the matrix of one or more of the microneedles.
  • In another alternate embodiment, these microneedles may be purposefully sheared off from the substrate after penetrating the biological barrier. In this way, a portion of the microneedles would remain within or on the other side of the biological barrier and a portion of the microneedles and their substrate would be removed from the biological barrier. In the case of skin, this could involve inserting an array into the skin, manually or otherwise breaking off the microneedles tips and then remove the base of the microneedles. The portion of the microneedles which remains in the skin or in or across another biological barrier could then release drug over time according to a profile determined by the composition and geometry of the microneedles, the concentration of the drug and other factors: In a preferred embodiment, the microneedles are made of a biodegradable polymer. The release of drug from the biodegradable microneedle tips could be controlled by the rate of polymer degradation. Microneedle tips could release drugs for local or systemic effect, but could also release other agents, such as perfume, insect repellent and sun block.
  • Microneedle shape and content could be designed to control the breakage of microneedles. For example, a notch could be introduced into microneedles either at the time of fabrication or as a subsequent step. In this way, microneedles would preferentially break at the site of the notch. Moreover, the size and shape of the portion of microneedles which break off could be controlled not only for specific drug release patterns, but also for specific interactions with cells in the body. For example, objects of a few microns in size are known to be taken up by macrophages. The portions of microneedles that break off could be controlled to be bigger or smaller than that to prevent uptake by macrophages or could be that size to promote uptake by macrophages, which could be desirable for delivery of vaccines.
  • b. Diagnostic Sensing of Body Fluids (Biosensors)
  • One embodiment of the devices described herein may be used to remove material from the body across a biological barrier, i.e. for minimally invasive diagnostic sensing. For example, fluids can be transported from interstitial fluid in a tissue into a reservoir in the upper portion of the device. The fluid can then be assayed while in the reservoir or the fluid can be removed from the reservoir to be assayed, for diagnostic or other purposes. For example, interstitial fluids can be removed from the epidermis across the stratum corneum to assay for glucose concentration, which should be useful in aiding diabetics in determining their required insulin dose. Other substances or properties that would be desirable to detect include lactate (important for athletes), oxygen, pH, alcohol, tobacco metabolites, and illegal drugs (important for both medical diagnosis and law enforcement).
  • The sensing device can be in or attached to one or more microneedles, or in a housing adapted to the substrate. Sensing information or signals can be transferred optically (e.g., refractive index) or electrically (e.g., measuring changes in electrical impedance, resistance, current, voltage, or combination thereof). For example, it may be useful to measure a change as a function of change in resistance of tissue to an electrical current or voltage, or a change in response to channel binding or other criteria (such as an optical change) wherein different resistances are calibrated to signal that more or less flow of drug is needed, or that delivery has been completed.
  • In one embodiment, one or more microneedle devices can be used for (1) withdrawal of interstitial fluid, (2) assay of the fluid, and/or (3) delivery of the appropriate amount of a therapeutic agent based on the results of the assay, either automatically or with human intervention. For example, a sensor delivery system may be combined to form, for example, a system which withdraws bodily fluid, measures its glucose content, and delivers an appropriate amount of insulin. The sensing or delivery step also can be performed using conventional techniques, which would be integrated into use of the microneedle device. For example, the microneedle device could be used to withdraw and assay glucose, and a conventional syringe and needle used to administer the insulin, or vice versa.
  • In an alternate embodiment, microneedles may be purposefully sheared off from the substrate after penetrating the biological barrier, as described above. The portion of the microneedles which remain within or on the other side of the biological barrier could contain one or more biosensors. For example, the sensor could change color as its output. For microneedles sheared off in the skin, this color change could be observed through the skin by visual inspection or with the aid of an optical apparatus.
  • Other than transport of drugs and biological molecules, the microneedles may be used to transmit or transfer other materials and energy forms, such as light, electricity, heat, or pressure. The microneedles, for example, could be used to direct light to specific locations within the body, in order that the light can directly act on a tissue or on an intermediary, such as light-sensitive molecules in photodynamic therapy. The microneedles can also be used for aerosolization or delivery for example directly to a mucosal surface in the nasal or buccal regions or to the pulmonary system.
  • The microneedle devices disclosed herein also should be useful for controlling transport across tissues other than skin. For example, microneedles could be inserted into the eye across, for example, conjunctiva, sclera, and/or cornea, to facilitate delivery of drugs into the eye. Similarly, microneedles inserted into the eye could facilitate transport of fluid out of the eye, which may be of benefit for treatment of glaucoma. Microneedles may also be inserted into the buccal (oral), nasal, vaginal, or other accessible mucosa to facilitate transport into, out of, or across those tissues. For example, a drug may be delivered across the buccal mucosa for local treatment in the mouth or for systemic uptake and delivery. As another example, microneedle devices may be used internally within the body on, for example, the lining of the gastrointestinal tract to facilitate uptake of orally-ingested drugs or the lining of blood vessels to facilitate penetration of drugs into the vessel wall. For example, cardiovascular applications include using microneedle devices to facilitate vessel distension or immobilization, similarly to a stent, wherein the microneedles/substrate can function as a “staple-like” device to penetrate into different tissue segments and hold their relative positions for a period of time to permit tissue regeneration. This application would be particularly useful with biodegradable devices. These uses may involve invasive procedures to introduce the microneedle devices into the body or could involve swallowing, inhaling, injecting or otherwise introducing the devices in a non-invasive or minimally-invasive manner.
  • The present invention will be further understood with reference to the following non-limiting examples.
  • EXAMPLE 1 Fabrication of Solid Silicon Microneedles
  • A chromium masking material was deposited onto silicon wafers and patterned into dots having a diameter approximately equal to the base of the desired microneedles. The wafers were then loaded into a reactive ion etcher and subjected to a carefully controlled plasma based on fluorine/oxygen chemistries to etch very deep, high aspect ratio valleys into the silicon. Those regions protected by the metal mask remain and form the microneedles.
  • <100>-oriented, prime grade, 450-550 μm thick, 10-15 Ω-cm silicon wafers (Nova Electronic Materials Inc., Richardson, Tex.) were used as the starting material. The wafers were cleaned in a solution of 5 parts by volume deionized water, 1 part 30% hydrogen peroxide, and 1 part 30% ammonium hydroxide (J. T. Baker, Phillipsburg, N.J.) at approximately 80° C. for 15 minutes, and then dried in an oven (Blue M Electric, Watertown, Wis.) at 150° C. for 10 minutes. Approximately 1000 Å of chromium (Mat-Vac Technology, Flagler Beach, Fla.) was deposited onto the wafers using a DC-sputterer (601 Sputtering System, CVC Products, Rochester, N.Y.). The chromium layer was patterned into 20 by 20 arrays of 80 μm diameter dots with 150 μm center-to-center spacing using the lithographic process described below.
  • A layer of photosensitive material (1827 photoresist, Shipley, Marlborough, Mass.) was deposited onto the chromium layer covering the silicon wafers. A standard lithographic mask (Telic, Santa Monica, Calif.) bearing the appropriate dot array pattern was positioned on top of the photoresist layer. The wafer and photoreist were then exposed to ultraviolet (UV) Light through the mask by means of an optical mask aligner (Hybralign Series 500, Optical Associates, Inc., Milpitas, Calif.). The exposed photoresist was removed by soaking the wafers in a liquid developer (354 developer, Shipley, Marlborough, Mass.) leaving the desired dot array of photoresist on the chromium layer. Subsequently, the wafers were dipped into a chromium etchant (CR-75; Cyanteck Fremont, Calif.), which etched the chromium that had been exposed during the photolithography step, leaving dot arrays of chromium (covered with photoresist) on the surface of the silicon wafer. The photoresist still present on the chromium dots formed the masks needed for fabrication of the microneedles, described below.
  • The microneedles were fabricated using a reactive ion etching techniques based on the Black Silicon Method developed at the University of Twente. The patterned wafers were etched in a reactive ion etcher (700 series wafer/batch Plasma Processing System, Plasma Therm, St. Petersburg, Fla.) with means for ensuring good thermal contact between the wafers and the underlying platen (Apiezon N, K. J. Lesker, Clairton, Pa.). The wafers were etched using the following gases and conditions: SF6 (20 standard cubic centimeters per minute) and O2 (15 standard cubic centimeters per minute) at a pressure of 150 mTorr and a power of 150 W for a run time of approximately 250 minutes. These conditions caused both deep vertical etching and slight lateral underetching. By controlling the ratio of flow rates of the SF6 and O2 gases used to form the plasma, the aspect ratio of the microneedles could be adjusted. The regions protected by the chromium masks remained and formed the microneedles. Etching was allowed to proceed until the masks fell off due to underetching, resulting in an array of sharp silicon spikes.
  • EXAMPLE 2 Transdermal Transport Using Solid Microneedles
  • To determine if microfabricated microneedles could be used to enhance transdermal drug delivery, arrays of microneedles were made using a deep plasma etching technique. Their ability to penetrate human skin without breaking was tested and the resulting changes in transdermal transport were measured.
  • Arrays of microneedles were fabricated having extremely sharp tips (radius of curvature less than 1 μm) which facilitate easy piercing into the skin, and are approximately 150 μm long. Because the skin surface is not flat due to dermatoglyphics and hair, the full length of these microneedles will not penetrate the skin. All experiments were performed at room temperature (23±2° C.).
  • The ability of the microneedles to pierce skin without breaking was then tested. Insertion of the arrays into skin required only gentle pushing. Inspection by light and electron microscopy showed that more than 95% of microneedles within an array pierced across the stratum corneum of the epidermis samples. Moreover, essentially all of the microneedles that penetrated the epidermis remained intact. On those very few which broke, only the top 5-10 μm was damaged. Microneedle arrays could also be removed without difficulty or additional damage, as well as re-inserted into skin multiple times.
  • To quantitatively assess the ability of microneedles to increase transdermal transport, calcein permeability of human epidermis with and without inserted microneedle arrays was measured. Calcein crosses skin very poorly under normal circumstances and therefore represents an especially difficult compound to deliver. As expected, passive permeability of calcein across unaltered skin was very low, indicating that the epidermis samples were intact.
  • Insertion of microneedles into skin was capable of dramatically increasing permeability to calcein. When microneedles were inserted and left embedded in the skin, calcein permeability was increased by more than 1000-fold. Insertion of microneedles for 10 s, followed by their removal, yielded an almost 10,000-fold increase. Finally, insertion of a microneedle array for 1 h, followed by its removal, increased skin permeability by about 25,000-fold. Permeabilities for skin with microneedles inserted and then removed are higher than for skin with microneedles remaining embedded probably because the microneedles themselves or the silicon plate supporting the array may block access to the microscopic holes created in the skin. Light microscopy showed that the holes which remained in the skin after microneedles were removed were approximately 1 μm in size.
  • To confirm in vitro experiments which showed that skin permeability can be significantly increased by microneedles, studies were conducted with human volunteers. They indicated that microneedles could be easily inserted into the skin of the forearm or hand. Moreover, insertion of microneedle arrays was never reported to be painful, but sometimes elicited a mild “wearing” sensation described as a weak pressure or the feeling of a piece of tape affixed to the skin. Although transport experiments were not performed in vivo, skin electrical resistance was measured before and after microneedle insertion. Microneedles caused a 50-fold drop in skin resistance, a drop similar to that caused by the insertion of a 30-gauge “macroneedle.” Inspection of the site immediately after microneedle insertion showed no holes visible by light microscopy. No erythema, edema or other reaction to microneedles was observed over the hours and days which followed. This indicates that microneedle arrays can permeabilize skin in human subjects in a non-painful and safe manner.
  • EXAMPLE 3 Fabrication of Silicon Microtubes
  • Three-dimensional arrays of microtubes were fabricated from silicon, using deep reactive ion etching combined with a modified black silicon process in a conventional reactive ion etcher. The fabrication process is illustrated in FIGS. 5 a-d. First, arrays of 40 μm diameter circular holes 32 were patterned through photoresist 34 into a 1 μm thick SiO2 layer 36 on a two inch silicon wafer 38 (FIG. 5 a). The wafer 38 was then etched using deep reactive ion etching (DRIE) (Laermer, et al., “Bosch Deep Silicon Etching: Improving Uniformity and Etch Rate for Advanced MEMS Applications,” Micro Electro Mechanical Systems, Orlando, Fla., USA (Jan. 17-21, 1999)) in an inductively coupled plasma (ICP) reactor to etch deep vertical holes 40. The deep silicon etch was stopped after the holes 40 are approximately 200 μm deep into the silicon substrate 38 (FIG. 5 b) and the photoresist 34 was removed. A second photolithography step patterned the remaining SiO2 layer 36 into circles concentric to the holes, thus leaving ring shaped oxide masks 34 surrounding the holes (FIG. 5 c). The photoresist 34 was then removed and the wafer 38 was again deep silicon etched, while simultaneously the holes 40 were etched completely through the wafer 38 (inside the SiO2 ring) and the silicon was etched around the SiO2 ring 38 leaving a cylinder 42 (FIG. 5 d). The resulting tubes were 150 μm in height, with an outer diameter of 80 μm, an inner diameter of 40 μm, and a tube center-to-center spacing of 300 μm.
  • EXAMPLE 4 Micromold Fabrication of Metal Microtubes
  • Hollow metal microtubes were prepared without dry silicon etching, using a thick, photo-defined mold of epoxy. The sequences are illustrated in FIGS. 6 a-e. First, a thick layer of SU-8 epoxy 44 was spin cast onto a silicon or glass substrate 46 that had been coated with 30 nm of titanium 48, the sacrificial layer. Arrays of cylindrical holes 49 were then photolithographically defined through an epoxy layer 44, typically 150 μm thick (FIG. 6 a). The sacrificial layer then was partially removed using a wet etching solution containing hydrofluoric acid and water at the bottom of the cylindrical holes in the SU-8 photoresist 46 (FIG. 6 b). A seed layer of Ti/Cu/Ti (30 nm/200 nm/30 nm) 48 was then conformally DC sputter-deposited onto the upper surface of the epoxy mold and onto the sidewalls of the cylindrical holes 49 (FIG. 6 c). As shown in FIG. 6 c, the seed layer 48 was electrically isolated from the substrate. Subsequently, NiFe was electroplated onto the seed layer 48 (FIG. 6 d), the epoxy 44 was removed from the substrate, and the surrounding epoxy 44 was removed (FIG. 6 e). The resulting microtubes are 200 μm in height with an outer diameter of 80 μm, an inner diameter of 60 μm, and a tube center-to-center spacing of 150 μm. The holes in the interior of the microtubes protrude through the base metal supporting the tubes.
  • EXAMPLE 5 Micromold Fabrication of Tapered Microneedles
  • A micromold having tapered walls was fabricated by molding a preexisting 3-D array of microneedles, i.e. the mold-insert, and subsequently removing the mold insert. The micromold was then surface plated in a manner similar to that for the microtubes described in Example 4. The fabrication sequence is illustrated in FIGS. 7 a-7 d.
  • First, an array of solid silicon microneedles 50 were prepared as described in Henry, et al., “Micromachined Needles for the Transdermal Delivery of Drugs,” Micro Electro Mechanical Systems, Heidelberg, Germany, Jan. 26-29, pp. 494-498 (1998). Then, a layer of epoxy 52 (SU-8) was spin cast onto the microneedle array to completely blanket the array (FIG. 7 a). The epoxy 52 settled during pre-bake to create a planar surface above the tips of the microneedles 50. The epoxy 52 was then fully pre-baked, photolithographically cross-linked, and post-baked.
  • Then, the upper surface of the epoxy 52 was etched away using an O2/CHF3 plasma until approximately 1 to 2 μm of the needle tips 54 were exposed, protruding from the epoxy 52 (FIG. 7 b). The silicon was then selectively removed by using a SF6 plasma (FIG. 7 c). The remaining epoxy mold 52 provided a negative of the microneedles with a small diameter hole where the tip of the silicon needle protruded. After the removal of the silicon, a seed layer of Ti—Cu—Ti 54 was conformally sputter-deposited onto the top and sidewalls of the epoxy micromold 52. Following the same process sequence as described in Example 4, NiFe was then electroplated onto the seed layer 54 (FIG. 7 c). Finally, the epoxy was removed using an O2/CHF3 plasma, leaving a 20×20 array of NiFe hollow metal microneedles 54 (FIG. 7 d). The microneedles 54 were 150 μm in height with a base diameter of 80 μm, a tip diameter of 10 μm, and a needle to needle spacing of 150 μm.
  • EXAMPLE 6 Micromold Fabrication of Tapered Microneedles Using Laser-Formed Molds
  • A micromold having tapered walls was fabricated by use of laser ablation techniques, as shown in FIGS. 8 a-d. A laser-ablatable polymer sheet 60 such as KAPTON™ polymide approximately 150 microns in thickness was optionally laminated to a thin (10-30 micron) metal sheet 62 such as titanium (FIG. 8 a). A tapered hole 64 was formed in the metal/polymer laminate 60/62 using a laser technique such as excimer laser ablation (FIG. 8 b). The entry hole of the laser spot was on the metal side 62, and a through hole was made through both the metal sheet and the polymer film. The through hole 64 was tapered in combination with either defocusing or appropriate substrate motion to create a taper such that the wide end of the hole 64 (typically 40-50 microns) was on the metal side 62 and the narrow end of the hole 64 (typically 10-20 microns) was on the polymer 60 side. A thin layer of metal 66, e.g. titanium, of thickness 0.1 micron was then deposited, e.g., using a sputter-deposition technique, in such a way that the metal 66 deposited on the metal film side and coated the polymer sidewalls, but did not coat the polymer 60 side of the laminate (FIG. 8 c). Electrodeposition of metal 68, e.g., gold, to a thickness of 1-5 microns was then performed on the titanium-coated metal surface 66, and polymer sidewalls curved section of 60 next to 64. Finally, the polymer 60 was removed, using e.g. an oxygen plasma, to form the completed microneedles (FIG. 8 d).
  • Alternate polymer removal methods, such as thermal, solvent, aqueous, or phodegradation followed by solvent or aqueous removal, are also possible if the polymer material is chosen appropriately (e.g., a photoresist resin).
  • EXAMPLE 7 Formation of Microneedles by Embossing
  • Formation of a microneedle by embossing is shown in FIGS. 9 a-9 f. A polymeric layer 70 (FIG. 9 a) is embossed by a solid microneedle or microneedle array 72 (FIG. 9 b). The array 72 is removed (FIG. 9 c), and the layer 70 is etched from the non-embossed side 74 until the embossed cavity 76 is exposed (FIG. 9 d). A metallic layer 78 is then deposited on the embossed side and the sidewalls, but not on the non-embossed side 74 (FIG. 9 e). This layer 78 is optionally thickened by electrodeposition of an additional metal layer 80 on top of it (FIG. 9 e). The polymer layer 70 is then removed to form the microneedles 78/80 (FIG. 9 f).
  • EXAMPLE 8 Transdermal Application of Hollow Microneedles
  • The bore of hollow microneedles must provide fluid flow with minimal clogging in order to be suitable to transport material, such as in transdermal drug delivery. Therefore, microneedles and microtubes were evaluated to determine their suitability for these functions.
  • Hollow metal and silicon microneedles, produced as described in Examples 3-5, were inserted through human skin epidermis with no apparent clogging of the needle bores. Scanning electron microscopy of a hollow metal (NiFe) microneedle penetrating up through the underside of human epidermis showed the microneedle remains intact, with the tip free of debris. Similarly, silicon microneedles, metal microneedles, and metal microtubes were successfully inserted through human skin. Also, the hollow microneedles were shown to permit the flow of water through their bores.
  • EXAMPLE 9 Transport of Drugs through Microneedles inserted into Skin
  • Studies were performed with solid and hollow microneedles to demonstrate transport of molecules and fluids. As shown in Table 1, transport of a number of different compounds across skin is possible using microneedles. These studies were performed using either solid silicon microneedles or using hollow silicon microneedles made by methods described in this patent. Transport was measured across human cadaver epidermis in vitro using Franz diffusion chambers at 37° C. using methods described in S. Henry, D. McAllister, M. G. Allen and M. R. Prausnitz. Microfabricated microneedles: A novel method to increase transdermal drug delivery. J. Pharm. Sci. 87, 922-925 (1998).
  • The transdermal delivery of calcein, insulin, bovine serum albumin and nanoparticles was measured. Delivery refers to the ability to transport these compounds from the stratum corneum side of the epidermis to the viable epidermis side. This is the direction of transport associated with delivering drugs into the body. Removal of calcein was also measured. Removal refers to the ability to transport calcein from the viable epidermis side of the epidermis to the stratum corneum side. This is the direction of transport associated with removing from the body compounds found in the body, such as glucose.
  • In all cases shown in Table 1, transport of these compounds across skin occurred at levels below our detection limit when no needles were inserted into the skin. Intact skin provides an excellent barrier to transport of these compounds. In all cases examined, when solid microneedles were inserted into the skin and left in place, large skin permeabilities were measured, indicating that the microneedles had created pathways for transport across the skin. Furthermore, in all cases, when solid microneedles were inserted into the skin and then removed, even greater skin permeabilities resulted. Finally, when hollow microneedles were inserted into the skin and left in place, still greater skin permeabilities resulted for those compounds tested. These studies show that microneedles can dramatically increase skin permeability and can thereby increase transport of a number of different compounds across the skin. It also shows that when solid microneedles are used, a preferred embodiment involves inserting and then removing microneedles, rather than leaving them in place. It also shows that using hollow microneedles are a preferred embodiment over the use of solid microneedles.
  • In Table 2, the flow rate of water through hollow silicon microneedles is shown as a function of applied pressure. These data demonstrate that significant flow rates of water through microneedles can be achieved at modest pressures.
  • TABLE 1
    Transport of Drugs through Microneedles inserted into Skin.
    Solid needles
    No Solid needles inserted and Hollow needle
    Compound needles inserted removed inserted
    Calcein delivery ** 4 × 10−3 1 × 10−2 1 × 10−1
    Calcein removal ** 2 × 10−3 1 × 10−2 n.a.
    Insulin delivery ** 1 × 10−4 1 × 10−2 n.a.
    Bovine serum ** 9 × 10−4 8 × 10−3 9 × 10−2
    albumin
    delivery
    Nanoparticle ** n.a. 3 × 10−5 n.a.
    delivery
    ** means that the transport was below the detection limit.
    n.a. means that the data are not available.
    Nanoparticles were made of latex with a diameter of approximately 100 nm.
  • TABLE 2
    Flow rate of water through hollow silicon microneedles
    as a function of applied pressure
    Pressure (psi) Flow rate (ml/min)
    1.0 16
    1.5 24
    2.0 31
    2.5 38
    3.0 45
  • Publications cited herein and the material for which they are cited are specifically incorporated by reference.
  • Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims (48)

1. A device comprising one or more microneedles which are formed using a microfabricated mold.
2. The device of claim 1 wherein the microneedle is hollow.
3. The device of claim 2 wherein the microneedle is formed by a method comprising the steps:
(a) forming a micromold having sidewalls which define a surface of the microneedle;
(b) depositing material on sidewalls to form the hollow microneedle; and
(c) removing the micromold from the microneedle.
4. The device of claim 1 wherein the microneedles are formed of a metal.
5. The device of claim 4 wherein the metal is selected from the group consisting of nickel, iron, gold, titanium, tin, copper, stainless steel, platinum, palladium, and alloys thereof.
6. The device of claim 1 wherein the microneedles is formed of a polymer.
7. The device of claim 6 wherein the polymer is a biodegradable polymer selected from the group consisting of poly(hydroxy acid)s, polyanhydrides, poly(ortho)esters, polyurethanes, poly (butyric acid)s, poly(valeric acid)s, and poly(lactide-co-caprolactone)s.
8. The device of claim 1 wherein the microneedle is a microtube.
9. The device of claim 1 wherein the microneedle comprises a shaft having a circular or non-circular cross-sectional area perpendicular to the axis of the microneedle.
10. The device of claim 2 wherein the microneedle has an outer diameter between about 10 μm and about 100 μm.
11. The device of claim 10 wherein the microneedle has an inner diameter between about 3 μm and about 80 μm.
12. The device of claim 1 wherein the device comprises one or more shafts oriented perpendicular to the substrate.
13. The device of claim 1 further comprising gates or valves.
14. The device of claim 1 wherein the device is electrochemically, thermally, mechanically or magnetically active.
15. The device of claim 3 further comprising forming the mold using a laser to selectively remove material.
16. The device of claim 1 wherein the microneedles have a configured or grooved outer surface.
17. The device of claim 1 wherein the surface of the microneedles is formed of a material, or shaped to facilitate, passage of the microneedles or drug to be transported by means of the microneedles, through the skin.
18. The device of claim 1 wherein the microneedles form a mechanical support when inserted into a tissue.
19. The device of claim 18 wherein the mechanical support forms a vascular or urethral stent.
20. The device of claim 1 with flexible backing.
21. The device of claim 1 further comprising molecules to be released or delivered.
22. The device of claim 21 wherein the molecules are is incorporated into and released from the microneedles after the microneedles are administered.
23. The device of claim 22 wherein the microneedlers are formed of a biodegradable material and sheared off at the site of administration.
24. A method for making a microneedle, the method comprising forming a micromold having sidewalls which define a surface of the microneedle.
25. The method of claim 25 wherein one or more holes are photolithographically defined in a substrate, thereby forming the micromold.
26. The method of claim 24 further comprising applying a metal, or other material having different properties than the material forming the mold, to the sidewalls to form the hollow microneedle, and then removing the micromold from the microneedle.
27. The method of claim 24 further comprising filling the micromold with a fluid material that is hardened in the mold to form the microneedle.
28. The method of claim 27 which utilizes injection molding or reaction injection molding.
29. The method of claim 24 wherein the micromold is fabricated by forming a mold from a mold-insert.
30. The method of claim 29 wherein the mold insert is an array of microneedles.
31. The method of claim 30 for forming hollow microneedles, comprising the steps of
(a) layering a removable material onto the array to cover the microneedles of the mold-insert,
(b) removing a part of the layer of removable material to expose the tips the microneedles of the mold-insert, and
(c) removing the mold-insert to yield a micromold.
32. The method of claim 31 further comprising
(d) applying a metal, or other material having properties distinct from the material forming the mold, onto the micromold to form the microneedle, and
(e) removing the micromold from the microneedle.
33. The method of claim 24 wherein the micromold is shaped by embossing.
34. The method of 24 wherein the micromold is shaped using a laser to selectively remove material.
35. A device for delivery of material or energy into or across a biological barrier comprising one or more microneedles, wherein the microneedles are porous and/or comprise one or more hollow bores, and wherein the material or energy is delivered from one or more chambers in connection with at least one of the microneedles.
36. The device of claim 35 further comprising a means for controlling the flow of material or energy through the microneedles.
37. The device of claim 35 wherein the means is selected from the group consisting of permeable membranes, fracturable impermeable membranes, valves, and pumps.
38. The device of claim 35 further comprising a means for temporarily securing the microneedle device to the biological barrier.
39. The device of claim 38 wherein the securing means is selected from the group consisting of collars, tabs, adhesive agents, and combinations thereof.
40. A method of transporting a material or energy into or across a biological barrier comprising
inserting into the biological barrier one or more microneedles which are porous and/or comprises one or more hollow bores, and
providing a driving force to transport the material or energy through at least one of the microneedles from one or more chambers which are in communication with at least one of the microneedles.
41. The method of claim 40 wherein the device has at least two chambers having one or more materials to be transported.
42. The method of claim 41 wherein at least one chamber contains a drug and at least one other chamber contains an administration vehicle, wherein the drug and vehicle are mixed together to form the material transported through at least one microneedle.
43. The method of claim 40 wherein the driving force is selected from the group consisting of diffusion, capillary action, electroosmosis, electrophoresis, mechanical pumps, convection, and combinations thereof.
44. A method for making hollow microneedles or microtubes comprising
forming a mask on a substrate,
selectively removing the substrate to form the microneedle or microtube shape, and
making a hollow bore in the microneedle or microtube shape.
45. The method of claim 44 wherein the bore is made prior to forming the microneedle or microtube shape.
46. The method of claim 44 wherein the bore is made after forming the microneedle or microtube shape.
47. The method of claim 44 for forming microneedles wherein the microneedle shape is formed by tapered outer walls of the substrate.
48. The method of claim 44 for forming microtubes wherein the bore is formed prior to initiating formation of the outer walls of the microtubes.
US12/150,945 1998-06-10 2008-05-01 Microneedle devices and methods of manufacture and use thereof Abandoned US20090131905A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/150,945 US20090131905A1 (en) 1998-06-10 2008-05-01 Microneedle devices and methods of manufacture and use thereof
US12/853,082 US8708966B2 (en) 1998-06-10 2010-08-09 Microneedle devices and methods of manufacture and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/095,221 US6503231B1 (en) 1998-06-10 1998-06-10 Microneedle device for transport of molecules across tissue
US09/316,229 US6334856B1 (en) 1998-06-10 1999-05-21 Microneedle devices and methods of manufacture and use thereof
US10/010,723 US20020138049A1 (en) 1998-06-10 2001-12-06 Microneedle devices and methods of manufacture and use thereof
US12/150,945 US20090131905A1 (en) 1998-06-10 2008-05-01 Microneedle devices and methods of manufacture and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/010,723 Continuation US20020138049A1 (en) 1998-06-10 2001-12-06 Microneedle devices and methods of manufacture and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/853,082 Continuation US8708966B2 (en) 1998-06-10 2010-08-09 Microneedle devices and methods of manufacture and use thereof

Publications (1)

Publication Number Publication Date
US20090131905A1 true US20090131905A1 (en) 2009-05-21

Family

ID=22250743

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/095,221 Expired - Lifetime US6503231B1 (en) 1998-06-10 1998-06-10 Microneedle device for transport of molecules across tissue
US09/316,229 Expired - Lifetime US6334856B1 (en) 1998-06-10 1999-05-21 Microneedle devices and methods of manufacture and use thereof
US12/150,945 Abandoned US20090131905A1 (en) 1998-06-10 2008-05-01 Microneedle devices and methods of manufacture and use thereof
US12/853,082 Expired - Fee Related US8708966B2 (en) 1998-06-10 2010-08-09 Microneedle devices and methods of manufacture and use thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/095,221 Expired - Lifetime US6503231B1 (en) 1998-06-10 1998-06-10 Microneedle device for transport of molecules across tissue
US09/316,229 Expired - Lifetime US6334856B1 (en) 1998-06-10 1999-05-21 Microneedle devices and methods of manufacture and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/853,082 Expired - Fee Related US8708966B2 (en) 1998-06-10 2010-08-09 Microneedle devices and methods of manufacture and use thereof

Country Status (5)

Country Link
US (4) US6503231B1 (en)
JP (1) JP2009119296A (en)
AT (1) ATE449841T1 (en)
DE (1) DE69941696D1 (en)
ES (1) ES2356337T3 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082543A1 (en) * 2000-12-14 2002-06-27 Jung-Hwan Park Microneedle devices and production thereof
US20050137531A1 (en) * 1999-11-23 2005-06-23 Prausnitz Mark R. Devices and methods for enhanced microneedle penetration of biological barriers
US20090043279A1 (en) * 2007-08-06 2009-02-12 Kaspar Roger L Microneedle arrays formed from polymer films
US20090069788A1 (en) * 2004-11-18 2009-03-12 Nanopass Technologies Ltd., System And Method For Delivering Fluid Into Flexible Biological Barrier
US20090240217A1 (en) * 2008-03-21 2009-09-24 Ut-Battelle, Llc Novel microfabricated instruments and methods to treat recurrent corneal erosion
US7699819B2 (en) 2006-02-21 2010-04-20 The Hong Kong University Of Science And Technology Molecular sieve and zeolite microneedles and preparation thereof
US20100312191A1 (en) * 1998-06-10 2010-12-09 Georgia Tech Research Corporation Microneedle Devices and Methods of Manufacture and Use Thereof
US20110040236A1 (en) * 2009-08-17 2011-02-17 Pangaea Laboratories, Ltd. Microneedle roller
US8257324B2 (en) 1999-06-04 2012-09-04 Georgia Tech Research Corporation Microneedle drug delivery device
US20130035662A1 (en) * 2011-08-05 2013-02-07 Unitract Syringe Pty Ltd Injectable drug delivery arrangement with controlled delivery cannula position relative to point of delivery
US20130041310A1 (en) * 2010-04-28 2013-02-14 Stephen V. Kemmerrer Oral Mucosal Electroporation Device and Use Thereof
EP2737923A2 (en) * 2011-07-26 2014-06-04 Raphas Co., Ltd. Electro-microneedle integrated body for in-situ cutaneous gene transfer and method of manufacturing same
US20140342441A1 (en) * 2013-02-18 2014-11-20 Anpac Bio-Medical Science Co., Ltd. Apparatus for disease detection
US20150141924A1 (en) * 2012-05-11 2015-05-21 10X Technology Llc Hollow Silica Glass Microneedle Arrays and Method and Apparatus for Manufacturing Same
US9168200B2 (en) 2011-03-30 2015-10-27 Cosmed Pharmaceutical Co., Ltd. Microneedle patch container
US20160045720A1 (en) * 2014-08-18 2016-02-18 Noven Pharmaceuticals, Inc. Microneedle device and methods
US20160157764A1 (en) * 2014-12-03 2016-06-09 IMAST scarl Microneedle array device and method of making
US9457183B2 (en) 2011-06-15 2016-10-04 Tripep Ab Injection needle and device
US9993423B2 (en) 2011-10-20 2018-06-12 Cosmed Pharmaceutical Co., Ltd. Microneedle deposition method
US10603477B2 (en) 2014-03-28 2020-03-31 Allergan, Inc. Dissolvable microneedles for skin treatment
US10736840B2 (en) 2013-09-03 2020-08-11 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
US10821275B2 (en) 2012-06-27 2020-11-03 Cosmed Pharmaceutical Co., Ltd. Protective release sheet for microneedle patch
US10940301B2 (en) 2015-04-17 2021-03-09 Georgia Tech Research Corporation Drug delivery devices having separable microneedles
US11065428B2 (en) 2017-02-17 2021-07-20 Allergan, Inc. Microneedle array with active ingredient
US11085923B2 (en) 2011-03-24 2021-08-10 Anpac Bio-Medical Science Co., Ltd Micro-devices for disease detection
US11635549B2 (en) 2016-12-21 2023-04-25 Samsung Electronics Co., Ltd. Reflectionless window, method for manufacturing same, and reflectionless window for invasive sensor
US11730937B2 (en) 2017-10-11 2023-08-22 Georgia Tech Research Corporation Separable microneedle arrays for sustained release of drug

Families Citing this family (866)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422574B2 (en) * 1995-05-19 2008-09-09 Applied Tissue Technologies, Llc Microseeding device for gene delivery by microneedle injection
US7070590B1 (en) 1996-07-02 2006-07-04 Massachusetts Institute Of Technology Microchip drug delivery devices
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US7344499B1 (en) * 1998-06-10 2008-03-18 Georgia Tech Research Corporation Microneedle device for extraction and sensing of bodily fluids
US6922576B2 (en) * 1998-06-19 2005-07-26 Becton, Dickinson And Company Micro optical sensor device
US6355021B1 (en) * 1998-07-14 2002-03-12 Maersk Medical A/S Medical puncturing device
GB9815819D0 (en) * 1998-07-22 1998-09-16 Secr Defence Transferring materials into cells and a microneedle array
GB9815820D0 (en) * 1998-07-22 1998-09-16 Secr Defence Improvements relating to micro-machining
US7967855B2 (en) * 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US8070796B2 (en) * 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US6535753B1 (en) * 1998-08-20 2003-03-18 Microsense International, Llc Micro-invasive method for painless detection of analytes in extra-cellular space
US7048723B1 (en) 1998-09-18 2006-05-23 The University Of Utah Research Foundation Surface micromachined microneedles
US6379324B1 (en) 1999-06-09 2002-04-30 The Procter & Gamble Company Intracutaneous microneedle array apparatus
US6256533B1 (en) * 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6312612B1 (en) * 1999-06-09 2001-11-06 The Procter & Gamble Company Apparatus and method for manufacturing an intracutaneous microneedle array
EP1106681A4 (en) * 1999-06-10 2005-03-23 Matsushita Electric Ind Co Ltd Electrochemical device for moving particles covered with protein
US20030078499A1 (en) * 1999-08-12 2003-04-24 Eppstein Jonathan A. Microporation of tissue for delivery of bioactive agents
US6623457B1 (en) * 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
US6835184B1 (en) 1999-09-24 2004-12-28 Becton, Dickinson And Company Method and device for abrading skin
US6331266B1 (en) * 1999-09-29 2001-12-18 Becton Dickinson And Company Process of making a molded device
US20040209376A1 (en) * 1999-10-01 2004-10-21 Surromed, Inc. Assemblies of differentiable segmented particles
US6919009B2 (en) * 1999-10-01 2005-07-19 Nanoplex Technologies, Inc. Method of manufacture of colloidal rod particles as nanobarcodes
US7045049B1 (en) 1999-10-01 2006-05-16 Nanoplex Technologies, Inc. Method of manufacture of colloidal rod particles as nanobar codes
US20040178076A1 (en) * 1999-10-01 2004-09-16 Stonas Walter J. Method of manufacture of colloidal rod particles as nanobarcodes
US7225082B1 (en) 1999-10-01 2007-05-29 Oxonica, Inc. Colloidal rod particles as nanobar codes
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
US20020095134A1 (en) * 1999-10-14 2002-07-18 Pettis Ronald J. Method for altering drug pharmacokinetics based on medical delivery platform
US20020156453A1 (en) * 1999-10-14 2002-10-24 Pettis Ronald J. Method and device for reducing therapeutic dosage
US6494865B1 (en) * 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US6511463B1 (en) * 1999-11-18 2003-01-28 Jds Uniphase Corporation Methods of fabricating microneedle arrays using sacrificial molds
AU782639B2 (en) * 1999-12-10 2005-08-18 Massachusetts Institute Of Technology Microchip devices for delivery of molecules and methods of fabrication thereof
US7013179B2 (en) * 2000-01-07 2006-03-14 Biowave Corporation Percutaneous electrode array
US20080033492A1 (en) * 2000-01-07 2008-02-07 Biowave Corporation Electro-therapy method
US6622035B1 (en) 2000-01-21 2003-09-16 Instrumentarium Corp. Electrode for measurement of weak bioelectrical signals
EP1164928B1 (en) * 2000-01-21 2005-06-01 Instrumentarium Corporation Method of fabricating a medical electrode
DE10003507B4 (en) * 2000-01-27 2004-06-03 Knoll, Meinhard, Prof. Dr. Device and method for the removal of liquids from the body's own tissue and determination of substance concentrations in this liquid
JP3960802B2 (en) * 2000-03-02 2007-08-15 マイクロチップス・インコーポレーテッド Microfabricated devices for storing and selectively exposing chemicals and devices
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6595947B1 (en) 2000-05-22 2003-07-22 Becton, Dickinson And Company Topical delivery of vaccines
US6565532B1 (en) 2000-07-12 2003-05-20 The Procter & Gamble Company Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup
US7473244B2 (en) * 2000-06-02 2009-01-06 The University Of Utah Research Foundation Active needle devices with integrated functionality
US6537242B1 (en) * 2000-06-06 2003-03-25 Becton, Dickinson And Company Method and apparatus for enhancing penetration of a member for the intradermal sampling or administration of a substance
US6540675B2 (en) * 2000-06-27 2003-04-01 Rosedale Medical, Inc. Analyte monitor
US20040175360A1 (en) * 2000-06-29 2004-09-09 Pettis Ronald J. Method for altering drug pharmacokinetics based on medical delivery platform
US20050008683A1 (en) * 2000-06-29 2005-01-13 Becton Dickinson And Company Method for delivering interferons to the intradermal compartment
US6603987B2 (en) * 2000-07-11 2003-08-05 Bayer Corporation Hollow microneedle patch
US6440096B1 (en) * 2000-07-14 2002-08-27 Becton, Dickinson And Co. Microdevice and method of manufacturing a microdevice
US20020118850A1 (en) * 2000-08-02 2002-08-29 Yeh Jer-Liang (Andrew) Micromachine directional microphone and associated method
CA2424520C (en) * 2000-08-21 2007-01-02 The Cleveland Clinic Foundation Microneedle array module and method of fabricating the same
US6533949B1 (en) * 2000-08-28 2003-03-18 Nanopass Ltd. Microneedle structure and production method therefor
US6660648B1 (en) * 2000-10-02 2003-12-09 Sandia Corporation Process for manufacture of semipermeable silicon nitride membranes
WO2002029136A1 (en) * 2000-10-02 2002-04-11 Surromed, Inc. Method of manufacture of colloidal rod particles as nanobarcodes
US7131987B2 (en) 2000-10-16 2006-11-07 Corium International, Inc. Microstructures and method for treating and conditioning skin which cause less irritation during exfoliation
US7828827B2 (en) 2002-05-24 2010-11-09 Corium International, Inc. Method of exfoliation of skin using closely-packed microstructures
US6821281B2 (en) 2000-10-16 2004-11-23 The Procter & Gamble Company Microstructures for treating and conditioning skin
US8641644B2 (en) * 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
DE10057832C1 (en) * 2000-11-21 2002-02-21 Hartmann Paul Ag Blood analysis device has syringe mounted in casing, annular mounting carrying needles mounted behind test strip and being swiveled so that needle can be pushed through strip and aperture in casing to take blood sample
US6638246B1 (en) * 2000-11-28 2003-10-28 Scimed Life Systems, Inc. Medical device for delivery of a biologically active material to a lumen
DE10063634B4 (en) * 2000-12-20 2006-01-12 Liebl, Horst, Zelsheim Device and method for introducing an active substance into the skin
US6524936B2 (en) * 2000-12-22 2003-02-25 Axcelis Technologies, Inc. Process for removal of photoresist after post ion implantation
WO2002062202A2 (en) * 2001-02-05 2002-08-15 Becton, Dickinson And Company Microprotrusion array and methods of making a microprotrusion
AU2002250071B2 (en) * 2001-02-13 2008-02-14 Government Of The United States, As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
US6663820B2 (en) 2001-03-14 2003-12-16 The Procter & Gamble Company Method of manufacturing microneedle structures using soft lithography and photolithography
CA2441530A1 (en) 2001-03-19 2002-09-26 Iomai Corporation Transcutaneous immunostimulation
US7310543B2 (en) * 2001-03-26 2007-12-18 Kumetrix, Inc. Silicon microprobe with integrated biosensor
US7601286B2 (en) * 2001-03-26 2009-10-13 Lawrence Livermore National Security, Llc Polymer-based platform for microfluidic systems
AU2002307090A1 (en) * 2001-04-03 2002-10-21 Surromed, Inc. Methods and reagents for multiplexed analyte capture, surface array self-assembly, and analysis of complex biological samples
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
BR0116972A (en) * 2001-04-13 2004-12-21 Becton Dickinson Co Methods and devices for administering substances to the intradermal skin layer for systemic absorption
US20020169066A1 (en) * 2001-04-16 2002-11-14 Cerabio, L.L.C. Dense porous structures for use as bone substitutes
DE60233939D1 (en) * 2001-04-20 2009-11-19 Alza Corp MICROPROJECTION ARRANGEMENT WITH A COATING CONTAINING ADVANTAGEOUS MEDIUM
AU2002305357A1 (en) * 2001-05-01 2002-11-11 Second Sight, Llc High-density array of micro-machined electrodes for neural stimulation
US6591124B2 (en) 2001-05-11 2003-07-08 The Procter & Gamble Company Portable interstitial fluid monitoring system
US20020188310A1 (en) * 2001-06-08 2002-12-12 Seward Kirk Partick Microfabricated surgical device
AU2002312380A1 (en) * 2001-06-08 2002-12-23 Becton, Dickinson And Company Device for manipulating a needle or abrader array
US7127284B2 (en) * 2001-06-11 2006-10-24 Mercator Medsystems, Inc. Electroporation microneedle and methods for its use
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
WO2002100254A2 (en) * 2001-06-12 2002-12-19 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US9226699B2 (en) * 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
CA2448905C (en) 2001-06-12 2010-09-07 Pelikan Technologies, Inc. Blood sampling apparatus and method
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7316700B2 (en) 2001-06-12 2008-01-08 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
ATE497731T1 (en) 2001-06-12 2011-02-15 Pelikan Technologies Inc DEVICE FOR INCREASING THE SUCCESS RATE OF BLOOD YIELD OBTAINED BY A FINGER PICK
US7344507B2 (en) 2002-04-19 2008-03-18 Pelikan Technologies, Inc. Method and apparatus for lancet actuation
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US20070100255A1 (en) * 2002-04-19 2007-05-03 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
ATE485766T1 (en) * 2001-06-12 2010-11-15 Pelikan Technologies Inc ELECTRICAL ACTUATING ELEMENT FOR A LANCET
US6767341B2 (en) * 2001-06-13 2004-07-27 Abbott Laboratories Microneedles for minimally invasive drug delivery
US20050010193A1 (en) * 2002-05-06 2005-01-13 Laurent Philippe E. Novel methods for administration of drugs and devices useful thereof
US20030073609A1 (en) * 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
US20060018877A1 (en) * 2001-06-29 2006-01-26 Mikszta John A Intradermal delivery of vacccines and therapeutic agents
MXPA03011611A (en) * 2001-06-29 2004-07-01 Becton Dickinson Co Intradermal delivery of vaccines and gene therapeutic agents via microcannula.
US7094228B2 (en) * 2001-07-31 2006-08-22 Zars, Inc. Methods and formulations for photodynamic therapy
US20050226918A1 (en) * 2001-08-13 2005-10-13 Macdonald Stuart G Delivery system for insulin and other therapeutic agents
SE0102736D0 (en) * 2001-08-14 2001-08-14 Patrick Griss Side opened out-of-plane microneedles for microfluidic transdermal interfacing and fabrication process of side opened out-of-plane microneedles
GB0120202D0 (en) * 2001-08-18 2001-10-10 Psimedica Body fluid collection and analysis
US20030038105A1 (en) * 2001-08-27 2003-02-27 Harker Alan B. Tool for embossing high aspect ratio microstructures
US7286864B1 (en) 2001-09-07 2007-10-23 Orbital Research, Inc. Dry physiological recording device
US6782283B2 (en) * 2001-09-07 2004-08-24 Robert N. Schmidt Dry penetrating recording device
US6785569B2 (en) 2001-09-07 2004-08-31 Orbital Research Dry physiological recording electrode
US8201330B1 (en) * 2001-09-07 2012-06-19 Orbital Research Inc Physiological recording device or electrode
US20040087992A1 (en) * 2002-08-09 2004-05-06 Vladimir Gartstein Microstructures for delivering a composition cutaneously to skin using rotatable structures
WO2003024507A2 (en) * 2001-09-19 2003-03-27 Biovalve Technologies, Inc. Microneedles, microneedle arrays, and systems and methods relating to same
US6977515B2 (en) * 2001-09-20 2005-12-20 Wentworth Laboratories, Inc. Method for forming photo-defined micro electrical contacts
US6906540B2 (en) * 2001-09-20 2005-06-14 Wentworth Laboratories, Inc. Method for chemically etching photo-defined micro electrical contacts
WO2003024508A2 (en) * 2001-09-21 2003-03-27 Biovalve Technologies, Inc. Gas pressure actuated microneedle arrays, and systems and methods relating to same
US6830562B2 (en) * 2001-09-27 2004-12-14 Unomedical A/S Injector device for placing a subcutaneous infusion set
CA2500453A1 (en) * 2001-09-28 2003-04-03 Biovalve Technologies, Inc. Microneedle with membrane
CA2500452A1 (en) * 2001-09-28 2003-04-03 Biovalve Technologies, Inc. Switchable microneedle arrays and systems and methods relating to same
FR2830766B1 (en) 2001-10-12 2004-03-12 Optis France Sa DEVICE   OF   ISSUE   OF   DRUGS   THROUGH   IONTOPHORESIS   TRANSPALPEBRALE
US8740973B2 (en) * 2001-10-26 2014-06-03 Icon Medical Corp. Polymer biodegradable medical device
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
JP2005511248A (en) * 2001-10-29 2005-04-28 ベクトン・ディキンソン・アンド・カンパニー Methods and devices for delivering substances
ITTO20011228A1 (en) * 2001-12-28 2003-06-28 Cane Srl DISPOSABLE NEEDLE CONTAINER.
US20040073175A1 (en) * 2002-01-07 2004-04-15 Jacobson James D. Infusion system
US6908453B2 (en) * 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
AU2003205315A1 (en) * 2002-01-22 2003-09-02 Endobionics, Inc. Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia
US7744584B2 (en) 2002-01-22 2010-06-29 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
US10441747B2 (en) 2002-01-22 2019-10-15 Mercator Medsystems, Inc. Methods and systems for inhibiting vascular inflammation
US20040060902A1 (en) * 2002-02-05 2004-04-01 Evans John D. Microprotrusion array and methods of making a microprotrusion
US7004928B2 (en) * 2002-02-08 2006-02-28 Rosedale Medical, Inc. Autonomous, ambulatory analyte monitor or drug delivery device
AU2003208296A1 (en) * 2002-02-12 2003-09-04 Unomedial A/S Infusion device with needle shield
WO2003074102A2 (en) * 2002-03-04 2003-09-12 Nano Pass Technologies Ltd. Devices and methods for transporting fluid across a biological barrier
US7387742B2 (en) * 2002-03-11 2008-06-17 Becton, Dickinson And Company Silicon blades for surgical and non-surgical use
EP2319578B1 (en) * 2002-03-11 2016-11-02 Nitto Denko Corporation Transdermal drug delievery patch system, method of making same and method of using same
US8116860B2 (en) 2002-03-11 2012-02-14 Altea Therapeutics Corporation Transdermal porator and patch system and method for using same
US9918665B2 (en) 2002-03-11 2018-03-20 Nitto Denko Corporation Transdermal porator and patch system and method for using same
CN1298292C (en) 2002-03-11 2007-02-07 贝克顿迪肯森公司 System and method for the manufacture of surgical blades
US7050847B2 (en) 2002-03-26 2006-05-23 Stig Ollmar Non-invasive in vivo determination of body fluid parameter
US20030186405A1 (en) * 2002-04-01 2003-10-02 The Ohio State University Research Foundation Micro/nano-embossing process and useful applications thereof
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7226461B2 (en) * 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7582099B2 (en) * 2002-04-19 2009-09-01 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US7524293B2 (en) * 2002-04-19 2009-04-28 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7485128B2 (en) * 2002-04-19 2009-02-03 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7892185B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US8267870B2 (en) * 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US9795334B2 (en) * 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7374544B2 (en) * 2002-04-19 2008-05-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US20070142748A1 (en) * 2002-04-19 2007-06-21 Ajay Deshmukh Tissue penetration device
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7892183B2 (en) * 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US8360992B2 (en) * 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7717863B2 (en) * 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8784335B2 (en) * 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7244265B2 (en) * 2002-04-19 2007-07-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8221334B2 (en) * 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
WO2004054455A1 (en) * 2002-12-13 2004-07-01 Pelikan Technologies, Inc. Method and apparatus for measuring analytes
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7291117B2 (en) 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
JP4764626B2 (en) 2002-05-06 2011-09-07 ベクトン・ディキンソン・アンド・カンパニー Method and device for controlling the pharmacokinetics of a drug
US20060264886A9 (en) * 2002-05-06 2006-11-23 Pettis Ronald J Method for altering insulin pharmacokinetics
US20030143113A2 (en) * 2002-05-09 2003-07-31 Lifescan, Inc. Physiological sample collection devices and methods of using the same
US20030212344A1 (en) * 2002-05-09 2003-11-13 Vadim Yuzhakov Physiological sample collection devices and methods of using the same
US20030211619A1 (en) * 2002-05-09 2003-11-13 Lorin Olson Continuous strip of fluid sampling and testing devices and methods of making, packaging and using the same
US7060192B2 (en) * 2002-05-09 2006-06-13 Lifescan, Inc. Methods of fabricating physiological sample collection devices
US20040067481A1 (en) * 2002-06-12 2004-04-08 Leslie Leonard Thermal sensor for fluid detection
US6945952B2 (en) * 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
WO2004000389A2 (en) * 2002-06-25 2003-12-31 Sung-Yun Kwon Rapidly dissolving micro-perforator for drug delivery and other applications
US6960378B1 (en) * 2002-06-27 2005-11-01 Rensselaer Polytechnic Institute Tubular microstructures via controlled nanoparticle assembly
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US6899838B2 (en) * 2002-07-12 2005-05-31 Becton, Dickinson And Company Method of forming a mold and molding a micro-device
KR101323980B1 (en) 2002-07-19 2013-10-30 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Microneedle device, method of using microneedle device and method of delivering microneedle device
DE10235689A1 (en) * 2002-07-31 2004-02-19 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Implant to administer small doses of an active agent directly into the bloodstream at a blood vessel, comprising a base body against the blood vessel wall with micro-injectors through the artery wall
DE10236149A1 (en) * 2002-08-05 2004-02-26 Universität Kassel Production of a structure having a sharp tip or cutting edge comprises providing a semiconductor substrate on a surface having a recess with a tip section, side walls and a layer, and deforming the substrate in the region of the recess
US20050255989A1 (en) * 2002-08-26 2005-11-17 Kyoto Monotech Co., Ltd Process for producing integrated reactive porous carrier
WO2004020015A2 (en) * 2002-08-29 2004-03-11 Becton Dickinson And Company Microprotrusion arrays and methods for using same to deliver substances into tissue
JP2005537054A (en) * 2002-08-30 2005-12-08 ベクトン・ディキンソン・アンド・カンパニー Methods for controlling the pharmacokinetics of immunomodulatory compounds
DK1556124T3 (en) * 2002-09-02 2008-02-18 Unomedical As Apparatus and method for adjusting the length of an infusion tube
WO2004020035A1 (en) * 2002-09-02 2004-03-11 Unomedical A/S A device for subcutaneous administration of a medicament to a patient and tubing for same
DE60325624D1 (en) * 2002-09-02 2009-02-12 Unomedical As DEVICE FOR THE SUBCUTANEOUS ADMINISTRATION OF A MEDICAMENT TO A PATIENT
US20040051019A1 (en) * 2002-09-02 2004-03-18 Mogensen Lasse Wesseltoft Apparatus for and a method of adjusting the length of an infusion tube
US6946362B2 (en) * 2002-09-06 2005-09-20 Hewlett-Packard Development Company, L.P. Method and apparatus for forming high surface area material films and membranes
AU2003275311A1 (en) * 2002-09-16 2004-04-30 Sung-Yun Kwon Solid micro-perforators and methods of use
US20040106904A1 (en) * 2002-10-07 2004-06-03 Gonnelli Robert R. Microneedle array patch
CA2444211C (en) * 2002-10-11 2013-11-19 Dermal Therapy (Barbados) Inc. Determination of biological conditions using impedance measurements
IL152271A (en) * 2002-10-13 2006-04-10 Meir Hefetz Microneedles structures and production methods
US7045069B2 (en) * 2002-11-14 2006-05-16 Gennady Ozeryansky Microfabrication method based on metal matrix composite technology
DK200201823A (en) * 2002-11-26 2004-05-27 Maersk Medical As Connection piece for a hose connection
US20040162542A1 (en) * 2002-12-03 2004-08-19 Endobionics, Inc. Methods and systems for treating the vasculature with estrogens
US7001669B2 (en) * 2002-12-23 2006-02-21 The Administration Of The Tulane Educational Fund Process for the preparation of metal-containing nanostructured films
US6962772B2 (en) * 2002-12-27 2005-11-08 Industrial Technology Research Inst. Method for manufacturing 3-D high aspect-ratio microneedle array device
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US20040132167A1 (en) * 2003-01-06 2004-07-08 Peter Rule Cartridge lance
US20040158202A1 (en) * 2003-02-12 2004-08-12 Soren Jensen Cover
KR100562498B1 (en) * 2003-02-12 2006-03-21 삼성전자주식회사 Pad conditioner of cmp equipment
US7578954B2 (en) * 2003-02-24 2009-08-25 Corium International, Inc. Method for manufacturing microstructures having multiple microelements with through-holes
US20050155955A1 (en) * 2003-03-10 2005-07-21 Daskal Vadim M. Method for reducing glare and creating matte finish of controlled density on a silicon surface
US20090007436A1 (en) * 2003-03-10 2009-01-08 Daskal Vadim M Silicon blades for surgical and non-surgical use
US7052652B2 (en) 2003-03-24 2006-05-30 Rosedale Medical, Inc. Analyte concentration detection devices and methods
MXPA05010221A (en) 2003-03-25 2006-02-22 Terry O Herndon Drill device and method for forming microconduits.
US20050070819A1 (en) * 2003-03-31 2005-03-31 Rosedale Medical, Inc. Body fluid sampling constructions and techniques
US7070580B2 (en) * 2003-04-01 2006-07-04 Unomedical A/S Infusion device and an adhesive sheet material and a release liner
US7415299B2 (en) * 2003-04-18 2008-08-19 The Regents Of The University Of California Monitoring method and/or apparatus
ES2737835T3 (en) 2003-04-23 2020-01-16 Valeritas Inc Hydraulically driven pump for long-term medication administration
JP2004343275A (en) * 2003-05-14 2004-12-02 Murata Mach Ltd Image processing system and scanner
ATE476137T1 (en) 2003-05-30 2010-08-15 Pelikan Technologies Inc METHOD AND DEVICE FOR INJECTING LIQUID
WO2004107964A2 (en) * 2003-06-06 2004-12-16 Pelikan Technologies, Inc. Blood harvesting device with electronic control
WO2004108204A1 (en) * 2003-06-10 2004-12-16 Medrx Co., Ltd. Process for producing pad base for transdermal drug administration, pad base for transdermal drug administration and needle
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US20050163711A1 (en) * 2003-06-13 2005-07-28 Becton, Dickinson And Company, Inc. Intra-dermal delivery of biologically active agents
US7273474B2 (en) * 2003-06-17 2007-09-25 Industrial Technology Research Institute Flexible substrate structure for microneedle arrays and its manufacturing method
US6961603B2 (en) 2003-06-17 2005-11-01 Instrumentarim Corp. Unitary multi-electrode biopotential signal sensor and method for making same
WO2004113869A2 (en) * 2003-06-17 2004-12-29 Surromed, Inc. Labeling and authentication of metal objects
DE10327839A1 (en) * 2003-06-20 2005-01-05 Arvinmeritor Gmbh Vehicle roof module
WO2005020890A2 (en) * 2003-07-11 2005-03-10 Surromed, Inc. Multiplexed molecular beacon assay for detection of pathogens
US20050027350A1 (en) * 2003-07-30 2005-02-03 Biotronik Mess-Und Therapiegeraete Gmbh & Co Ingenieurbuero Berlin Endovascular implant for the injection of an active substance into the media of a blood vessel
CA2534823A1 (en) * 2003-08-04 2005-02-24 Alza Corporation Method and device for enhancing transdermal agent flux
WO2005020912A2 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
MXPA06002159A (en) * 2003-08-26 2006-05-22 Becton Dickinson Co Methods for intradermal delivery of therapeutics agents.
CA2896407A1 (en) * 2003-09-11 2005-03-24 Theranos, Inc. Medical device for analyte monitoring and drug delivery
WO2005027728A2 (en) * 2003-09-17 2005-03-31 Becton, Dickinson And Company Method for creating trenches in silicon wafers using a router
US8353861B2 (en) * 2003-09-18 2013-01-15 Texmac, Inc. Applicator for applying functional substances into human skin
EP1671096A4 (en) * 2003-09-29 2009-09-16 Pelikan Technologies Inc Method and apparatus for an improved sample capture device
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc Method and apparatus for a variable user interface
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
WO2005044364A1 (en) * 2003-11-10 2005-05-19 Agency For Science, Technology And Research Microneedles and microneedle fabrication
CN100595598C (en) * 2003-11-14 2010-03-24 温特沃斯实验室公司 Die design with integrated assembly aid
DE10353629A1 (en) * 2003-11-17 2005-06-16 Lts Lohmann Therapie-Systeme Ag Device for the transdermal administration of active substances
US8017145B2 (en) * 2003-12-22 2011-09-13 Conopco, Inc. Exfoliating personal care wipe article containing an array of projections
CN100355470C (en) * 2003-12-26 2007-12-19 中国科学院理化技术研究所 Minisize solid silicon needle array chip and its preparation method and use
AU2004311977A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Medical devices and kits including same
US7822454B1 (en) * 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
KR20060134050A (en) * 2004-01-09 2006-12-27 알자 코포레이션 Frequency assisted transdermal agent delivery method and system
US7150726B2 (en) * 2004-01-23 2006-12-19 Norfolk Medical Device for subcutaneous infusion of fluids
GB0402131D0 (en) 2004-01-30 2004-03-03 Isis Innovation Delivery method
US8551391B2 (en) * 2004-02-17 2013-10-08 Avery Dennison Corporation Method of making microneedles
JP2007523771A (en) * 2004-02-23 2007-08-23 スリーエム イノベイティブ プロパティズ カンパニー Microneedle array molding method
US7591618B2 (en) * 2004-02-25 2009-09-22 Agency For Science, Technology And Research Machining method for micro abraders and micro abraders produced thereby
US20050256499A1 (en) * 2004-03-03 2005-11-17 Pettis Ronald J Methods and devices for improving delivery of a substance to skin
US8671544B2 (en) * 2004-03-12 2014-03-18 Agency For Science, Technology And Research Methods and moulds for use in fabricating side-ported microneedles
AU2005228145B2 (en) * 2004-03-24 2011-03-03 Corium Pharma Solutions, Inc. Transdermal delivery device
DK1727576T3 (en) * 2004-03-26 2009-07-06 Unomedical As Infusion
CN100402107C (en) * 2004-03-31 2008-07-16 中国科学院理化技术研究所 Metal micro needles array chip and preparation method, and usage
US20080082090A1 (en) * 2004-04-01 2008-04-03 The General Hospital Corporation Method and apparatus for dermatological treatment and tissue reshaping
JP5065005B2 (en) 2004-04-01 2012-10-31 ザ ジェネラル ホスピタル コーポレイション Method and apparatus for dermatological treatment and tissue remodeling
CA2562932A1 (en) * 2004-04-01 2005-10-27 Alza Corporation Apparatus and method for transdermal delivery of influenza vaccine
CA2562642A1 (en) * 2004-04-13 2005-11-03 Alza Corporation Apparatus and method for transdermal delivery of multiple vaccines
US20050240154A1 (en) * 2004-04-21 2005-10-27 Unomedical A/S: Infusion set with patch
US7396484B2 (en) * 2004-04-30 2008-07-08 Becton, Dickinson And Company Methods of fabricating complex blade geometries from silicon wafers and strengthening blade geometries
US7909776B2 (en) * 2004-04-30 2011-03-22 Roche Diagnostics Operations, Inc. Lancets for bodily fluid sampling supplied on a tape
US8591436B2 (en) * 2004-04-30 2013-11-26 Roche Diagnostics Operations, Inc. Lancets for bodily fluid sampling supplied on a tape
WO2005115360A2 (en) * 2004-05-11 2005-12-08 Becton, Dickinson And Company Formulations of anti-pain agents and methods of using the same
US7591806B2 (en) * 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US8828203B2 (en) * 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
DE102004026087A1 (en) * 2004-05-25 2005-12-15 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Nano-cannula
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc Method and apparatus for a fluid sampling device
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
EP3329960A1 (en) * 2004-06-10 2018-06-06 3M Innovative Properties Company Patch application device and kit
WO2006014425A1 (en) * 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
TWI246929B (en) * 2004-07-16 2006-01-11 Ind Tech Res Inst Microneedle array device and its fabrication method
US7150904B2 (en) * 2004-07-27 2006-12-19 Ut-Battelle, Llc Composite, ordered material having sharp surface features
US7537590B2 (en) * 2004-07-30 2009-05-26 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
US20060030811A1 (en) * 2004-08-03 2006-02-09 Wong Patrick S Method and device for enhancing transdermal agent flux
US20060105453A1 (en) 2004-09-09 2006-05-18 Brenan Colin J Coating process for microfluidic sample arrays
US7086266B2 (en) * 2004-08-05 2006-08-08 Becton, Dickinson And Company Method of producing tapered or pointed cannula
US7076987B2 (en) * 2004-08-05 2006-07-18 Becton, Dickinson And Company Method of producing tapered or pointed cannula
US8062250B2 (en) * 2004-08-10 2011-11-22 Unomedical A/S Cannula device
US7024817B2 (en) * 2004-08-14 2006-04-11 Jeffrey Zehner Magic bean wishes
US7132054B1 (en) * 2004-09-08 2006-11-07 Sandia Corporation Method to fabricate hollow microneedle arrays
US20090023127A1 (en) * 2004-10-12 2009-01-22 Agency For Science, Technology And Research Tissue system and methods of use
EP1802737A4 (en) * 2004-10-12 2010-08-18 Agency Science Tech & Res Tissue system and methods of use
US7627938B2 (en) * 2004-10-15 2009-12-08 Board Of Regents, The Univeristy Of Texas System Tapered hollow metallic microneedle array assembly and method of making and using the same
US7250550B2 (en) * 2004-10-22 2007-07-31 Wright Medical Technology, Inc. Synthetic bone substitute material
US7097776B2 (en) * 2004-10-22 2006-08-29 Hewlett-Packard Development Company, L.P. Method of fabricating microneedles
US7785459B2 (en) 2004-10-22 2010-08-31 Hewlett-Packard Development Company, L.P. Microneedles and methods of fabricating
US7771803B2 (en) 2004-10-27 2010-08-10 Palo Alto Research Center Incorporated Oblique parts or surfaces
CA2586690A1 (en) * 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics, Inc. Influenza vaccination
US7455688B2 (en) * 2004-11-12 2008-11-25 Con Interventional Systems, Inc. Ostial stent
US9339403B2 (en) * 2004-11-12 2016-05-17 Icon Medical Corp. Medical adhesive for medical devices
CA2587386C (en) 2004-11-18 2013-01-15 3M Innovative Properties Company Microneedle array applicator and retainer
KR20130026511A (en) 2004-11-18 2013-03-13 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Low-profile microneedle array applicator
US8057842B2 (en) 2004-11-18 2011-11-15 3M Innovative Properties Company Method of contact coating a microneedle array
JP4927751B2 (en) * 2004-11-18 2012-05-09 スリーエム イノベイティブ プロパティズ カンパニー Microneedle array coating method
WO2006055844A2 (en) 2004-11-18 2006-05-26 3M Innovative Properties Company Method of contact coating a microneedle array
JP5039559B2 (en) * 2004-11-26 2012-10-03 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ Fine structure manufacturing method and fine structure manufacturing apparatus
CN100528091C (en) * 2004-11-30 2009-08-19 苏州纳生微电子有限公司 Cosmetic skin needle, its manufacturing method and use
US20080009800A1 (en) * 2004-12-02 2008-01-10 Nickel Janice H Transdermal drug delivery device
JP2008522875A (en) 2004-12-07 2008-07-03 スリーエム イノベイティブ プロパティズ カンパニー Microneedle molding method
US20060124466A1 (en) * 2004-12-09 2006-06-15 Scimed Life Systems, Inc. Method and apparatus for coating a medical device by electroplating
JP4964141B2 (en) * 2004-12-10 2012-06-27 ウノメディカル アクティーゼルスカブ Insertion tool
US7517043B2 (en) * 2004-12-16 2009-04-14 Xerox Corporation Fluidic structures
US7288327B2 (en) * 2004-12-16 2007-10-30 Xerox Corporation Plated structures or components
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US20080214917A1 (en) * 2004-12-30 2008-09-04 Dirk Boecker Method and apparatus for analyte measurement test time
KR20070100820A (en) * 2005-01-31 2007-10-11 가부시키가이샤 바이오세렌택 Transdermal absorption preparation, sheet holding transdermal absorption preparation and transdermal absorption preparation holder
KR20060089314A (en) * 2005-02-03 2006-08-09 삼성전자주식회사 Method for fabrication of micor needle array
US20060184065A1 (en) * 2005-02-10 2006-08-17 Ajay Deshmukh Method and apparatus for storing an analyte sampling and measurement device
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
WO2006110197A2 (en) * 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
US20060200048A1 (en) * 2005-03-03 2006-09-07 Icon Medical Corp. Removable sheath for device protection
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
US20060198869A1 (en) * 2005-03-03 2006-09-07 Icon Medical Corp. Bioabsorable medical devices
WO2006096251A2 (en) * 2005-03-03 2006-09-14 Icon Medical Corp. Improved metal alloys for medical device
US7452501B2 (en) * 2005-03-03 2008-11-18 Icon Medical Corp. Metal alloy for a stent
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
US7985199B2 (en) 2005-03-17 2011-07-26 Unomedical A/S Gateway system
KR20070121731A (en) * 2005-03-21 2007-12-27 우노메디컬 에이/에스 A mounting pad, an adhesive device comprising such mounting pad, and methods of applying such devices to a patient
JP4793806B2 (en) * 2005-03-22 2011-10-12 Tti・エルビュー株式会社 Iontophoresis device
WO2006101459A1 (en) * 2005-03-23 2006-09-28 Agency For Science, Technology And Research Microneedles
CA2602259A1 (en) * 2005-03-29 2006-10-05 Arkal Medical, Inc. Devices, systems, methods and tools for continuous glucose monitoring
US20070066138A1 (en) * 2005-04-05 2007-03-22 The Ohio State University Research Foundation Diffusion Delivery Systems and Methods of Fabrication
WO2006108185A1 (en) 2005-04-07 2006-10-12 3M Innovative Properties Company System and method for tool feedback sensing
US7999353B1 (en) 2005-04-26 2011-08-16 Northwestern University Mesoscale pyramids, hole arrays and methods of preparation
ES2820430T3 (en) * 2005-05-09 2021-04-21 Labrador Diagnostics Llc Fluid systems for care centers and their uses
US7442029B2 (en) * 2005-05-16 2008-10-28 Asml Netherlands B.V. Imprint lithography
US8048017B2 (en) * 2005-05-18 2011-11-01 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US8043250B2 (en) * 2005-05-18 2011-10-25 Nanomed Devices, Inc. High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US20080269666A1 (en) * 2005-05-25 2008-10-30 Georgia Tech Research Corporation Microneedles and Methods for Microinfusion
US20070032846A1 (en) * 2005-08-05 2007-02-08 Bran Ferren Holographic tattoo
JP4646705B2 (en) * 2005-06-03 2011-03-09 アルプス電気株式会社 Mold manufacturing method and molded product manufacturing method
EP1899001B1 (en) * 2005-06-08 2017-10-25 Novocure Limited Apparatus for treating cancer with electric fields that are guided to desired locations within a body
US20060281187A1 (en) * 2005-06-13 2006-12-14 Rosedale Medical, Inc. Analyte detection devices and methods with hematocrit/volume correction and feedback control
US20060283465A1 (en) * 2005-06-16 2006-12-21 Nickel Janice H Smart drug delivery system and a method of implementation thereof
EP1893130A4 (en) * 2005-06-17 2015-08-26 Georgia Tech Res Inst Coated microstructures and method of manufacture thereof
US20080195035A1 (en) * 2005-06-24 2008-08-14 Frederickson Franklyn L Collapsible Patch and Method of Application
WO2007002522A1 (en) 2005-06-27 2007-01-04 3M Innovative Properties Company Microneedle cartridge assembly and method of applying
CA2613111C (en) * 2005-06-27 2015-05-26 3M Innovative Properties Company Microneedle array applicator device and method of array application
DK1896097T3 (en) * 2005-06-28 2010-11-22 Unomedical As Packaging for infusion sets and method of using an infusion set
CN101227940A (en) * 2005-07-25 2008-07-23 纳米技术维多利亚有限公司 Microarray device
US20070078414A1 (en) * 2005-08-05 2007-04-05 Mcallister Devin V Methods and devices for delivering agents across biological barriers
US20070043381A1 (en) * 2005-08-19 2007-02-22 Icon Medical Corp. Medical device deployment instrument
CN101687094B (en) * 2005-09-06 2012-09-26 谢拉杰克特股份有限公司 Solid solution perforator containing drug particle and/or drug-adsorbed particles
US8025903B2 (en) 2005-09-09 2011-09-27 Wright Medical Technology, Inc. Composite bone graft substitute cement and articles produced therefrom
ES2402651T3 (en) 2005-09-09 2013-05-07 Agnovos Healthcare, Llc Cement substitute for bone graft of composite material and articles produced from it
PL1762259T3 (en) 2005-09-12 2011-03-31 Unomedical As Inserter for an infusion set with a first and second spring units
US20070088264A1 (en) * 2005-09-14 2007-04-19 Liebl Horst Device for introducing an active ingredient into the skin
WO2007032446A1 (en) * 2005-09-15 2007-03-22 Tti Ellebeau, Inc. Rod type iontophoresis device
US20070066934A1 (en) * 2005-09-19 2007-03-22 Transport Pharmaceuticals, Inc. Electrokinetic delivery system and methods therefor
US20070185432A1 (en) * 2005-09-19 2007-08-09 Transport Pharmaceuticals, Inc. Electrokinetic system and method for delivering methotrexate
WO2007038601A2 (en) * 2005-09-27 2007-04-05 Northeastern University Nanoloom for controlling polymer assembly
US20070073212A1 (en) * 2005-09-28 2007-03-29 Takehiko Matsumura Iontophoresis apparatus and method to deliver active agents to biological interfaces
WO2007041323A1 (en) * 2005-09-30 2007-04-12 Tti Ellebeau, Inc. Iontophoretic delivery of vesicle-encapsulated active agents
US8801631B2 (en) 2005-09-30 2014-08-12 Intuity Medical, Inc. Devices and methods for facilitating fluid transport
JP2009509685A (en) * 2005-09-30 2009-03-12 Tti・エルビュー株式会社 Iontophoresis device and method for delivery of angiogenic factors to enhance healing of damaged tissue
CA2623589C (en) * 2005-09-30 2014-07-22 Intuity Medical, Inc. Catalysts for body fluid sample extraction
US8233954B2 (en) * 2005-09-30 2012-07-31 Nellcor Puritan Bennett Llc Mucosal sensor for the assessment of tissue and blood constituents and technique for using the same
WO2007041314A2 (en) * 2005-09-30 2007-04-12 Tti Ellebeau, Inc. Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles
EP1928539A1 (en) * 2005-09-30 2008-06-11 Tti Ellebeau, Inc. Functionalized microneedles transdermal drug delivery systems, devices, and methods
WO2007041118A1 (en) * 2005-09-30 2007-04-12 Tti Ellebeau, Inc. Iontophoretic device and method of delivery of active agents to biological interface
RU2008117153A (en) * 2005-09-30 2009-11-10 ТиТиАй ЭЛЛЕБО, ИНК. (JP) IONTOPHORESIS DEVICE DELIVERING MANY ACTIVE AGENTS TO BIOLOGICAL BARRIERS
KR20080066712A (en) * 2005-09-30 2008-07-16 티티아이 엘뷰 가부시키가이샤 Functionalized microneedles transdermal drug delivery systems, devices, and methods
US20070191736A1 (en) * 2005-10-04 2007-08-16 Don Alden Method for loading penetrating members in a collection device
US20070276290A1 (en) * 2005-10-04 2007-11-29 Dirk Boecker Tissue Penetrating Apparatus
KR100682534B1 (en) 2005-10-10 2007-02-15 한국과학기술원 Method for manufacturing microneedle array
US20080262416A1 (en) * 2005-11-18 2008-10-23 Duan Daniel C Microneedle Arrays and Methods of Preparing Same
US8900180B2 (en) * 2005-11-18 2014-12-02 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
WO2007059289A1 (en) * 2005-11-18 2007-05-24 3M Innovative Properties Company Microneedle arrays and methods of preparing same
WO2007059979A2 (en) * 2005-11-23 2007-05-31 Universität Zürich Allergy treatment by epicutaneous allergen administration
EP1957145A4 (en) * 2005-11-30 2011-03-23 3M Innovative Properties Co Microneedle arrays and methods of use thereof
EP1957132A4 (en) * 2005-12-08 2010-04-21 Nanopass Technologies Ltd Microneedle adapter for dosed drug delivery devices
USD655807S1 (en) 2005-12-09 2012-03-13 Unomedical A/S Medical device
US7626123B2 (en) * 2005-12-12 2009-12-01 Raytheon Sarcos, Llc Electrical microfilament to circuit interface
US7603153B2 (en) * 2005-12-12 2009-10-13 Sterling Investments Lc Multi-element probe array
US7333699B2 (en) * 2005-12-12 2008-02-19 Raytheon Sarcos, Llc Ultra-high density connector
US8308960B2 (en) 2005-12-14 2012-11-13 Silex Microsystems Ab Methods for making micro needles and applications thereof
US9636035B2 (en) * 2005-12-14 2017-05-02 Scibase Ab Medical apparatus for determination of biological conditions using impedance measurements
WO2007075614A1 (en) * 2005-12-21 2007-07-05 3M Innovative Properties Company Microneedle devices
ATE429260T1 (en) * 2005-12-23 2009-05-15 Unomedical As ADMINISTRATION DEVICE
WO2007075806A2 (en) * 2005-12-23 2007-07-05 3M Innovative Properties Company Manufacturing microneedle arrays
WO2007079116A1 (en) * 2005-12-28 2007-07-12 Tti Ellebeau, Inc. Electroosmotic pump apparatus and method to deliver active agents to biological interfaces
WO2007079193A2 (en) * 2005-12-30 2007-07-12 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
US7658728B2 (en) * 2006-01-10 2010-02-09 Yuzhakov Vadim V Microneedle array, patch, and applicator for transdermal drug delivery
US20100168501A1 (en) * 2006-10-02 2010-07-01 Daniel Rogers Burnett Method and apparatus for magnetic induction therapy
US9610459B2 (en) * 2009-07-24 2017-04-04 Emkinetics, Inc. Cooling systems and methods for conductive coils
US9339641B2 (en) 2006-01-17 2016-05-17 Emkinetics, Inc. Method and apparatus for transdermal stimulation over the palmar and plantar surfaces
US7691077B2 (en) * 2006-01-31 2010-04-06 Kralick Francis A Implantable micro-system for treatment of hydrocephalus
US20070179599A1 (en) * 2006-01-31 2007-08-02 Icon Medical Corp. Vascular protective device
US20070191811A1 (en) * 2006-02-10 2007-08-16 Joseph Berglund System and Method for Treating a Vascular Condition
US20090218243A1 (en) * 2006-02-13 2009-09-03 Unomedical A/S Packing for Injection Device
JP2009527275A (en) * 2006-02-17 2009-07-30 ゾゲニクス インコーポレーティッド Methods and systems for delivery of neurotoxins
US7415858B2 (en) 2006-02-21 2008-08-26 Tyco Healthcare Group Lp Grindless surgical needle manufacture
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
NZ570115A (en) * 2006-02-28 2010-07-30 Unomedical As Inserter for infusion part and infusion part provided with needle protector
US8741230B2 (en) * 2006-03-24 2014-06-03 Theranos, Inc. Systems and methods of sample processing and fluid control in a fluidic system
US20070224235A1 (en) * 2006-03-24 2007-09-27 Barron Tenney Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US11287421B2 (en) 2006-03-24 2022-03-29 Labrador Diagnostics Llc Systems and methods of sample processing and fluid control in a fluidic system
US20070224252A1 (en) * 2006-03-27 2007-09-27 Trautman Joseph C Microprojections with capillary control features and method
US20080154107A1 (en) * 2006-12-20 2008-06-26 Jina Arvind N Device, systems, methods and tools for continuous glucose monitoring
US20090131778A1 (en) * 2006-03-28 2009-05-21 Jina Arvind N Devices, systems, methods and tools for continuous glucose monitoring
US20100049021A1 (en) * 2006-03-28 2010-02-25 Jina Arvind N Devices, systems, methods and tools for continuous analyte monitoring
US20080004564A1 (en) * 2006-03-30 2008-01-03 Transcutaneous Technologies Inc. Controlled release membrane and methods of use
CA2646324C (en) 2006-03-30 2016-06-07 Valeritas, Llc Multi-cartridge fluid delivery device
CN1830496A (en) * 2006-04-10 2006-09-13 清华大学 '-'-shaped structure three-dimensional micre solid, hollow silicone meedle orknife
CN100457211C (en) * 2006-04-10 2009-02-04 清华大学 'I' structured three-dimensional micro solid/hollow silicon needle and silicon knife
WO2007124411A1 (en) * 2006-04-20 2007-11-01 3M Innovative Properties Company Device for applying a microneedle array
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US7918814B2 (en) * 2006-05-02 2011-04-05 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
US8007999B2 (en) 2006-05-10 2011-08-30 Theranos, Inc. Real-time detection of influenza virus
US20080063866A1 (en) * 2006-05-26 2008-03-13 Georgia Tech Research Corporation Method for Making Electrically Conductive Three-Dimensional Structures
US20070276318A1 (en) * 2006-05-26 2007-11-29 Mit, Llp Iontosonic-microneedle applicator apparatus and methods
US20070276330A1 (en) * 2006-05-28 2007-11-29 Beck Patricia A Microneedles and methods of fabricating thereof
US20070282246A1 (en) * 2006-06-05 2007-12-06 Mit, Llp Iontosonic-microneedle biosensor apparatus and methods
EP2023818A2 (en) * 2006-06-07 2009-02-18 Unomedical A/S Inserter for transcutaneous sensor
TW200744534A (en) * 2006-06-09 2007-12-16 Univ Nat Chiao Tung Microprobe array structure and manufacturing method thereof
CN101489604B (en) * 2006-06-09 2012-05-23 优诺医疗有限公司 Mounting pad
US20080008745A1 (en) * 2006-06-21 2008-01-10 University Of Kentucky Research Foundation Transdermal delivery of naltrexone hydrochloride, naltrexol hydrochloride, and bis(hydroxy-methyl)propionyl-3-0 ester naltrexone using microneedles
DE102006028781A1 (en) * 2006-06-23 2007-12-27 Robert Bosch Gmbh Process for making porous microneedles and their use
US8815275B2 (en) * 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
KR100792382B1 (en) * 2006-07-03 2008-01-08 호남석유화학 주식회사 A micro needle roller and forming mold thereof
WO2008004781A1 (en) * 2006-07-03 2008-01-10 Honam Petrochemical Corp. Micro neddle roller assembly
JP4265696B2 (en) * 2006-07-04 2009-05-20 凸版印刷株式会社 Manufacturing method of microneedle
US20080015494A1 (en) * 2006-07-11 2008-01-17 Microchips, Inc. Multi-reservoir pump device for dialysis, biosensing, or delivery of substances
US20080015522A1 (en) * 2006-07-11 2008-01-17 Nanopass Technologies Ltd. Dual Chamber Injector Integrated With Micro-Needles
US8250729B2 (en) * 2006-07-12 2012-08-28 University Of Utah Research Foundation 3D fabrication of needle tip geometry and knife blade
US8012566B2 (en) * 2006-07-12 2011-09-06 Hewlett-Packard Development Company, L.P. Microneedles formed by electroplating and selectively releasing temperature sensitive layers
WO2008008291A2 (en) * 2006-07-13 2008-01-17 Icon Medical Corp. Stent
US20080138581A1 (en) * 2006-07-17 2008-06-12 Rajmohan Bhandari Masking high-aspect aspect ratio structures
US8865288B2 (en) * 2006-07-17 2014-10-21 University Of Utah Research Foundation Micro-needle arrays having non-planar tips and methods of manufacture thereof
KR100793615B1 (en) 2006-07-21 2008-01-10 연세대학교 산학협력단 A biodegradable solid type microneedle and methods for preparing it
KR100781702B1 (en) * 2006-07-21 2007-12-03 연세대학교 산학협력단 A hollow type microneedle and methods for preparing it
US20090182306A1 (en) * 2006-07-21 2009-07-16 Georgia Tech Research Corporation Microneedle Devices and Methods of Drug Delivery or Fluid Withdrawal
EP2047882B1 (en) * 2006-07-27 2014-09-10 Toppan Printing Co., Ltd. Microneedle and method for producing microneedle
CN101500627B (en) 2006-08-02 2012-03-14 优诺医疗有限公司 Cannula and delivery device
JPWO2008020632A1 (en) * 2006-08-18 2010-01-07 凸版印刷株式会社 Microneedle and microneedle patch
JP2010502267A (en) * 2006-08-28 2010-01-28 エージェンシー・フォー・サイエンス・テクノロジー・アンド・リサーチ Microneedle and method for producing microneedle
WO2008054362A2 (en) * 2006-08-29 2008-05-08 Nanomed Devices, Inc. High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US20080058726A1 (en) * 2006-08-30 2008-03-06 Arvind Jina Methods and Apparatus Incorporating a Surface Penetration Device
CA2661879A1 (en) * 2006-09-05 2008-03-13 Tti Ellebeau, Inc. Transdermal drug delivery systems, devices, and methods using inductive power supplies
US20080097352A1 (en) * 2006-09-12 2008-04-24 Beck Patricia A Methods of fabricating microneedles with bio-sensory functionality
US20090318833A1 (en) * 2006-09-18 2009-12-24 Agency For Science Technology And Research Needle Structures and Methods for Fabricating Needle Structures
US10786669B2 (en) 2006-10-02 2020-09-29 Emkinetics, Inc. Method and apparatus for transdermal stimulation over the palmar and plantar surfaces
JP2010505471A (en) * 2006-10-02 2010-02-25 エムキネティクス, インコーポレイテッド Method and apparatus for magnetic induction therapy
US9005102B2 (en) 2006-10-02 2015-04-14 Emkinetics, Inc. Method and apparatus for electrical stimulation therapy
US11224742B2 (en) 2006-10-02 2022-01-18 Emkinetics, Inc. Methods and devices for performing electrical stimulation to treat various conditions
US9017697B2 (en) 2006-10-12 2015-04-28 The University Of Queensland Compositions and methods for modulating immune responses
EP1917990A1 (en) 2006-10-31 2008-05-07 Unomedical A/S Infusion set
US20080113391A1 (en) * 2006-11-14 2008-05-15 Ian Gibbons Detection and quantification of analytes in bodily fluids
AT504709B1 (en) 2006-11-23 2008-09-15 Erema METHOD AND DEVICE FOR INTRODUCING ADDITIVES
US8255061B2 (en) * 2008-07-29 2012-08-28 The Regents Of The University Of Michigan Compact multilevel electrical integration of microsystems
US7785301B2 (en) * 2006-11-28 2010-08-31 Vadim V Yuzhakov Tissue conforming microneedle array and patch for transdermal drug delivery or biological fluid collection
EP2061551A2 (en) * 2006-12-01 2009-05-27 TTI ellebeau, Inc. Systems, devices, and methods for powering and/or controlling devices, for instance transdermal delivery devices
US8238995B2 (en) * 2006-12-08 2012-08-07 General Electric Company Self-adhering electrodes and methods of making the same
US20080152592A1 (en) * 2006-12-21 2008-06-26 Bayer Healthcare Llc Method of therapeutic drug monitoring
US20080214987A1 (en) * 2006-12-22 2008-09-04 Nanomed Devices, Inc. Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances
US10525246B2 (en) 2006-12-22 2020-01-07 Nanomed Skincare, Inc. Microdevice and method for transdermal delivery and sampling of active substances
TW200829215A (en) * 2007-01-03 2008-07-16 Univ Nat Chiao Tung Micro probe array and manufacturing method of the trans-print mold thereof
DE102007002832A1 (en) * 2007-01-19 2008-07-24 Robert Bosch Gmbh Method for manufacturing device with arrangement of micro-needles, involves preparing silicon semiconductor substrate, whose surface is applied and structured with masking layer
AU2008209537B2 (en) * 2007-01-22 2013-01-31 Corium Pharma Solutions, Inc. Applicators for microneedle arrays
DE102007004344A1 (en) 2007-01-29 2008-07-31 Robert Bosch Gmbh Method for producing half taper micro needles in silicon semiconductor substrate for application of substances into skin, involves applying and structuring masking layer on external surface of front side of silicon semiconductor substrate
AU2008209700A1 (en) * 2007-02-02 2008-08-07 Unomedical A/S A gateway device
KR20080076434A (en) * 2007-02-16 2008-08-20 박정철 Biological information measuring apparatus and manufacturing method thereof
EP1967581B1 (en) * 2007-03-08 2016-08-17 Imec CMOS compatible method for manufacturing microneedle structures
US7713196B2 (en) 2007-03-09 2010-05-11 Nellcor Puritan Bennett Llc Method for evaluating skin hydration and fluid compartmentalization
US8560059B2 (en) * 2007-03-09 2013-10-15 Covidien Lp System and methods for optical sensing and drug delivery using microneedles
US20080234562A1 (en) * 2007-03-19 2008-09-25 Jina Arvind N Continuous analyte monitor with multi-point self-calibration
WO2008115224A2 (en) * 2007-03-20 2008-09-25 Bayer Healthcare Llc Method of analyzing an analyte
US20080249469A1 (en) * 2007-03-22 2008-10-09 Ponnambalam Selvaganapathy Method and apparatus for active control of drug delivery using electro-osmotic flow control
ES2817249T3 (en) 2007-04-16 2021-04-06 Corium Inc Microneedle matrices obtained by dissolution and casting containing an active principle
US20080269735A1 (en) * 2007-04-26 2008-10-30 Agustina Vila Echague Optical array for treating biological tissue
ES2911529T3 (en) * 2007-05-07 2022-05-19 Unomedical As supply device
US9149496B2 (en) 2007-05-10 2015-10-06 Cormatrix Cardiovascular, Inc. ECM Constructs for treating damaged biological tissue
US8694070B2 (en) 2007-05-22 2014-04-08 Persyst Development Corporation Electrode applicator for quick press on EEG electrode
WO2008147909A2 (en) 2007-05-22 2008-12-04 Persyst Development Corporation Method and device for quick press on eeg electrode
ES2351273T3 (en) * 2007-06-06 2011-02-02 Unomedical A/S PACKING THAT ALLOWS GAS STERILIZATION.
US20080312518A1 (en) * 2007-06-14 2008-12-18 Arkal Medical, Inc On-demand analyte monitor and method of use
EP2155296B1 (en) * 2007-06-20 2019-08-28 Unomedical A/S Cannula insertion device with automatic needle retraction comprising only one spring
DE202008017390U1 (en) 2007-06-20 2009-08-13 Unomedical A/S Catheter and device for making such a catheter
US8109904B1 (en) 2007-06-25 2012-02-07 Abbott Cardiovascular Systems Inc. Drug delivery medical devices
DE102007030710A1 (en) 2007-07-02 2009-01-08 Robert Bosch Gmbh Device for the storage and administration of active substances and a method for the administration of active substances by means of such a device
WO2009004026A1 (en) 2007-07-03 2009-01-08 Unomedical A/S Inserter having bistable equilibrium states
RU2010104457A (en) 2007-07-10 2011-08-20 Уномедикал А/С (Dk) TWO SPRING INPUT DEVICE
US7959969B2 (en) 2007-07-10 2011-06-14 California Institute Of Technology Fabrication of anchored carbon nanotube array devices for integrated light collection and energy conversion
RU2010105684A (en) * 2007-07-18 2011-08-27 Уномедикал А/С (Dk) TURNING INTRODUCTION DEVICE
US8815273B2 (en) * 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
WO2009020520A1 (en) * 2007-08-03 2009-02-12 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8158430B1 (en) 2007-08-06 2012-04-17 Theranos, Inc. Systems and methods of fluidic sample processing
US20090053673A1 (en) * 2007-08-23 2009-02-26 Zimmer, Inc. Method for localized treatment of periodontal tissue
WO2009029572A1 (en) * 2007-08-24 2009-03-05 Deka Products Limited Partnership Microneedle systems and apparatus
US20100121307A1 (en) * 2007-08-24 2010-05-13 Microfabrica Inc. Microneedles, Microneedle Arrays, Methods for Making, and Transdermal and/or Intradermal Applications
US9656019B2 (en) 2007-10-02 2017-05-23 Medimop Medical Projects Ltd. Apparatuses for securing components of a drug delivery system during transport and methods of using same
WO2009044401A2 (en) 2007-10-02 2009-04-09 Yossi Gross External drug pump
US10420880B2 (en) 2007-10-02 2019-09-24 West Pharma. Services IL, Ltd. Key for securing components of a drug delivery system during assembly and/or transport and methods of using same
US9345836B2 (en) 2007-10-02 2016-05-24 Medimop Medical Projects Ltd. Disengagement resistant telescoping assembly and unidirectional method of assembly for such
US7967795B1 (en) 2010-01-19 2011-06-28 Lamodel Ltd. Cartridge interface assembly with driving plunger
WO2009048607A1 (en) * 2007-10-10 2009-04-16 Corium International, Inc. Vaccine delivery via microneedle arrays
JP5178132B2 (en) * 2007-10-11 2013-04-10 キヤノン株式会社 Image processing system and image processing method
US20090099427A1 (en) * 2007-10-12 2009-04-16 Arkal Medical, Inc. Microneedle array with diverse needle configurations
WO2009065078A1 (en) * 2007-11-14 2009-05-22 Pathway Medical Technologies, Inc. Delivery and administration of compositions using interventional catheters
MY157968A (en) * 2007-11-14 2016-08-30 Mimos Berhad Method for fabricating microneedled and microneedle fabricated from the same
JP5461427B2 (en) 2007-12-17 2014-04-02 ニューワールド ファーマシューティカルズ,エルエルシー Integrated intradermal delivery, diagnosis and communication system
WO2009079712A1 (en) 2007-12-24 2009-07-02 The University Of Queensland Coating method
US8750978B2 (en) * 2007-12-31 2014-06-10 Covidien Lp System and sensor for early detection of shock or perfusion failure and technique for using the same
WO2009094394A1 (en) * 2008-01-23 2009-07-30 Georgia Tech Research Corporation Microneedle devices and methods of drug delivery or fluid withdrawal
EP2247527A4 (en) * 2008-02-07 2014-10-29 Univ Queensland Patch production
EP2452709B1 (en) * 2008-02-08 2022-01-19 Unomedical A/S Cannula part
US20110046456A1 (en) * 2008-02-08 2011-02-24 Hoerdum Elo Lau Assembly Comprising Inserter, Cannula Part and Base Part
US20090204077A1 (en) * 2008-02-13 2009-08-13 Hasted Soren B Moulded Connection Between Cannula and Delivery Part
GB0802447D0 (en) 2008-02-09 2008-03-19 Univ Manchester Fluid extraction device, associated materials and methods
NZ587111A (en) * 2008-02-13 2012-03-30 Unomedical As Infusion part including seal between cannula and fluid inlet or outlet
AU2009216703A1 (en) 2008-02-20 2009-08-27 Unomedical A/S Insertion device with horizontally moving part
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
BRPI0908258A2 (en) * 2008-02-25 2017-10-17 Unomedical As membrane completely covering an opening of a needle giving access to a space in a device, device and assembly comprising a device
US8398397B2 (en) * 2008-03-12 2013-03-19 Ultradent Products, Inc. Dental intraligamentary injection needles and related methods of manufacture
EP2265324B1 (en) 2008-04-11 2015-01-28 Sanofi-Aventis Deutschland GmbH Integrated analyte measurement system
WO2009131911A2 (en) 2008-04-22 2009-10-29 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
WO2009132176A2 (en) * 2008-04-24 2009-10-29 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
WO2009137609A2 (en) * 2008-05-06 2009-11-12 Cellutions, Inc. Apparatus and systems for treating a human tissue condition
US20090301994A1 (en) * 2008-05-12 2009-12-10 Rajmohan Bhandari Methods for Wafer Scale Processing of Needle Array Devices
CN102105108B (en) * 2008-05-21 2013-12-04 谢拉杰克特股份有限公司 Method of manufacturing solid solution peforator patches and uses thereof
CA2760680A1 (en) * 2008-05-23 2009-11-26 The University Of Queensland Analyte detection by microneedle patch with analyte selective reagents
WO2009145920A1 (en) 2008-05-30 2009-12-03 Intuity Medical, Inc. Body fluid sampling device -- sampling site interface
US8886279B2 (en) 2008-06-03 2014-11-11 University Of Utah Research Foundation High aspect ratio microelectrode arrays enabled to have customizable lengths and methods of making the same
WO2009149308A2 (en) * 2008-06-04 2009-12-10 Seventh Sense Biosystems, Inc. Compositions and methods for rapid one-step diagnosis
ES2907152T3 (en) 2008-06-06 2022-04-22 Intuity Medical Inc Blood glucose meter and method of operation
JP5642066B2 (en) 2008-06-06 2014-12-17 インテュイティ メディカル インコーポレイテッド Method and apparatus for performing an assay to determine the presence or concentration of an analyte contained in a sample of body fluid
EP2303350A2 (en) * 2008-06-18 2011-04-06 Boston Scientific Scimed, Inc. Endoprosthesis coating
KR100938631B1 (en) * 2008-06-18 2010-01-22 주식회사 누리엠웰니스 Process for Preparing Solid Microstructures
WO2009158477A1 (en) * 2008-06-25 2009-12-30 Us Worldmeds Llc Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
WO2010003886A1 (en) * 2008-07-07 2010-01-14 Unomedical A/S Inserter for transcutaneous device
CN101347652B (en) * 2008-09-09 2011-01-12 南京大学 Method for preparing hollow micro-needle array injection syringe
US9393369B2 (en) 2008-09-15 2016-07-19 Medimop Medical Projects Ltd. Stabilized pen injector
US20110226652A1 (en) * 2008-09-29 2011-09-22 Richard Morgan Hickmott Packing for Inserter
WO2010039006A2 (en) * 2008-10-02 2010-04-08 연세대학교 산학협력단 Method of manufacturing solid microstructure and solid microstructure manufactured based on same
US20100145305A1 (en) * 2008-11-10 2010-06-10 Ruth Alon Low volume accurate injector
KR20190064676A (en) * 2008-11-18 2019-06-10 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Hollow microneedle array
US8639312B2 (en) * 2008-12-10 2014-01-28 University Of Utah Research Foundation System and method for electrically shielding a microelectrode array in a physiological pathway from electrical noise
CN102325563A (en) * 2008-12-22 2012-01-18 昆士兰大学 Patch production
KR20110127642A (en) 2008-12-22 2011-11-25 우노메디컬 에이/에스 Medical device comprising adhesive pad
US20100187132A1 (en) * 2008-12-29 2010-07-29 Don Alden Determination of the real electrochemical surface areas of screen printed electrodes
US8152779B2 (en) * 2008-12-30 2012-04-10 Medimop Medical Projects Ltd. Needle assembly for drug pump
EP2381972A2 (en) 2009-01-27 2011-11-02 California Institute Of Technology Drug delivery and substance transfer facilitated by nano-enhanced device having aligned carbon nanotubes protruding from device surface
US9375169B2 (en) * 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
CN102307590A (en) 2009-02-10 2012-01-04 诺华有限公司 Influenza vaccines with reduced amounts of squalene
CN102421479A (en) 2009-02-26 2012-04-18 北卡罗来纳大学查珀尔希尔分校 Interventional drug delivery system and associated methods
US20110105951A1 (en) 2009-10-30 2011-05-05 Seventh Sense Biosystems, Inc. Systems and methods for treating, sanitizing, and/or shielding the skin or devices applied to the skin
US20110172508A1 (en) * 2010-01-13 2011-07-14 Seventh Sense Biosystems, Inc. Sampling device interfaces
US20110288389A9 (en) 2009-03-02 2011-11-24 Seventh Sense Biosystems, Inc. Oxygen sensor
US9033898B2 (en) 2010-06-23 2015-05-19 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
WO2012018486A2 (en) 2010-07-26 2012-02-09 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
CN102405015B (en) 2009-03-02 2017-01-18 第七感生物系统有限公司 Devices and methods for the analysis of an extractable medium
US20110172510A1 (en) * 2010-01-13 2011-07-14 Seventh Sense Biosystems, Inc. Rapid delivery and/or withdrawal of fluids
US9295417B2 (en) 2011-04-29 2016-03-29 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
US9041541B2 (en) * 2010-01-28 2015-05-26 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
PL2403482T3 (en) 2009-03-04 2018-06-29 Emplicure Ab Abuse resistant formulation
WO2010110916A2 (en) 2009-03-26 2010-09-30 Seventh Sense Biosystems, Inc. Determination of tracers within subjects
WO2010110919A1 (en) 2009-03-26 2010-09-30 Seventh Sense Biosystems, Inc. Monitoring of implants and other devices
EP2416835B1 (en) 2009-04-10 2019-05-15 3M Innovative Properties Company Methods of making hollow microneedle arrays
BRPI1015460A2 (en) 2009-04-22 2020-08-18 Mercator Medsystems, Inc. guanetidine for use in the treatment of hypertension and hypertension treatment system
US20100274352A1 (en) * 2009-04-24 2010-10-28 Boston Scientific Scrimed, Inc. Endoprosthesis with Selective Drug Coatings
ES2634667T3 (en) * 2009-04-24 2017-09-28 Corium International, Inc. Methods for manufacturing microprojection assemblies
ES2626433T3 (en) 2009-04-27 2017-07-25 Avery Dennison Corporation Releasable adhesive that has a multilayer substrate
US8957277B2 (en) 2009-04-27 2015-02-17 Avery Dennison Corporation Disruptable adhesive layer for fluid activated debonding
WO2010129899A1 (en) * 2009-05-08 2010-11-11 Cellutions, Inc. Treatment system with a pulse forming network for achieving plasma in tissue
WO2010128300A1 (en) 2009-05-08 2010-11-11 Aduro Materials Ab Composition for sustained drug delivery comprising geopolymeric binder
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
KR101213223B1 (en) * 2009-07-07 2013-01-09 한국전자통신연구원 The method for manufacturing hallow microneedle structures
EP2275164A1 (en) 2009-07-15 2011-01-19 Debiotech S.A. Multichannel micro-needles
KR101261466B1 (en) * 2009-07-17 2013-05-10 한국전자통신연구원 The method for manufacturing hallow micro needle structures
KR20120054598A (en) 2009-07-30 2012-05-30 우노메디컬 에이/에스 Inserter device with horizontal moving part
CA2766961A1 (en) 2009-08-07 2011-02-10 Unomedical A/S Delivery device with sensor and one or more cannulas
US8062568B2 (en) * 2009-08-27 2011-11-22 Korea University Research And Business Foundation Nano pattern writer
US10071196B2 (en) 2012-05-15 2018-09-11 West Pharma. Services IL, Ltd. Method for selectively powering a battery-operated drug-delivery device and device therefor
US10071198B2 (en) 2012-11-02 2018-09-11 West Pharma. Servicees IL, Ltd. Adhesive structure for medical device
US8157769B2 (en) * 2009-09-15 2012-04-17 Medimop Medical Projects Ltd. Cartridge insertion assembly for drug delivery system
CN102781463A (en) 2009-10-07 2012-11-14 戈诺珍公司 Methods and compositions for skin regeneration
KR101875858B1 (en) 2009-10-19 2018-07-06 테라노스, 인코포레이티드 Integrated health data capture and analysis system
US8834423B2 (en) 2009-10-23 2014-09-16 University of Pittsburgh—of the Commonwealth System of Higher Education Dissolvable microneedle arrays for transdermal delivery to human skin
JP2013508119A (en) 2009-10-26 2013-03-07 エムキネティクス, インコーポレイテッド Method and apparatus for electromagnetic stimulation of nerves, muscles and body tissues
WO2011053787A2 (en) 2009-10-30 2011-05-05 Seventh Sense Biosystems, Inc. Systems and methods for application to skin and control of actuation, delivery and/or perception thereof
CN102648015B (en) 2009-10-30 2016-10-19 第七感生物系统有限公司 It is applied to less device, modular system and the using method thereof of skin
WO2011065972A2 (en) 2009-11-24 2011-06-03 Seventh Sense Biosystems, Inc. Patient-enacted sampling technique
EP2506768B1 (en) 2009-11-30 2016-07-06 Intuity Medical, Inc. Calibration material delivery devices and methods
JP5785559B2 (en) 2009-12-16 2015-09-30 クロンテック ファーマ アーベー Injection needle and injection device
US20110172638A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including multi-functional cover
US20110172609A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
US20110172639A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Device and method for delivery of microneedle to desired depth within the skin
US20110172637A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including tissue support structure
US20110172645A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Wearable drug delivery device including integrated pumping and activation elements
EP3243435A1 (en) 2010-01-13 2017-11-15 Seventh Sense Biosystems, Inc. Sampling device interfaces
US8348898B2 (en) 2010-01-19 2013-01-08 Medimop Medical Projects Ltd. Automatic needle for drug pump
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
WO2011112713A2 (en) * 2010-03-09 2011-09-15 Toxcure, Inc. Microneedle nasal delivery device
US9327105B2 (en) * 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
BR112012024635A2 (en) 2010-03-30 2017-08-08 Unomedical As medical device
KR101254240B1 (en) * 2010-12-17 2013-04-12 주식회사 라파스 Process for preparing microstructures
US9115424B2 (en) 2010-04-07 2015-08-25 California Institute Of Technology Simple method for producing superhydrophobic carbon nanotube array
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
JP5868953B2 (en) 2010-04-28 2016-02-24 キンバリー クラーク ワールドワイド インコーポレイテッド Injection mold microneedle array and manufacturing method thereof
WO2011135531A2 (en) 2010-04-28 2011-11-03 Kimberly-Clark Worldwide, Inc. MEDICAL DEVICES FOR DELIVERY OF siRNA
FR2959599B1 (en) * 2010-04-28 2013-12-20 Commissariat Energie Atomique DEVICE AND METHOD FOR MECHANICAL TEXTURATION OF A SILICON PLATELET FOR CONSTITUTING A PHOTOVOLTAIC CELL, SILICON PLATE OBTAINED
CA2796965C (en) * 2010-04-28 2019-04-16 Kimberly-Clark Worldwide, Inc. Method for increasing permeability of an epithelial barrier
MX345837B (en) 2010-04-28 2017-02-16 Kimberly-Clark Worldwide Incorporated Device for delivery of rheumatoid arthritis medication.
EP2563303A4 (en) 2010-04-30 2013-11-06 Seros Medical Llc Method and apparatus for treatment of ocular tissue using combined modalities
ES2719595T3 (en) 2010-05-04 2019-07-11 Corium Int Inc Method and device for transdermal administration of parathyroid hormone using a microprojection matrix
US9452261B2 (en) 2010-05-10 2016-09-27 Medimop Medical Projects Ltd. Low volume accurate injector
US8920490B2 (en) * 2010-05-13 2014-12-30 Boston Scientific Scimed, Inc. Endoprostheses
US8588884B2 (en) 2010-05-28 2013-11-19 Emkinetics, Inc. Microneedle electrode
TWI455722B (en) 2010-06-04 2014-10-11 Pfizer Vaccines Llc Conjugates for the prevention or treatment of nicotine addiction
CN101905856B (en) * 2010-06-11 2012-10-10 北京大学 Method for preparing plane hollow microneedle for transdermal administration
EP2584964B1 (en) 2010-06-25 2021-08-04 Intuity Medical, Inc. Analyte monitoring devices
WO2012006677A1 (en) 2010-07-14 2012-01-19 The University Of Queensland Patch applying apparatus
CN103068308B (en) 2010-07-16 2016-03-16 第七感生物系统有限公司 For the lower pressure environment of fluid conveying device
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
US20120039809A1 (en) 2010-08-13 2012-02-16 Seventh Sense Biosystems, Inc. Systems and techniques for monitoring subjects
EP2603256B1 (en) 2010-08-13 2015-07-22 Seventh Sense Biosystems, Inc. Clinical and/or consumer techniques and devices
CA2809927C (en) * 2010-09-07 2019-08-20 Orexo Ab A transdermal drug administration device
EP2433663A1 (en) 2010-09-27 2012-03-28 Unomedical A/S Insertion system
CN104531671A (en) 2010-10-01 2015-04-22 现代治疗公司 Engineered nucleic acids and methods of use thereof
EP2436412A1 (en) 2010-10-04 2012-04-04 Unomedical A/S A sprinkler cannula
EP2627292B1 (en) 2010-10-15 2018-10-10 Clearside Biomedical, Inc. Device for ocular access
EP4218891A1 (en) 2010-10-19 2023-08-02 Trustees Of Tufts College Silk fibroin-based microneedles and methods of making the same
EP2635596B8 (en) 2010-11-01 2020-03-11 University of Technology Sydney Immune-modulating agents and uses therefor
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
US8808202B2 (en) 2010-11-09 2014-08-19 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
US8609458B2 (en) 2010-12-10 2013-12-17 California Institute Of Technology Method for producing graphene oxide with tunable gap
KR101159697B1 (en) 2010-12-30 2012-06-26 광주과학기술원 Fabrication method of invasive microelectode based on glass wafer
WO2012112543A2 (en) 2011-02-15 2012-08-23 Seros Medical, Llc Method and apparatus for the delivery of photo-chemical (cross-linking) treatment to scleral tissue
JP5995954B2 (en) * 2011-03-22 2016-09-28 チャン へ バイオ−メディカル サイエンス(ヤンジョウ) カンパニー リミテッド Medical device and manufacturing method thereof
USD702834S1 (en) 2011-03-22 2014-04-15 Medimop Medical Projects Ltd. Cartridge for use in injection device
US8976507B2 (en) 2011-03-29 2015-03-10 California Institute Of Technology Method to increase the capacitance of electrochemical carbon nanotube capacitors by conformal deposition of nanoparticles
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20120271125A1 (en) 2011-04-11 2012-10-25 Seventh Sense Biosystems, Inc. Devices and methods for delivery and/or withdrawal of fluids and preservation of withdrawn fluids
US9120669B2 (en) 2011-04-21 2015-09-01 Massachusetts Institute Of Technology Process for making nanocone structures and using the structures to manufacture nanostructured glass
AU2012249692A1 (en) 2011-04-29 2013-11-14 Seventh Sense Biosystems, Inc. Delivering and/or receiving fluids
US20130158468A1 (en) 2011-12-19 2013-06-20 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
CN103874461B (en) 2011-04-29 2017-05-10 第七感生物系统有限公司 Devices for collection and/or manipulation of blood spots or other bodily fluids
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CN106929401B (en) * 2011-05-05 2020-06-09 安派科生物医学科技有限公司 Tumor cell detector
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
WO2012170204A1 (en) * 2011-06-08 2012-12-13 3M Innovative Properties Company Photoresists containing polymer-tethered nanoparticles
RU2014102493A (en) 2011-06-29 2015-08-10 Аллерган, Инк. ALCAFTADINE FOR USE IN THE TREATMENT OF URTICARIA
EP4339613A2 (en) 2011-08-03 2024-03-20 Intuity Medical, Inc. Body fluid sampling arrangement
EP2744562A1 (en) * 2011-08-16 2014-06-25 Institut National de la Santé et de la Recherche Medicale Device for the treatment of an ocular disease
DK2750705T3 (en) * 2011-08-31 2023-01-23 Perosphere Tech Inc Methods for effectively and rapidly desensitizing allergic patients
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2013059424A (en) 2011-09-12 2013-04-04 Daicel Corp Needleless syringe
ES2549785T3 (en) * 2011-09-23 2015-11-02 F. Hoffmann-La Roche Ag Engraving procedure by mask of a puncture element
US9700245B2 (en) 2011-09-23 2017-07-11 Itrace Biomedical Inc. Transdermal analyte extraction and detection system and the method thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013050277A1 (en) 2011-10-05 2013-04-11 Unomedical A/S Inserter for simultaneous insertion of multiple transcutaneous parts
US11179553B2 (en) 2011-10-12 2021-11-23 Vaxxas Pty Limited Delivery device
US20130096532A1 (en) * 2011-10-17 2013-04-18 Rutgers, The State University Of New Jersey Polymer-Based Micro-Needle Array Designs, Fabrication Processes, and Methods of Use Thereof for Drug Delivery
EP2583715A1 (en) 2011-10-19 2013-04-24 Unomedical A/S Infusion tube system and method for manufacture
CA2887597C (en) 2011-10-19 2018-01-09 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
US9949677B2 (en) * 2011-10-21 2018-04-24 Incube Labs, Llc Implantable oximetric measurement apparatus and method of use
KR20140079429A (en) 2011-10-27 2014-06-26 킴벌리-클라크 월드와이드, 인크. Implantable devices for delivery of bioactive agents
US20170246439A9 (en) 2011-10-27 2017-08-31 Kimberly-Clark Worldwide, Inc. Increased Bioavailability of Transdermally Delivered Agents
EP2771059B1 (en) * 2011-10-27 2019-07-17 Sorrento Therapeutics, Inc. Transdermal delivery of high viscosity bioactive agents
US9440051B2 (en) 2011-10-27 2016-09-13 Unomedical A/S Inserter for a multiplicity of subcutaneous parts
DK2773304T3 (en) 2011-10-31 2016-05-02 Avery Dennison Corp Adhesive layers, which can be torn apart, to the fluid-activated solution.
ES2728143T3 (en) 2011-11-11 2019-10-22 Univ California Transcutaneous spinal cord stimulation: non-invasive tool for locomotor circuit activation
US8666484B2 (en) 2011-11-25 2014-03-04 Persyst Development Corporation Method and system for displaying EEG data
US9055927B2 (en) 2011-11-25 2015-06-16 Persyst Development Corporation User interface for artifact removal in an EEG
CN104039221B (en) 2011-11-26 2016-03-16 珀西斯特发展公司 For detecting and removing the method and system of EEG pseudomorphism
WO2013090844A1 (en) 2011-12-14 2013-06-20 California Institute Of Technology Sharp tip carbon nanotube microneedle devices and their fabrication
JP2015501844A (en) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. Modified nucleosides, nucleotides and nucleic acid compositions
US9872982B2 (en) 2012-01-10 2018-01-23 University of Pittsburgh—of the Commonwealth System of Higher Education Electroosmotic convection-enhanced delivery system
US20150038911A1 (en) 2012-01-24 2015-02-05 Nanopass Technologies Ltd Microneedle adapter for dosed drug delivery devices
CN103301092B (en) 2012-03-06 2014-12-03 中国科学院理化技术研究所 Polymer micro-needle array chip, and preparation method and application thereof
US9072827B2 (en) 2012-03-26 2015-07-07 Medimop Medical Projects Ltd. Fail safe point protector for needle safety flap
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (en) 2012-04-02 2021-10-21 Modernatx, Inc. MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH DISEASES IN HUMANS
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9944019B2 (en) 2012-05-01 2018-04-17 University of Pittsburgh—of the Commonwealth System of Higher Education Tip-loaded microneedle arrays for transdermal insertion
ES2743733T3 (en) 2012-06-15 2020-02-20 Univ Washington Through Its Center For Commercialization Wound closure devices based on microstructures
KR101575039B1 (en) * 2012-07-19 2015-12-07 (주)아모레퍼시픽 Nozzle device and minimal invasive injection device comprising the same
US9349543B2 (en) 2012-07-30 2016-05-24 California Institute Of Technology Nano tri-carbon composite systems and manufacture
US10980865B2 (en) 2012-08-10 2021-04-20 Aquavit Pharmaceuticals, Inc. Direct application system and method for the delivery of bioactive compositions and formulations
WO2014053081A1 (en) 2012-10-01 2014-04-10 The Hong Kong University Of Science And Technology Design and manufacture of nonelectronic, active-infusion patch and device for transdermal delivery across skin
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
CN104870567B (en) 2012-10-22 2018-09-07 艾利丹尼森公司 It is dispersed in the hybrid material of the crosslinked micro-gel particles in adhesive
KR20210133321A (en) 2012-11-08 2021-11-05 클리어사이드 바이오메디컬, 인코포레이드 Methods and devices for the treatment of ocular disease in human subjects
HRP20220607T1 (en) 2012-11-26 2022-06-24 Modernatx, Inc. Terminally modified rna
US9540684B2 (en) 2012-12-14 2017-01-10 Mindera Corporation Methods and devices for detection and acquisition of biomarkers
EP2937111B1 (en) * 2012-12-21 2020-03-18 Hisamitsu Pharmaceutical Co., Inc. Applicator
CA2896188C (en) 2012-12-21 2021-02-23 Corium International, Inc. Microarray for delivery of therapeutic agent and methods of use
US9421323B2 (en) 2013-01-03 2016-08-23 Medimop Medical Projects Ltd. Door and doorstop for portable one use drug delivery apparatus
US10179239B2 (en) 2013-01-15 2019-01-15 Itrace Biomedical Inc. Personalized pain management treatments
US9710607B2 (en) 2013-01-15 2017-07-18 Itrace Biomedical Inc. Portable electronic therapy device and the method thereof
WO2014113679A1 (en) * 2013-01-18 2014-07-24 The University Of North Carolina At Chapel Hill High-throughput manufacturing of microneedles
US20140207046A1 (en) * 2013-01-24 2014-07-24 InrexRem LED induced tattoo removal system and method of use
US9345487B2 (en) 2013-02-05 2016-05-24 Path Scientific, Llc Precision bone drill and method of use
ES2588485T5 (en) 2013-02-12 2020-02-27 Carbon Inc Continuous liquid interface printing
FI2964088T3 (en) * 2013-03-08 2023-05-31 Li Galli B V I O Vaginal drug delivery and/or diagnostic system
AU2014249471B2 (en) 2013-03-12 2019-01-24 Corium Pharma Solutions, Inc. Microprojection applicators
US9192313B1 (en) 2013-03-14 2015-11-24 Orbital Research Inc. Dry physiological recording device and method of manufacturing
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MX2015012933A (en) 2013-03-15 2016-09-19 Corium Int Inc Microarray for delivery of therapeutic agent and methods of use.
WO2014150601A2 (en) 2013-03-15 2014-09-25 Bridge Labs, Llc Scleral translocation elasto-modulation methods and apparatus
US9993642B2 (en) 2013-03-15 2018-06-12 The Regents Of The University Of California Multi-site transcutaneous electrical stimulation of the spinal cord for facilitation of locomotion
ES2939317T3 (en) 2013-03-15 2023-04-20 Corium Pharma Solutions Inc Multi-impact micro-spray applicators
CA2903763C (en) 2013-03-15 2021-11-16 Corium International, Inc. Microarray with polymer-free microstructures, methods of making, and methods of use
JP2016512754A (en) 2013-03-15 2016-05-09 コリウム インターナショナル, インコーポレイテッド Microarray, method of use and manufacturing for delivery of therapeutic agents
US9011164B2 (en) 2013-04-30 2015-04-21 Medimop Medical Projects Ltd. Clip contact for easy installation of printed circuit board PCB
WO2014179698A2 (en) 2013-05-03 2014-11-06 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US10188550B2 (en) 2013-06-03 2019-01-29 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
JP6533520B2 (en) 2013-06-13 2019-06-19 マイクロダーミクス インコーポレイテッドMicrodermics Inc. Method of making metal microneedle
JP2016522070A (en) 2013-06-21 2016-07-28 インテュイティ メディカル インコーポレイテッド Analyte monitoring system using audible feedback
US9355790B2 (en) * 2013-06-27 2016-05-31 Intel Corporation Energy storage devices having enhanced specific energy and associated methods
GB2517707B (en) 2013-08-28 2020-09-02 Pci Biotech As A device for light-induced rupture of endocytic vesicles to effect the delivery of an antigen
US11185271B2 (en) 2013-09-13 2021-11-30 University Of Utah Research Foundation Methods of making micro-molded electrodes and arrays
DE102013219432A1 (en) * 2013-09-26 2015-03-26 Peter Röhr Blood collection device and method for withdrawing blood
AU2014324660A1 (en) 2013-09-27 2016-04-21 The Regents Of The University Of California Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
EP3067088B1 (en) 2013-11-05 2019-09-04 Hisamitsu Pharmaceutical Co., Inc. Applicator
WO2015073919A1 (en) * 2013-11-14 2015-05-21 University Medical Pharmaceuticals Corporation Microneedles for therapeutic agent delivery with improved mechanical properties
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
WO2015095772A2 (en) 2013-12-20 2015-06-25 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents
WO2015108510A1 (en) * 2014-01-15 2015-07-23 Cormatrix Cardiovascular, Inc. Ecm constructs for treating damaged biological tissue
US10929753B1 (en) 2014-01-20 2021-02-23 Persyst Development Corporation System and method for generating a probability value for an event
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
US9828284B2 (en) 2014-03-28 2017-11-28 Ut-Battelle, Llc Thermal history-based etching
US11351347B2 (en) 2014-04-23 2022-06-07 Vacu-Site Medical, Inc. Vacuum-assisted drug delivery device and method
US10426659B2 (en) 2014-04-23 2019-10-01 Vacu-Site Medical, Inc. Vacuum-assisted drug delivery device and method
CN113908424A (en) 2014-04-24 2022-01-11 佐治亚科技研究公司 Microneedle and method for producing same
KR101724251B1 (en) * 2014-04-30 2017-04-06 킴벌리-클라크 월드와이드, 인크. Draped microneedle array
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN106794321A (en) 2014-06-20 2017-05-31 科尼尔赛德生物医学公司 Variable-diameter intubation and for controlling the method to the insertion depth of drug delivery
JP6611801B2 (en) 2014-06-20 2019-11-27 カーボン,インコーポレイテッド Three-dimensional printing by reciprocating supply of polymerizable liquid
CN106535826A (en) 2014-06-24 2017-03-22 怡康医疗股份有限公司 Improved metal alloys for medical devices
AU2015305237B2 (en) 2014-08-21 2020-06-18 The Regents Of The University Of California Regulation of autonomic control of bladder voiding after a complete spinal cord injury
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
CA2959378A1 (en) 2014-08-27 2016-03-03 The Regents Of The University Of California Multi-electrode array for spinal cord epidural stimulation
US10624843B2 (en) 2014-09-04 2020-04-21 Corium, Inc. Microstructure array, methods of making, and methods of use
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
US10292734B1 (en) * 2014-10-24 2019-05-21 Verily Life Sciences Llc Micro-structures with magnetic removal capability and optionally clear optical path
US10105080B1 (en) * 2014-10-24 2018-10-23 Verily Life Sciences Llc Interstitial fluid sampling above microneedle array
US9974471B1 (en) 2014-10-24 2018-05-22 Verily Life Sciences Llc Analyte detection system and method for intradermal implantation of biocompatible optode nanosensors
CA2966191A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
US9986988B2 (en) 2014-11-27 2018-06-05 AOD Holdings, LLC Surgical retractor
US10792042B2 (en) * 2015-01-15 2020-10-06 Ethicon, Inc. Circular staplers having resorbable microneedles containing active agents
EP3253440B1 (en) 2015-02-02 2022-12-21 Vaxxas Pty Limited Microprojection array applicator
TWI585201B (en) * 2015-02-24 2017-06-01 國立清華大學 Fabrication of tethered/untethered 3d rolled-up tube/ring with patterned thin films
WO2016149673A1 (en) 2015-03-18 2016-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bioactive components conjugated to substrates of microneedle arrays
US10293120B2 (en) 2015-04-10 2019-05-21 West Pharma. Services IL, Ltd. Redundant injection device status indication
JP6803856B2 (en) 2015-05-11 2020-12-23 ディクロニス サーグル Composition for circulatory system visualization
US10149943B2 (en) 2015-05-29 2018-12-11 West Pharma. Services IL, Ltd. Linear rotation stabilizer for a telescoping syringe stopper driverdriving assembly
WO2017004067A1 (en) 2015-06-29 2017-01-05 Corium International, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
US10098574B1 (en) 2015-07-07 2018-10-16 Verily Life Sciences Llc Porous microneedles through sacrificial sugar incorporation, analyte detection system, and method for intradermal optode nanosensor implantation
US20170014247A1 (en) * 2015-07-15 2017-01-19 Cook Medical Technologies Llc Stent Anti-Migration Mechanism
DK3325081T3 (en) * 2015-07-24 2021-10-11 Sorrento Therapeutics Inc PROCEDURES FOR LYMPHATIC DELIVERY OF ACTIVE SUBSTANCES
CN108136177A (en) * 2015-08-06 2018-06-08 加利福尼亚大学董事会 For carrying out electrod-array of transcutaneous electrostimulation and application thereof to spinal cord
US11298533B2 (en) 2015-08-26 2022-04-12 The Regents Of The University Of California Concerted use of noninvasive neuromodulation device with exoskeleton to enable voluntary movement and greater muscle activation when stepping in a chronically paralyzed subject
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
JP6676644B2 (en) 2015-09-02 2020-04-08 久光製薬株式会社 applicator
GB2547062B (en) 2015-09-09 2020-03-04 Drawbridge Health Inc Systems, methods, and devices for sample collection, stabilization and preservation
WO2017045031A1 (en) 2015-09-18 2017-03-23 Vaxxas Pty Limited Microprojection arrays with microprojections having large surface area profiles
US10576207B2 (en) 2015-10-09 2020-03-03 West Pharma. Services IL, Ltd. Angled syringe patch injector
US9987432B2 (en) 2015-09-22 2018-06-05 West Pharma. Services IL, Ltd. Rotation resistant friction adapter for plunger driver of drug delivery device
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CN108430536B (en) 2015-10-09 2022-04-08 西医药服务以色列分公司 Method of filling a custom syringe
WO2017065570A1 (en) * 2015-10-14 2017-04-20 주식회사 주빅 Microstructure using gel-type polymer material, and method of manufacturing same
WO2017066768A1 (en) 2015-10-16 2017-04-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Mullti-component biio-active drug delivery and controlled release to the skin by microneedle array devices
US11097122B2 (en) 2015-11-04 2021-08-24 The Regents Of The University Of California Magnetic stimulation of the spinal cord to restore control of bladder and/or bowel
WO2017117133A1 (en) * 2015-12-28 2017-07-06 North Carolina State University Devices and methods for transdermal treatment of basal cell carcinoma
WO2017116076A1 (en) 2015-12-28 2017-07-06 주식회사 엔도더마 Microstructure for percutaneous absorption, and method for preparing same
CA3009853C (en) 2015-12-29 2023-08-01 Gajanan Kulkarni Transdermal microneedle drug delivery device and method
US11078453B2 (en) * 2016-01-04 2021-08-03 King Abdullah University Of Science And Technology Nanoneedles for intracellular applications
WO2017120322A1 (en) 2016-01-05 2017-07-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Skin microenvironment targeted delivery for promoting immune and other responses
WO2017123652A1 (en) 2016-01-11 2017-07-20 Verndari, Inc. Microneedle compositions and methods of using same
WO2017127215A1 (en) 2016-01-21 2017-07-27 Medimop Medical Projects Ltd. Needle insertion and retraction mechanism
JP6885960B2 (en) 2016-01-21 2021-06-16 ウェスト ファーマ サービシーズ イスラエル リミテッド Drug delivery device with visual indicators
CN111544704B (en) 2016-01-21 2022-06-03 西医药服务以色列有限公司 Force containment in autoinjectors
KR102206955B1 (en) * 2016-01-28 2021-01-25 가부시키가이샤 리코 Microneedle Array and Microneedle Sheet
EP3413851B1 (en) 2016-02-10 2023-09-27 Clearside Biomedical, Inc. Packaging
WO2017143153A1 (en) 2016-02-19 2017-08-24 North Carolina State University Methods and compositions related to physiologically responsive microneedle delivery systems
CN117462479A (en) 2016-03-01 2024-01-30 佐治亚科技研究公司 Microneedle particles, compositions, and methods of treating and delivering a substance of interest
US10939912B2 (en) 2016-03-01 2021-03-09 Kitotech Medical, Inc. Microstructure-based systems, apparatus, and methods for wound closure
WO2017151548A1 (en) 2016-03-04 2017-09-08 Mirus Llc Stent device for spinal fusion
WO2017161076A1 (en) 2016-03-16 2017-09-21 Medimop Medical Projects Ltd. Staged telescopic screw assembly having different visual indicators
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
KR101719319B1 (en) * 2016-04-05 2017-03-23 주식회사 엘지생활건강 Micro Needle structure for efficient skin-piercing
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
EP3452165A1 (en) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
JP6957525B2 (en) 2016-06-02 2021-11-02 ウェスト ファーマ サービシーズ イスラエル リミテッド Needle evacuation by 3 positions
US9629991B1 (en) 2016-06-08 2017-04-25 Eclipse Aesthetics, LLC Disposable radio frequency needle cartridges having absorbing containment barriers
US9636491B1 (en) 2016-06-08 2017-05-02 Eclipse Aesthetics, LLC Disposable needle cartridges having absorbing contaminant barriers
US10220195B2 (en) 2016-06-08 2019-03-05 Eclipse Medcorp, Llc Radio frequency needling device for use with disposable needle cartridges
KR101779393B1 (en) * 2016-07-22 2017-09-19 주식회사 파마리서치프로덕트 Microneedle array comprising nucleic acid and manufacture method thereof
EP3490453B1 (en) 2016-07-29 2021-12-01 YourBio Health, Inc. Device for receiving bodily fluid from a subject
EP3490635B1 (en) 2016-08-01 2021-11-17 West Pharma. Services Il, Ltd. Partial door closure prevention spring
JP6869327B2 (en) 2016-08-01 2021-05-12 ウェスト ファーマ サービシーズ イスラエル リミテッド Anti-rotation cartridge
WO2018031913A1 (en) 2016-08-12 2018-02-15 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
CN116585311A (en) 2016-09-22 2023-08-15 墨卡托医疗系统公司 Treatment of restenosis using temsirolimus
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
MX2019005833A (en) * 2016-11-21 2019-10-30 Eirion Therapeutics Inc Transdermal delivery of large agents.
AU2017378040B2 (en) 2016-12-16 2023-06-08 Sorrento Therapeutics, Inc. Application device for a fluid delivery apparatus and method of use
CN110494126A (en) 2016-12-22 2019-11-22 俄亥俄州国家创新基金会 Run through micro-structure for the cargo delivering based on nanochannel
WO2018132515A1 (en) 2017-01-10 2018-07-19 Drawbridge Health, Inc. Devices, systems, and methods for sample collection
US11197990B2 (en) * 2017-01-18 2021-12-14 Tc1 Llc Systems and methods for transcutaneous power transfer using microneedles
US11606948B2 (en) 2017-01-27 2023-03-21 Ariana Holdings Pty Ltd Chemical applicator for plant material
EP3595515A4 (en) 2017-03-14 2020-12-30 University of Connecticut Biodegradable pressure sensor
EP4306803A2 (en) 2017-03-31 2024-01-17 Vaxxas Pty Limited Device and method for coating surfaces
IL270450B2 (en) 2017-05-17 2023-09-01 Massachusetts Inst Technology Self-righting systems and related components and methods
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
KR20200008166A (en) 2017-05-26 2020-01-23 머케이터 메드시스템즈, 인크. Combination therapy for the treatment of restenosis
CN110869072B (en) 2017-05-30 2021-12-10 西部制药服务有限公司(以色列) Modular drive mechanism for a wearable injector
WO2018222874A1 (en) 2017-05-31 2018-12-06 Texas Tech University System Methods and devices for the treatment of food allergies
EP3639010A4 (en) 2017-06-13 2021-03-17 Vaxxas Pty Limited Quality control of substrate coatings
GB201709668D0 (en) * 2017-06-16 2017-08-02 Spts Technologies Ltd Microneedles
EP3974021B1 (en) 2017-06-30 2023-06-14 ONWARD Medical N.V. A system for neuromodulation
US10586751B2 (en) * 2017-08-03 2020-03-10 Advanced Semiconductor Engineering, Inc. Semiconductor package device and method of manufacturing the same
CA3071680A1 (en) 2017-08-04 2019-02-07 Vaxxas Pty Limited Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (map)
WO2019055594A1 (en) 2017-09-13 2019-03-21 North Carolina State University Locally-induced adipose tissue browning by microneedle patch for obesity treatment
CA3078555A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
GB2568287A (en) 2017-11-10 2019-05-15 Sisaf Ltd Apparatus and methods for the transdermal delivery of active agents
WO2019108570A2 (en) 2017-11-29 2019-06-06 Copernicus Therapeutics, Inc. Gene therapy for ocular improvement
WO2019115670A1 (en) * 2017-12-15 2019-06-20 Koninklijke Philips N.V. Wearable or insertable devices with microneedles that include mechanically-responsive material
EP3727141A4 (en) * 2017-12-21 2021-09-01 Georgia Tech Research Corporation Methods and systems for improved collection of interstitial fluid
JP7402799B2 (en) 2017-12-22 2023-12-21 ウェスト ファーマ サービシーズ イスラエル リミテッド Syringes available with different cartridge sizes
CN108237211B (en) * 2017-12-29 2020-05-19 广东工业大学 Manufacturing method of amorphous alloy microneedle
WO2019157319A1 (en) * 2018-02-12 2019-08-15 Flagship Pioneering Innovations V, Inc. Devices and methods for delivering material into a biological tissue or cell
CN112074227A (en) 2018-03-05 2020-12-11 康涅狄格大学 Core-shell microneedle platforms for transdermal and pulsatile drug/vaccine delivery and methods of making same
US11457855B2 (en) 2018-03-12 2022-10-04 Persyst Development Corporation Method and system for utilizing empirical null hypothesis for a biological time series
US11219416B2 (en) 2018-03-12 2022-01-11 Persyst Development Corporation Graphically displaying evoked potentials
WO2019178228A1 (en) 2018-03-14 2019-09-19 Mercator Medsystems, Inc. Medical instrument and medical method for localized drug delivery
US11202903B2 (en) 2018-05-17 2021-12-21 Massachusetts Institute Of Technology Systems for electrical stimulation
WO2019222605A1 (en) * 2018-05-18 2019-11-21 Northwestern University Devices and methods for light delivery
WO2020006413A1 (en) 2018-06-28 2020-01-02 Rand Kinneret Anti-clogging and anti-adhesive micro-capillary needle with enhanced tip visibility
US20220105068A1 (en) 2018-09-13 2022-04-07 Eirion Therapeutics, Inc. Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor
US20220079911A1 (en) 2018-09-13 2022-03-17 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
US20210308440A1 (en) 2018-09-24 2021-10-07 L'oreal Device comprising microneedles for skin-coloring
WO2020064085A1 (en) 2018-09-24 2020-04-02 L'oreal Device comprising microneedles for cosmetic fillers delivery
EP3856322A1 (en) 2018-09-24 2021-08-04 L'oreal Device comprising microneedles for in-situ reaction of a skin
EP3653256B1 (en) 2018-11-13 2022-03-30 ONWARD Medical N.V. Control system for movement reconstruction and/or restoration for a patient
US11562907B2 (en) 2018-11-29 2023-01-24 International Business Machines Corporation Nanostructure featuring nano-topography with optimized electrical and biochemical properties
US10940554B2 (en) 2018-11-30 2021-03-09 International Business Machines Corporation Planar fabrication of micro-needles
JP2022510007A (en) 2018-12-03 2022-01-25 エイリオン セラピューティクス, インコーポレイテッド Improved delivery of large drugs
WO2020160399A1 (en) 2019-02-01 2020-08-06 Massachusetts Institute Of Technology Systems and methods for liquid injection
EP3695878B1 (en) 2019-02-12 2023-04-19 ONWARD Medical N.V. A system for neuromodulation
US11678989B2 (en) 2019-03-01 2023-06-20 University Of Connecticut Biodegradable piezoelectric nanofiber scaffold for bone or tissue regeneration
US11826495B2 (en) 2019-03-01 2023-11-28 University Of Connecticut Biodegradable piezoelectric ultrasonic transducer system
JP2022531442A (en) 2019-05-02 2022-07-06 ユアバイオ ヘルス, インコーポレイテッド Devices and methods for receiving fluids
MX2021012739A (en) 2019-05-14 2021-11-17 Eirion Therapeutics Inc Delaying peak effect and/or extending duration of response.
US11813056B2 (en) * 2019-07-31 2023-11-14 Washington University Materials and methods for implementing immunoassay on microneedle patch for detection and quantification of bioanalytes in interstitial fluid
US20220387303A1 (en) * 2019-10-22 2022-12-08 The Regents Of The University Of California Vaginal Drug Delivery Device
US11541216B2 (en) 2019-11-21 2023-01-03 Massachusetts Institute Of Technology Methods for manufacturing tissue interfacing components
DE19211698T1 (en) 2019-11-27 2021-09-02 Onward Medical B.V. Neuromodulation system
USD987825S1 (en) 2019-12-18 2023-05-30 Caramel Creations, Inc Micro-exfoliation roller
US11745001B2 (en) 2020-03-10 2023-09-05 University Of Connecticut Therapeutic bandage
EP4142589A1 (en) 2020-05-01 2023-03-08 YourBio Health, Inc. Vacuum generation devices and methods
CN115734784A (en) 2020-05-21 2023-03-03 平衡治療有限責任公司 Microneedle device for controlling thyroid hormone levels
DK4048152T3 (en) 2020-07-29 2024-03-11 Biolinq Incorporated SYSTEM FOR CONTINUOUS ANALYTE MONITORING WITH MICRON NEEDLE ARRANGEMENT
US11690739B1 (en) 2020-08-25 2023-07-04 Francis A. Kralick Implantable device for treatment of hydrocephalus
CN116113454A (en) 2021-05-08 2023-05-12 比奥林股份有限公司 Continuous analyte monitoring device fault detection based on microneedle arrays
US11684298B2 (en) 2021-07-07 2023-06-27 The Regents Of The University Of California Wearable, non-intrusive microneedle sensor
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
WO2023159181A1 (en) 2022-02-18 2023-08-24 Kitotech Medical, Inc. Force modulating deep skin staples and instruments
WO2023220283A1 (en) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Poxvirus adjuvant for t-cell vaccination
US11717612B1 (en) 2022-09-14 2023-08-08 Robert Backstein Multi-purpose automatic injector

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
US6132755A (en) * 1995-07-14 2000-10-17 Boehringer Ingelheim Kg Transcorneal drug-release system

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE25637E (en) 1964-09-08 Means for vaccinating
US3123212A (en) 1964-03-03 Multiple disposable intracutaneous injector package
US1274081A (en) * 1917-05-10 1918-07-30 Herman A Metz Hypodermic needle.
US2559474A (en) * 1950-03-09 1951-07-03 Sonco Inc Hypodermic and spinal syringe
US2814296A (en) 1954-04-15 1957-11-26 S & R J Everett & Co Ltd Surgical needles
US2893392A (en) 1958-01-08 1959-07-07 American Cyanamid Co Article of manufacture for intracutaneous injections
GB885036A (en) 1958-12-10 1961-12-20 Allen & Hanburys Ltd Improvements relating to surgical multiple puncture devices
US3072122A (en) * 1959-01-15 1963-01-08 Rosenthal Sol Roy Package for transcutaneous injection
US3034507A (en) 1960-05-10 1962-05-15 American Cyanamid Co Intracutaneous injection device
US3136314A (en) 1960-08-01 1964-06-09 Kravitz Harvey Vaccinating devices
US3221739A (en) 1962-03-26 1965-12-07 Rosenthal Sol Roy Injection device
US3221740A (en) 1962-08-31 1965-12-07 Rosenthal Sol Roy Injection device
FR1584474A (en) * 1968-02-20 1969-12-26
US3556080A (en) 1968-04-08 1971-01-19 Lincoln Lab Inc Skin allergy testing device
CA873458A (en) * 1968-09-03 1971-06-15 F. Ritsky Anthony Self-aspirating syringe
US3596660A (en) 1969-05-12 1971-08-03 Illinois Tool Works Injection device
US3675766A (en) 1970-02-04 1972-07-11 Sol Roy Rosenthal Multiple puncture injector device
US3762307A (en) 1972-03-02 1973-10-02 P Badovinac Flavor cup
FR2232331B1 (en) 1973-06-06 1978-03-24 Guerin A Ets
OA05448A (en) 1975-10-16 1981-03-31 Manufrance Manufacture Francai Multi-penetrating vaccine device.
US4182002A (en) * 1976-03-01 1980-01-08 Lubomir Holec Meat tenderizer device
US4159659A (en) 1978-05-16 1979-07-03 Carol Nightingale Electrical marking device
US4222392A (en) 1979-05-23 1980-09-16 Alier-Screen, Inc. Allergy testing device with vented base
US4320758A (en) * 1979-05-07 1982-03-23 Alza Corporation Osmotically driven fluid dispenser
US4411657A (en) 1980-05-19 1983-10-25 Anibal Galindo Hypodermic needle
US4494950A (en) * 1982-01-19 1985-01-22 The Johns Hopkins University Plural module medication delivery system
US4512768A (en) * 1982-09-10 1985-04-23 Avvari Rangaswamy Analgesic syringe
CA1247960A (en) * 1983-03-24 1989-01-03 Hideki Aoki Transcutaneously implantable element
US5865786A (en) * 1983-08-18 1999-02-02 Drug Delivery Systems, Inc. Programmable control and mounting system for transdermal drug applicator
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4664651A (en) * 1985-03-01 1987-05-12 The Procter & Gamble Company Subatmospheric method and apparatus for expanding blood vessels to facilitate puncture with a cannula
US4671288A (en) * 1985-06-13 1987-06-09 The Regents Of The University Of California Electrochemical cell sensor for continuous short-term use in tissues and blood
US4653513A (en) * 1985-08-09 1987-03-31 Dombrowski Mitchell P Blood sampler
US4775361A (en) 1986-04-10 1988-10-04 The General Hospital Corporation Controlled removal of human stratum corneum by pulsed laser to enhance percutaneous transport
US5335670A (en) 1986-04-18 1994-08-09 Henry Fishman Allergy testing method and apparatus
US4969468A (en) 1986-06-17 1990-11-13 Alfred E. Mann Foundation For Scientific Research Electrode array for use in connection with a living body and method of manufacture
US4837049A (en) * 1986-06-17 1989-06-06 Alfred E. Mann Foundation For Scientific Research Method of making an electrode array
US4703761A (en) 1986-08-04 1987-11-03 Rathbone R Rodion Blood sampling device for obtaining small quantity of venous blood
CA1283827C (en) * 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
US4771660A (en) 1987-08-24 1988-09-20 Harold Yacowitz Needle holder
US4798582A (en) 1987-10-27 1989-01-17 Permark Corp. C/O Sci/Med Advances Corp. Needle cartridge
US4830217A (en) * 1988-02-19 1989-05-16 Becton, Dickinson And Company Body fluid sample collection tube assembly
US5147355A (en) * 1988-09-23 1992-09-15 Brigham And Womens Hospital Cryoablation catheter and method of performing cryoablation
EP0429842B1 (en) 1989-10-27 1996-08-28 Korea Research Institute Of Chemical Technology Device for the transdermal administration of protein or peptide drug
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5054339A (en) 1990-02-20 1991-10-08 Harold Yacowitz Tattooing assembly
US5858188A (en) * 1990-02-28 1999-01-12 Aclara Biosciences, Inc. Acrylic microchannels and their use in electrophoretic applications
US5257987A (en) 1990-05-21 1993-11-02 Pharmetrix Corporation Controlled release osmotic infusion system
US5138220A (en) 1990-12-05 1992-08-11 Science Applications International Corporation Field emission cathode of bio-molecular or semiconductor-metal eutectic composite microstructures
TW279133B (en) 1990-12-13 1996-06-21 Elan Med Tech
US5279544A (en) 1990-12-13 1994-01-18 Sil Medics Ltd. Transdermal or interdermal drug delivery devices
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5312456A (en) 1991-01-31 1994-05-17 Carnegie Mellon University Micromechanical barb and method for making the same
US5451210A (en) * 1991-04-29 1995-09-19 Lifequest Medical, Inc. System and method for rapid vascular drug delivery
US5605662A (en) * 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US5632957A (en) * 1993-11-01 1997-05-27 Nanogen Molecular biological diagnostic systems including electrodes
CA2153993A1 (en) * 1992-01-16 1993-08-05 Rakesh K. Jain Method and apparatus for locating tumors
AU4282793A (en) * 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
US5241969A (en) * 1992-06-10 1993-09-07 Carson Jay W Controlled and safe fine needle aspiration device
DK148592D0 (en) 1992-12-10 1992-12-10 Novo Nordisk As APPARATUS
US5279552A (en) 1993-01-11 1994-01-18 Anton Magnet Intradermal injection device
US5383512A (en) 1993-01-27 1995-01-24 Midwest Research Institute Method for fabricating a substrate having spaced apart microcapillaries thereon
US5401242A (en) 1993-02-25 1995-03-28 Yacowitz; Harold Apparatus for injecting a substance into the skin
US5582184A (en) * 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
US5618295A (en) 1993-10-16 1997-04-08 Samsung Electro-Mechanics Co., Ltd. Apparatus for preparing skin in advance
EP0895293B1 (en) 1993-11-02 2006-06-14 Matsushita Electric Industrial Co., Ltd. Semiconductor device comprising an aggregate of semiconductor micro-needles
JP3590805B2 (en) 1993-11-10 2004-11-17 株式会社ニコン Blood collection device
US5885211A (en) * 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5458140A (en) * 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
JPH07196314A (en) 1993-12-28 1995-08-01 Maruo Calcium Co Ltd Tubular synthetic inorganic fine particle
ES2247248T3 (en) * 1994-01-21 2006-03-01 Powderject Vaccines, Inc. GENES ADMINISTRATION INSTRUMENT MOVED BY COMPRESSED GAS.
US5457041A (en) * 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
US5899880A (en) * 1994-04-08 1999-05-04 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
US5611806A (en) 1994-05-23 1997-03-18 Samsung Electro-Mechanics Co., Ltd. Skin perforating device for transdermal medication
KR0134152B1 (en) 1994-05-23 1998-04-14 이형도 Skin treatment device for medication
US5591139A (en) * 1994-06-06 1997-01-07 The Regents Of The University Of California IC-processed microneedles
US5632270A (en) * 1994-09-12 1997-05-27 Puritan-Bennett Corporation Method and apparatus for control of lung ventilator exhalation circuit
GB9422260D0 (en) 1994-11-04 1994-12-21 Owen Mumford Ltd Improvements relating to skin prickers
IE72524B1 (en) * 1994-11-04 1997-04-23 Elan Med Tech Analyte-controlled liquid delivery device and analyte monitor
US5599302A (en) * 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5611942A (en) * 1995-03-02 1997-03-18 Kabushiki Kaisha Toshiba Method for producing tips for atomic force microscopes
AU5740496A (en) 1995-05-22 1996-12-11 General Hospital Corporation, The Micromechanical device and method for enhancing delivery of compounds through the skin
AU5869796A (en) 1995-05-22 1996-12-11 Ned A. Godshall Micromechanical patch for enhancing the delivery of compound s through the skin
AU6104896A (en) 1995-06-07 1996-12-30 Regents Of The University Of California, The Therapeutic microdevices and methods of making and using sam e
US5983130A (en) 1995-06-07 1999-11-09 Alza Corporation Electrotransport agent delivery method and apparatus
US5647851A (en) * 1995-06-12 1997-07-15 Pokras; Norman M. Method and apparatus for vibrating an injection device
TR199800347T1 (en) 1995-08-29 1998-05-21 Spectrx, Inc. Micro-poring of human skin for drug application and monitoring applications.
US5658515A (en) 1995-09-25 1997-08-19 Lee; Abraham P. Polymer micromold and fabrication process
US5758505C1 (en) * 1995-10-12 2001-10-30 Cryogen Inc Precooling system for joule-thomson probe
US5632730A (en) 1995-10-16 1997-05-27 Reinert; Charles B. Fluid injector
US5662619A (en) * 1995-11-27 1997-09-02 Zarate; Alfredo R. Venous dialysis needle
US5725494A (en) * 1995-11-30 1998-03-10 Pharmasonics, Inc. Apparatus and methods for ultrasonically enhanced intraluminal therapy
US5883211A (en) * 1996-01-19 1999-03-16 Aclara Biosciences, Inc. Thermoreversible hydrogels comprising linear copolymers and their use in electrophoresis
US5801057A (en) 1996-03-22 1998-09-01 Smart; Wilson H. Microsampling device and method of construction
US6230051B1 (en) * 1996-06-18 2001-05-08 Alza Corporation Device for enhancing transdermal agent delivery or sampling
US6234990B1 (en) 1996-06-28 2001-05-22 Sontra Medical, Inc. Ultrasound enhancement of transdermal transport
US6183434B1 (en) 1996-07-03 2001-02-06 Spectrx, Inc. Multiple mechanical microporation of skin or mucosa
US5699157A (en) 1996-07-16 1997-12-16 Caliper Technologies Corp. Fourier detection of species migrating in a microchannel
US5911223A (en) * 1996-08-09 1999-06-15 Massachusetts Institute Of Technology Introduction of modifying agents into skin by electroporation
KR100453132B1 (en) 1996-12-20 2004-10-15 앨자 코포레이션 Device and method for enhancing transdermal agent flux
US5876675A (en) * 1997-08-05 1999-03-02 Caliper Technologies Corp. Microfluidic devices and systems
US6155992A (en) 1997-12-02 2000-12-05 Abbott Laboratories Method and apparatus for obtaining interstitial fluid for diagnostic tests
ATE221400T1 (en) 1997-12-11 2002-08-15 Alza Corp DEVICE FOR INCREASE THE TRANSDERMAL FLOW OF ACTIVE INGREDIENTS
US6183442B1 (en) * 1998-03-02 2001-02-06 Board Of Regents Of The University Of Texas System Tissue penetrating device and methods for using same
US6503231B1 (en) * 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US7344499B1 (en) * 1998-06-10 2008-03-18 Georgia Tech Research Corporation Microneedle device for extraction and sensing of bodily fluids
US6532386B2 (en) * 1998-08-31 2003-03-11 Johnson & Johnson Consumer Companies, Inc. Electrotransort device comprising blades
US6669663B1 (en) 1999-04-30 2003-12-30 Medtronic, Inc. Closed loop medicament pump
US6689103B1 (en) * 1999-05-07 2004-02-10 Scimed Life System, Inc. Injection array apparatus and method
US6743211B1 (en) * 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6611707B1 (en) * 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
US6312612B1 (en) 1999-06-09 2001-11-06 The Procter & Gamble Company Apparatus and method for manufacturing an intracutaneous microneedle array
GB9916316D0 (en) * 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
US6623457B1 (en) * 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
US20010053891A1 (en) 1999-12-30 2001-12-20 Ackley Donald E. Stacked microneedle systems
US6537242B1 (en) * 2000-06-06 2003-03-25 Becton, Dickinson And Company Method and apparatus for enhancing penetration of a member for the intradermal sampling or administration of a substance
US6440096B1 (en) * 2000-07-14 2002-08-27 Becton, Dickinson And Co. Microdevice and method of manufacturing a microdevice
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
WO2002064193A2 (en) * 2000-12-14 2002-08-22 Georgia Tech Research Corporation Microneedle devices and production thereof
US6663820B2 (en) * 2001-03-14 2003-12-16 The Procter & Gamble Company Method of manufacturing microneedle structures using soft lithography and photolithography
WO2005000382A2 (en) * 2003-06-04 2005-01-06 Georgia Tech Research Corporation Drilling microneedle device
US8353861B2 (en) * 2003-09-18 2013-01-15 Texmac, Inc. Applicator for applying functional substances into human skin
US20060036209A1 (en) * 2003-11-13 2006-02-16 Janardhanan Subramony System and method for transdermal delivery
US20080058706A1 (en) * 2004-06-30 2008-03-06 Genetronics, Inc. Modular electroporation device with disposable electrode and drug delivery components
CN101267896A (en) 2005-09-12 2008-09-17 阿尔扎公司 Coatable transdermal delivery microprojection assembly
WO2007130389A2 (en) * 2006-05-01 2007-11-15 Georgia Tech Research Corporation Automatic video quality measurement system and method based on spatial-temporal coherence metrics
WO2007130425A2 (en) 2006-05-01 2007-11-15 Georgia Tech Research Corporation Expert system and method for elastic encoding of video according to regions of interest
US20080161747A1 (en) * 2006-12-20 2008-07-03 Justin Lee Electrically conductive microneedle roller
EP1967581B1 (en) 2007-03-08 2016-08-17 Imec CMOS compatible method for manufacturing microneedle structures
US9968742B2 (en) * 2007-08-29 2018-05-15 Medtronic Minimed, Inc. Combined sensor and infusion set using separated sites

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
US6132755A (en) * 1995-07-14 2000-10-17 Boehringer Ingelheim Kg Transcorneal drug-release system

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8708966B2 (en) 1998-06-10 2014-04-29 Georgia Tech Research Corporation Microneedle devices and methods of manufacture and use thereof
US20100312191A1 (en) * 1998-06-10 2010-12-09 Georgia Tech Research Corporation Microneedle Devices and Methods of Manufacture and Use Thereof
US8257324B2 (en) 1999-06-04 2012-09-04 Georgia Tech Research Corporation Microneedle drug delivery device
US20050137531A1 (en) * 1999-11-23 2005-06-23 Prausnitz Mark R. Devices and methods for enhanced microneedle penetration of biological barriers
US9302903B2 (en) 2000-12-14 2016-04-05 Georgia Tech Research Corporation Microneedle devices and production thereof
US20020082543A1 (en) * 2000-12-14 2002-06-27 Jung-Hwan Park Microneedle devices and production thereof
US20090069788A1 (en) * 2004-11-18 2009-03-12 Nanopass Technologies Ltd., System And Method For Delivering Fluid Into Flexible Biological Barrier
US8007466B2 (en) 2004-11-18 2011-08-30 Nanopass Technologies Ltd. System and method for delivering fluid into flexible biological barrier
US7699819B2 (en) 2006-02-21 2010-04-20 The Hong Kong University Of Science And Technology Molecular sieve and zeolite microneedles and preparation thereof
US10377062B2 (en) 2007-08-06 2019-08-13 Transderm, Inc. Microneedle arrays formed from polymer films
US8366677B2 (en) 2007-08-06 2013-02-05 Transderm, Inc. Microneedle arrays formed from polymer films
US20090043279A1 (en) * 2007-08-06 2009-02-12 Kaspar Roger L Microneedle arrays formed from polymer films
US9044299B2 (en) 2008-03-21 2015-06-02 Ut-Battelle, Llc Microfabricated instruments and methods to treat recurrent corneal erosions
US20090240217A1 (en) * 2008-03-21 2009-09-24 Ut-Battelle, Llc Novel microfabricated instruments and methods to treat recurrent corneal erosion
US8591481B2 (en) * 2008-03-21 2013-11-26 Ut-Battelle, Llc Microfabricated instruments and methods to treat recurrent corneal erosion
US20110040236A1 (en) * 2009-08-17 2011-02-17 Pangaea Laboratories, Ltd. Microneedle roller
KR20200141542A (en) * 2010-04-28 2020-12-18 이노비오 파마수티컬즈, 인크. Oral mucosal electroporation device and use thereof
KR20130065639A (en) * 2010-04-28 2013-06-19 이노비오 파마수티컬즈, 인크. Oral mucosal electroporation device and use thereof
KR102593818B1 (en) * 2010-04-28 2023-10-25 이노비오 파마수티컬즈, 인크. Oral mucosal electroporation device and use thereof
KR20210156331A (en) * 2010-04-28 2021-12-24 이노비오 파마수티컬즈, 인크. Oral mucosal electroporation device and use thereof
KR102341551B1 (en) 2010-04-28 2021-12-21 이노비오 파마수티컬즈, 인크. Oral mucosal electroporation device and use thereof
KR20180088500A (en) * 2010-04-28 2018-08-03 이노비오 파마수티컬즈, 인크. Oral mucosal electroporation device and use thereof
KR101883715B1 (en) * 2010-04-28 2018-07-31 이노비오 파마수티컬즈, 인크. Oral mucosal electroporation device and use thereof
US10124159B2 (en) * 2010-04-28 2018-11-13 Inovio Pharmaceuticals, Inc. Oral mucosal electroporation device and use thereof
US10905870B2 (en) 2010-04-28 2021-02-02 Inovio Pharmaceuticals, Inc. Oral mucosal electroporation device and use thereof
KR102192390B1 (en) 2010-04-28 2020-12-17 이노비오 파마수티컬즈, 인크. Oral mucosal electroporation device and use thereof
US20130041310A1 (en) * 2010-04-28 2013-02-14 Stephen V. Kemmerrer Oral Mucosal Electroporation Device and Use Thereof
KR20190020187A (en) * 2010-04-28 2019-02-27 이노비오 파마수티컬즈, 인크. Oral mucosal electroporation device and use thereof
KR101952155B1 (en) 2010-04-28 2019-02-26 이노비오 파마수티컬즈, 인크. Oral mucosal electroporation device and use thereof
US11085923B2 (en) 2011-03-24 2021-08-10 Anpac Bio-Medical Science Co., Ltd Micro-devices for disease detection
US9168200B2 (en) 2011-03-30 2015-10-27 Cosmed Pharmaceutical Co., Ltd. Microneedle patch container
US9457183B2 (en) 2011-06-15 2016-10-04 Tripep Ab Injection needle and device
EP2737923A4 (en) * 2011-07-26 2015-01-21 Raphas Co Ltd Electro-microneedle integrated body for in-situ cutaneous gene transfer and method of manufacturing same
EP2737923A2 (en) * 2011-07-26 2014-06-04 Raphas Co., Ltd. Electro-microneedle integrated body for in-situ cutaneous gene transfer and method of manufacturing same
US9352084B2 (en) * 2011-08-05 2016-05-31 Unitract Syringe Pty Ltd Injectable drug delivery arrangement with controlled delivery cannula position relative to point of delivery
US20130035662A1 (en) * 2011-08-05 2013-02-07 Unitract Syringe Pty Ltd Injectable drug delivery arrangement with controlled delivery cannula position relative to point of delivery
US9993423B2 (en) 2011-10-20 2018-06-12 Cosmed Pharmaceutical Co., Ltd. Microneedle deposition method
US9962535B2 (en) * 2012-05-11 2018-05-08 10X Technology Llc Hollow silica glass microneedle arrays and method and apparatus for manufacturing same
US20150141924A1 (en) * 2012-05-11 2015-05-21 10X Technology Llc Hollow Silica Glass Microneedle Arrays and Method and Apparatus for Manufacturing Same
US10821275B2 (en) 2012-06-27 2020-11-03 Cosmed Pharmaceutical Co., Ltd. Protective release sheet for microneedle patch
US10126291B2 (en) * 2013-02-18 2018-11-13 Anpac Bio-Medical Science Co., Ltd. Apparatus for disease detection
US20140342441A1 (en) * 2013-02-18 2014-11-20 Anpac Bio-Medical Science Co., Ltd. Apparatus for disease detection
US10736840B2 (en) 2013-09-03 2020-08-11 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
US10603477B2 (en) 2014-03-28 2020-03-31 Allergan, Inc. Dissolvable microneedles for skin treatment
US10987503B2 (en) 2014-03-28 2021-04-27 Allergan, Inc. Dissolvable microneedles for skin treatment
US20160045720A1 (en) * 2014-08-18 2016-02-18 Noven Pharmaceuticals, Inc. Microneedle device and methods
US11040182B2 (en) * 2014-08-18 2021-06-22 Noven Pharmaceuticals, Inc. Microneedle device and methods
US10987039B2 (en) * 2014-12-03 2021-04-27 Stmicroelectronics S.R.L. Microneedle array device and method of making
US20160157764A1 (en) * 2014-12-03 2016-06-09 IMAST scarl Microneedle array device and method of making
US10940301B2 (en) 2015-04-17 2021-03-09 Georgia Tech Research Corporation Drug delivery devices having separable microneedles
US11635549B2 (en) 2016-12-21 2023-04-25 Samsung Electronics Co., Ltd. Reflectionless window, method for manufacturing same, and reflectionless window for invasive sensor
US11065428B2 (en) 2017-02-17 2021-07-20 Allergan, Inc. Microneedle array with active ingredient
US11730937B2 (en) 2017-10-11 2023-08-22 Georgia Tech Research Corporation Separable microneedle arrays for sustained release of drug

Also Published As

Publication number Publication date
US6503231B1 (en) 2003-01-07
ES2356337T3 (en) 2011-04-07
US8708966B2 (en) 2014-04-29
US20100312191A1 (en) 2010-12-09
JP2009119296A (en) 2009-06-04
US6334856B1 (en) 2002-01-01
DE69941696D1 (en) 2010-01-07
ATE449841T1 (en) 2009-12-15

Similar Documents

Publication Publication Date Title
US6334856B1 (en) Microneedle devices and methods of manufacture and use thereof
EP1086214B1 (en) Microneedle devices and methods of their manufacture
US6743211B1 (en) Devices and methods for enhanced microneedle penetration of biological barriers
EP1187653B1 (en) Devices for enhanced microneedle penetration of biological barriers
US7344499B1 (en) Microneedle device for extraction and sensing of bodily fluids
US9302903B2 (en) Microneedle devices and production thereof
EP1471953B1 (en) Gas pressure actuated microneedle arrays, and systems and methods relating to same
US20090062752A1 (en) Switchcable microneedle arrays and systems and methods relating to same
WO2003024507A2 (en) Microneedles, microneedle arrays, and systems and methods relating to same
AU2005200910B2 (en) Devices and methods for enhanced microneedle penetration of biological barriers
AU2004200303B2 (en) Microneedle devices and methods of manufacture and use thereof
CA2510389A1 (en) Microneedle devices and methods of manufacture and use thereof
AU2008200252A1 (en) Microneedle devices and methods of manufacture and use thereof
AU2002253812A1 (en) Microneedle devices and production thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: GEORGIA TECH RESEARCH CORPORATION, GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALLEN, MARK G.;PRAUSNITZ, MARK R.;MCALLISTER, DEVIN V.;AND OTHERS;REEL/FRAME:021323/0789;SIGNING DATES FROM 19990604 TO 19990608

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION